indoor
pollut
lmic
manuel
e
pediatr
pulmonologist
clinic
epidemiologist
respiratori
depart
hospit
nacion
de
nation
hospit
san
costa
rica
email
msotom
hnnsacr
quiquesoto
gmailcom
introduct
accord
air
pollut
includ
indoor
outdoor
sourc
biggest
environment
caus
death
worldwid
contribut
million
prematur
death
everi
year
impact
vulner
poor
major
environment
risk
factor
demonstr
women
children
live
lmic
highest
exposur
household
air
pollut
especi
indoor
biomass
fuel
combust
global
nearli
billion
peopl
use
biomass
fuel
coal
wood
dung
crop
residu
domest
energi
product
either
cook
heat
light
home
chimney
ventil
smoke
exposur
toxic
amount
pollut
associ
variou
respiratori
diseas
includ
lower
respiratori
infect
lrti
children
interestingli
use
biomass
fuel
vari
locat
cultur
socioeconom
statu
determin
exposur
result
health
risk
effect
indoor
air
pollut
iap
children
respiratori
health
develop
countri
much
less
extrem
vari
observ
poorer
home
develop
world
howev
increas
evid
sourc
iap
eg
tobacco
smoke
exposur
contribut
respiratori
diseas
children
industri
countri
gauderman
et
al
show
advers
effect
air
pollut
lung
develop
children
year
old
lead
clinic
signific
deficit
attain
reach
adulthood
indoor
vs
outdoor
pollut
iap
equal
greater
impact
human
health
outdoor
pollut
associ
mani
health
effect
includ
acut
chronic
respiratori
system
disord
particularli
cardiovascular
main
reason
amount
time
peopl
especi
women
children
spend
indoor
wide
rang
household
emiss
sourc
increas
concentr
toxic
pollut
indoor
compar
outdoor
mani
pollut
eg
biolog
pollut
formaldehyd
volatil
organ
compound
concentr
higher
indoor
outdoor
import
sourc
indoor
pollut
tobacco
smoke
exposur
household
cleanser
mold
mildew
burn
incens
chemic
aromat
candl
mosquito
coil
howev
limit
factor
inform
indoor
pollut
difficult
collect
outdoor
pollut
pollut
concentr
must
measur
separ
differ
hous
assum
observ
made
short
space
time
even
singl
occas
repres
habitu
exposur
diseas
caus
iap
impos
great
econom
cost
public
health
calcul
peopl
spend
time
indoor
either
home
school
offic
children
averag
spend
hour
insid
home
also
pregnant
women
spend
time
insid
home
therefor
iap
exposur
may
also
critic
period
worldwid
environment
pollut
appreci
place
quantifi
caus
diseas
howev
given
lung
diseas
lead
caus
morbid
mortal
global
effect
air
pollut
lung
health
great
interest
multipl
earli
life
factor
advers
affect
lung
function
futur
respiratori
health
recent
gray
et
al
studi
group
infant
enrol
south
african
birth
cohort
assess
determin
earli
lung
function
african
infant
found
factor
matern
smoke
matern
alcohol
household
benzen
associ
alter
earli
lung
function
addit
increas
interest
ultrafin
particl
rise
due
specif
characterist
particl
commonli
known
nanoparticl
um
due
small
size
commonli
underestim
mani
pollut
measur
exposur
tobacco
smoke
tobacco
smoke
primari
indoor
pollut
develop
develop
countri
evid
increas
respiratori
morbid
tobacco
smoke
particularli
children
consist
although
decreas
frequenc
daili
smoker
report
last
three
decad
develop
countri
lmic
countri
remain
high
data
worldwid
reveal
high
preval
smoke
lmic
particular
asian
countri
china
india
vietnam
smoke
indoor
establish
sourc
particul
matter
pm
nicotin
carbon
monoxid
co
benzen
toxic
compound
accord
etzel
tobacco
smoke
number
one
caus
prevent
morbid
mortal
unfortun
children
expos
passiv
smoke
lower
respiratori
ill
children
without
smoker
higher
mother
smoker
addit
matern
smoke
also
encourag
children
smoke
potenti
worsen
health
also
children
live
home
smoker
like
becom
smoker
matern
smoke
pregnanc
continu
larg
public
health
problem
exposur
tobacco
smoke
often
begin
prenat
result
decreas
lung
function
birth
reduc
level
immun
increas
hospit
lrti
increas
preval
childhood
wheez
asthma
studi
estim
young
children
worldwid
expos
cigarett
smoke
home
contribut
mortal
children
becom
import
exposur
passiv
smoke
increas
risk
sever
pneumonia
children
independ
risk
factor
poor
outcom
recent
systemat
review
found
significantli
increas
risk
death
ic
among
young
children
cigarett
smoke
exposur
anoth
studi
et
al
report
children
hospit
citi
vietnam
pneumonia
household
cigarett
smoke
exposur
oxid
nitrogen
nitrogen
dioxid
import
compon
indoor
outdoor
air
pollut
indoor
sourc
includ
cooker
fire
water
heater
paraffin
heater
also
emit
small
amount
occur
tobacco
smoke
research
suggest
contribut
respiratori
symptom
children
particularli
asthmat
children
studi
suggest
increas
risk
lrti
children
expos
yet
exposur
vari
depend
proxim
children
sourc
major
difficulti
determin
health
impact
difficult
measur
person
exposur
particul
matter
smoke
particl
socioeconom
statu
major
predictor
exposur
iap
level
indoor
particul
matter
develop
countri
far
exceed
develop
countri
less
expens
fuel
option
gener
less
effici
produc
smoke
may
caus
complic
epidemiolog
studi
shown
approxim
global
exposur
pm
attribut
indoor
exposur
develop
countri
two
third
occur
rural
area
mainli
household
biomass
fuel
combust
type
pollut
result
substanti
carbon
load
alveolar
macrophag
risk
factor
childhood
pneumonia
increas
level
emiss
indoor
associ
open
poorli
ventil
stove
typic
develop
countri
fuel
usual
burn
open
fire
cook
heat
light
near
home
environ
guatemala
parallel
random
control
trial
respir
studi
show
signific
reduct
sever
pneumonia
children
heavili
expos
wood
smoke
cook
chimney
stove
intervent
place
reduc
iap
addit
heinzerl
et
al
report
delay
instal
chimney
stove
intervent
associ
poorer
lung
growth
immedi
stove
instal
biolog
pollut
includ
indoor
particl
whose
import
health
proport
concentr
includ
bacteria
virus
anim
dander
hous
dust
mite
cockroach
pollen
mould
spore
mani
biolog
contamin
small
enough
inhal
import
human
health
aris
increas
preval
allerg
respiratori
diseas
children
young
adult
sensit
key
factor
develop
allergi
sensit
individu
must
expos
particular
allergen
costa
rica
ly
et
al
show
multivari
analysi
parent
report
moldmildew
child
home
p
posit
ige
respons
der
p
p
significantli
associ
airway
hyperreact
children
asthma
fungal
spore
anoth
potenti
caus
symptom
allerg
patient
also
occurr
acut
pulmonari
hemorrhag
infant
expos
toxigen
mould
anoth
exampl
infant
vulner
environment
hazard
formaldehyd
role
formaldehyd
lower
respiratori
symptom
asthma
children
controversi
howev
sever
studi
report
associ
formaldehyd
concentr
home
school
asthma
asthma
sever
allergi
airway
inflamm
children
princip
sourc
formaldehyd
home
insul
materi
construct
materi
chipboard
plywood
paint
fabric
clean
agent
disinfect
tobacco
smoke
also
make
major
contribut
sourc
includ
heat
cook
volatil
organ
compound
voc
voc
organ
chemic
easili
vapor
room
temperatur
found
home
associ
measur
exposur
poor
respiratori
health
observ
infant
preschool
children
sourc
includ
build
materi
furnish
furnitur
adhes
clean
agent
cosmet
water
suppli
tobacco
smoke
fuel
combust
conclus
summari
indoor
pollut
seriou
problem
lmic
import
develop
countri
underestim
acut
chronic
diseas
becom
common
particularli
children
lmic
proportion
expos
environment
pollut
global
effort
promot
improv
program
pollut
control
need
instanc
specif
intervent
effect
cook
solut
use
improv
fuel
cookstov
heater
improv
ventil
improv
human
health
unfortun
despit
enorm
human
econom
cost
environment
pollut
larg
overlook
refer
gordon
sb
et
al
respiratori
risk
household
air
pollut
low
middl
incom
countri
lancet
respir
med
p
gauderman
wj
et
al
effect
air
pollut
lung
develop
year
age
n
engl
j
med
p
sonego
et
al
risk
factor
mortal
acut
lower
respiratori
infect
alri
children
five
year
age
low
countri
systemat
review
observ
studi
plo
one
p
gray
et
al
determin
lung
function
african
infant
thorax
burtscher
h
k
occurr
ultrafin
particl
specif
environ
children
paediatr
respiratori
review
p
etzel
ra
indoor
outdoor
air
pollut
tobacco
smoke
mould
diseas
infant
children
int
j
hyg
environ
health
p
cheraghi
salvi
environment
tobacco
smoke
et
respiratori
health
children
eur
j
pediatr
p
suzuki
et
al
associ
environment
tobacco
smoke
exposur
increas
risk
hospit
admiss
pneumonia
children
year
age
vietnam
thorax
p
ah
et
al
viral
etiolog
acut
respiratori
infect
among
hospit
vietnames
children
ho
chi
minh
citi
plo
one
p
smith
kr
et
al
effect
reduct
household
air
pollut
childhood
pneumonia
guatemala
respir
randomis
control
trial
lancet
p
heinzerl
ap
et
al
lung
function
guatemalan
children
follow
chimney
stove
intervent
thorax
p
ly
np
et
al
patern
asthma
mold
exposur
increas
airway
respons
among
children
asthma
costa
rica
chest
p
prenat
exposur
pollut
lung
diseas
judith
voynow
edwin
l
kendig
jr
correspond
judith
voynow
professor
pediatr
pulmonari
medicin
children
hospit
richmond
vcu
richmond
va
usa
email
judithvoynow
vcuhealthorg
air
pollut
constitut
one
greatest
health
threat
vulner
popul
includ
infant
children
major
sourc
pollut
indoor
exposur
environment
tobacco
smoke
et
combust
biomass
fuel
outdoor
exposur
combust
product
traffic
industri
includ
fuel
product
air
pollut
compris
heterogen
mix
ozon
carbon
monoxid
co
nitrogen
dioxid
sulphur
dioxid
polycycl
aromat
hydrocarbon
pah
lead
heavi
metal
fine
particul
matter
less
micron
diamet
less
micron
particul
matter
releas
motor
vehicl
particularli
diesel
engin
consist
organ
substanc
nitrat
sulfat
element
carbon
semiquinon
metal
ozon
gener
ultraviolet
light
interact
nitrogen
oxid
volatil
organ
compound
exposur
pollut
vari
local
season
howev
acceler
industri
develop
nation
urban
center
toxic
level
air
pollut
world
health
organ
estim
million
death
global
death
per
year
due
indoor
outdoor
air
pollut
asia
western
pacif
greatest
burden
air
pollut
region
greatest
morbid
mortal
associ
air
pollut
air
pollut
exposur
pregnanc
major
impact
fetal
develop
respiratori
health
child
pregnanc
physiolog
chang
increas
respiratori
rate
minut
ventil
increas
fat
accumul
promot
increas
uptak
concentr
pollut
bodi
pregnanc
oxygen
demand
increas
higher
concentr
circul
co
less
oxygen
carri
capac
risk
decreas
oxygen
deliveri
fetu
fetal
hypoxia
blunt
alveolar
develop
promot
primari
pulmonari
hypertens
pollut
cross
placent
barrier
nicotin
other
may
induc
inflamm
alter
growth
factor
pathway
exampl
prenat
exposur
throughout
pregnanc
induc
chang
fetal
cord
blood
biomark
high
tyrosin
decreas
placent
growth
factor
consist
state
possibl
placent
dysfunct
sever
systemat
review
identifi
associ
prenat
pollut
exposur
impact
birth
weight
preterm
deliveri
respiratori
diseas
signific
associ
matern
exposur
co
low
birth
weight
matern
exposur
preterm
deliveri
lower
birth
weight
prematur
birth
increas
risk
decreas
pulmonari
function
test
increas
respiratori
symptom
matern
exposur
co
associ
airflow
obstruct
children
start
age
week
persist
year
matern
exposur
pah
associ
increas
risk
wheez
cough
lower
respiratori
tract
infect
improv
quantit
local
time
pollut
exposur
opportun
refin
outcom
analys
one
epidemiolog
studi
boston
birth
cohort
follow
infant
demonstr
matern
exposur
specif
time
period
gestat
week
increas
risk
asthma
boy
girl
age
year
studi
demonstr
gestat
window
suscept
alter
lung
develop
result
risk
asthma
may
offspr
host
factor
mitig
risk
matern
smoke
pregnanc
larg
public
health
problem
rate
vari
worldwid
strong
epidemiolog
data
prenat
exposur
postnat
exposur
risk
factor
wheez
asthma
offspr
matern
smoke
pregnanc
major
caus
low
birth
weight
prematur
deliveri
factor
predispos
increas
risk
airflow
obstruct
impact
airflow
obstruct
observ
adulthood
nicotin
cross
placent
barrier
detect
neonat
cord
blood
thu
nicotin
may
neg
affect
lung
develop
evid
matern
smoke
pregnanc
induc
cord
blood
dna
methyl
norwegian
mother
child
cohort
studi
dna
methyl
cpg
affect
ten
gene
import
detoxif
develop
function
includ
ahrr
aryl
hydrocarbon
receptor
repressor
xenobiot
metabol
enzym
growth
factor
independ
transcript
repressor
importantli
dna
methyl
pattern
confirm
separ
valid
studi
support
conserv
epigenet
impact
due
matern
smoke
importantli
addit
effort
encourag
cessat
smoke
may
therapeut
approach
mitig
effect
matern
smoke
offspr
recent
placebo
control
random
doubl
blind
prospect
trial
administ
vitamin
c
smoke
pregnant
women
determin
whether
increas
matern
level
vitamin
c
prevent
airflow
obstruct
offspr
vitamin
c
administr
improv
tidal
lung
function
measur
newborn
infant
compar
control
infant
intervent
current
investig
larger
studi
determin
whether
vitamin
c
effect
protect
lung
function
offspr
mother
smoke
sever
complex
challeng
need
overcom
make
progress
studi
mechan
prenat
air
pollut
tobacco
smoke
exposur
affect
offspr
first
pregnant
women
may
expos
mixtur
pollut
vari
concentr
time
durat
new
model
incorpor
measur
monitor
devic
aerosol
optic
depth
spectroradiometri
improv
spatiotempor
accuraci
determin
pollut
exposur
howev
complex
multipl
pollut
still
complic
abil
model
exposur
attribut
outcom
specif
constitu
second
mani
host
factor
includ
socioeconom
statu
matern
stress
matern
genom
microbiom
metabolom
interact
pollut
exposur
togeth
creat
matern
exposom
factor
impact
fetal
develop
final
difficult
separ
antenat
pollut
exposur
exposur
infanc
childhood
determin
rel
impact
lung
diseas
child
alveolar
develop
continu
adolesc
therefor
interact
host
factor
child
exposur
pollut
et
may
continu
impact
lung
develop
risk
asthma
lower
respiratori
tract
infect
howev
potenti
new
lung
parenchym
growth
lung
repair
also
provid
opportun
mitig
earli
injuri
voynow
ja
auten
r
environment
pollut
develop
lung
clinic
pulmonari
medicin
nw
koppaka
r
lung
diseas
global
context
call
public
health
action
ann
thorac
soc
hh
chiu
yh
coull
ba
kloog
schwartz
j
lee
wright
ro
wright
rj
prenat
particul
air
pollut
asthma
onset
urban
children
identifi
sensit
window
sex
differ
j
respir
crit
care
med
mm
de
oliveira
alv
n
fajersztajn
l
saldiva
p
first
breath
prenat
exposur
air
pollut
lung
develop
cell
tissu
re
den
hooven
eh
pierik
fh
de
kluizenaar
hofman
van
ratingen
sw
zandveld
py
russcher
h
lindeman
j
miedema
hm
steeger
ea
et
al
air
pollut
exposur
marker
placent
growth
function
gener
r
studi
environ
health
perspect
br
haberg
se
nilsen
rm
wang
x
vollset
se
murphi
sk
huang
z
hoyo
c
midttun
la
et
al
scan
identifi
differenti
dna
methyl
newborn
relat
matern
smoke
pregnanc
environ
health
perspect
rm
mao
g
zhang
x
hong
x
chen
z
soria
cs
h
wang
g
caruso
pearson
c
et
al
intrauterin
inflamm
matern
exposur
ambient
preconcept
specif
period
pregnanc
boston
birth
cohort
environ
health
perspect
ct
spindel
er
pulmonari
effect
matern
smoke
fetu
child
effect
lung
develop
respiratori
morbid
life
long
lung
health
paediatr
respir
rev
h
london
sj
gene
environ
interact
ambient
air
pollut
proc
thorac
soc
ml
starkweath
ar
york
tp
mechan
matern
exposom
implic
health
outcom
an
adv
nur
sci
role
environ
sever
bronchiol
fernando
p
polack
professor
depart
pediatr
vanderbilt
univers
scientif
director
infant
foundat
bueno
air
argentina
email
fernandoppolack
vanderbiltedu
clear
diseas
sever
differ
among
healthi
infant
rsv
lrti
howev
viru
titer
inflamm
bia
propos
explan
associ
diseas
phenotyp
role
receptor
respiratori
syncyti
viru
rsv
pathogenesi
controversi
present
discuss
interact
environment
factor
rsv
diseas
defin
immun
mediat
associ
sever
ill
two
independ
popul
infant
rsv
bronchiol
reveal
sever
rsv
infect
determin
genotyp
individu
environment
exposur
lp
infant
sever
diseas
exhibit
high
ratio
manifest
high
ratio
respiratori
secret
ratio
present
infant
sever
rsv
indic
polar
murin
model
rsv
infect
confirm
lp
exposur
genotyp
polar
influenc
diseas
phenotyp
togeth
result
identifi
environment
genet
factor
influenc
rsv
pathogenesi
reveal
high
ratio
associ
sever
diseas
marker
sever
asthma
andrew
bush
imperi
colleg
royal
brompton
hospit
london
uk
email
abush
rbhtnhsuk
definit
sever
asthma
compris
three
categori
carri
differ
public
health
messag
challeng
untreat
sever
asthma
sever
asthma
sever
asthma
untreat
sever
asthma
compris
children
area
insuffici
access
asthma
care
discuss
sinc
solut
larg
lie
outsid
hand
pediatrician
note
dramat
benefit
make
simpl
low
cost
treatment
wide
avail
develop
world
need
rememb
vast
major
children
simpl
remedi
properli
use
need
howev
note
studi
low
middl
incom
set
marker
sever
outcom
set
adequ
treatment
avail
convent
sever
therapi
resist
asthma
stra
sever
asthma
defin
either
need
high
dose
treatment
control
diseas
b
either
uncontrol
symptom
acut
attack
despit
high
dose
treatment
see
tabl
revers
factor
address
defin
level
treatment
children
beclomethason
equival
mcgday
plu
long
act
agonist
leukotrien
receptor
antagonist
least
fail
trial
agent
tabl
convent
criteria
diagnos
uncontrol
asthma
first
second
forc
expir
volum
uncontrol
symptom
use
andor
asthma
control
test
asthma
attack
per
year
treat
oral
prednisolon
sever
attack
defin
need
hospit
intens
care
ventilationpersist
airflow
limit
mean
system
steroid
trial
plu
agonist
level
withhold
short
agonist
howev
although
stra
bad
outcom
uk
nation
review
asthma
death
nrad
around
die
meet
criteria
sever
asthma
despit
death
rather
sever
outcom
http
marker
sever
consid
asthmat
propos
framework
airway
diseas
compris
airway
diseas
lifestyleenvironment
factor
consid
clinic
trait
treatment
especi
treatabl
expect
benefit
treatment
would
also
add
physician
behavior
signific
effect
nrad
sinc
know
children
asthma
readili
treat
low
dose
inhal
corticosteroid
ic
regularli
properli
administ
focu
initi
outsid
airway
rather
uncrit
ad
therapi
subject
comprehens
review
elsewher
abstract
necessarili
select
extrapulmonari
marker
sever
food
allergi
common
anticip
children
ventil
asthma
pediatr
intens
care
unit
picu
though
whether
caus
fellow
travel
unclear
differenti
acut
asthma
acut
anaphylaxi
patholog
may
difficult
sever
atopi
food
allergi
unclear
whether
caus
marker
stra
either
way
children
multipl
aeroallergen
sensit
big
skin
prick
test
wheal
andor
high
specif
ige
high
risk
group
sever
asthma
fungal
sensit
saf
gener
agre
pediatr
definit
pragmat
stra
pattern
sensit
spt
sige
fungu
sinc
allerg
bronchopulmonari
aspergillosi
rare
ever
seen
children
asthma
includ
definit
ige
adult
shown
children
saf
wors
inflamm
given
level
treatment
thu
put
greater
risk
sever
asthma
obes
evid
asthma
complic
obes
patholog
differ
asthma
associ
steroid
resist
greater
likelihood
admiss
picu
certainli
obes
potenti
treatabl
trait
b
environmentlifestyl
marker
sever
probabl
singl
import
caus
asthma
attack
sever
outcom
manifest
underus
ic
agonist
saba
saba
readili
identifi
dispens
record
detect
ic
underus
difficult
questionnair
ineffect
hand
prescript
uptak
equat
inhal
electron
monitor
mere
mean
devic
activ
area
smart
technolog
need
also
identifi
one
thing
remedi
quit
anoth
pattern
seek
health
care
repeat
attend
emerg
depart
failur
attend
regular
review
anoth
concern
featur
like
marker
chaotic
famili
life
therefor
poor
supervis
treatment
well
environment
exposur
allergen
exposur
sensit
associ
steroid
resist
viral
infect
high
risk
asthma
attack
passiv
smoke
also
associ
steroid
resist
c
physician
behavior
asthma
sever
asthma
plan
failur
plan
deal
attack
anoth
advers
marker
nrad
asthma
plan
shown
effect
care
review
acut
attack
determin
follow
whether
modifi
airway
marker
sever
previou
sever
asthma
attack
root
mainli
lie
outsid
airway
quit
clear
sever
attack
major
risk
factor
anoth
sever
attack
death
asthma
well
long
term
associ
acceler
declin
lung
function
sever
attack
never
event
prompt
detail
asthma
manag
child
persist
airway
eosinophilia
adult
studi
least
marker
risk
acut
attack
certainli
biolog
plausibl
uncontrol
eosinophil
inflamm
contribut
sever
exacerb
whether
driven
children
dubiou
neither
sarp
abl
demonstr
due
classic
cytokin
two
studi
mean
monoclon
antibodi
use
uncrit
need
trial
children
extrapol
adult
studi
absenc
airway
eosinophilia
therapi
phenotyp
although
possibl
azithromycin
may
help
absenc
treatment
option
make
vulner
group
studi
need
absenc
neutrophil
airway
neutrophilia
bal
submucosa
featur
pediatr
stra
recent
shown
presenc
neutrophil
associ
less
sever
asthma
quit
differ
shown
adult
pediatr
stra
differ
diseas
take
home
messag
import
way
reduc
poor
asthma
control
reduc
asthma
attack
increas
airway
treatment
deploy
latest
monoclon
get
basic
right
includ
adher
environment
exposur
effect
manag
plan
attack
high
risk
patient
sever
attack
overus
saba
underus
ic
alway
best
kiss
keep
simpl
stupid
howev
experienc
patient
pediatrician
never
take
asthma
lightli
still
kill
diseas
refer
bousquet
j
mantzourani
e
cruz
aa
et
al
uniform
definit
asthma
sever
control
exacerb
document
present
world
health
organ
consult
sever
asthma
j
allergi
clin
immunol
chung
kf
wenzel
se
brozek
jl
et
al
intern
ersat
guidelin
definit
evalu
treatment
sever
asthma
eur
respir
j
puranik
forno
e
bush
jc
predict
sever
asthma
exacerb
children
j
respir
crit
care
med
oct
epub
robert
g
patel
n
f
habibi
p
lack
g
food
allergi
risk
factor
asthma
childhood
studi
j
allergi
clin
immunol
castanhinha
sherburn
r
walker
gupta
bossley
cj
buckley
j
ullmann
n
grychtol
r
campbel
g
maglion
koo
fleme
l
gregori
l
snelgrov
rj
bush
lloyd
cm
saglani
pediatr
sever
asthma
fungal
sensit
mediat
j
allergi
clin
immunol
murray
cs
poletti
g
kebadz
morri
j
woodcock
johnston
sl
custov
studi
modifi
risk
factor
asthma
exacerb
viru
infect
allergen
exposur
increas
risk
asthma
hospit
admiss
children
thorax
kobayashi
bossley
c
gupta
et
al
passiv
smoke
impair
histon
children
sever
asthma
chest
bossley
cj
fleme
l
gupta
regamey
n
frith
j
oat
tsartsali
l
lloyd
cm
bush
saglani
pediatr
sever
asthma
character
eosinophilia
remodel
without
h
cytokin
j
allergi
clin
immunol
fitzpatrick
higgin
holguin
f
brown
la
teagu
wg
nation
institut
healthnat
heart
lung
blood
institut
sever
asthma
research
program
molecular
phenotyp
sever
asthma
children
jaci
andersson
ck
adam
nagakumar
p
bossley
c
gupta
de
vri
adnan
bush
saglani
lloyd
cm
intraepitheli
neutrophil
pediatr
sever
asthma
associ
better
lung
function
j
allergi
clin
immunol
oct
pii
allerg
rhiniti
adnan
custov
depart
paediatr
imperi
colleg
london
uk
correspond
author
adnan
custov
md
phd
clinic
professor
paediatr
allergi
imperi
colleg
london
depart
paediatr
st
mari
campu
medic
school
london
pg
uk
tel
email
acustov
imperialacuk
allerg
rhiniti
one
common
chronic
diseas
childhood
intern
studi
asthma
allergi
childhood
report
averag
preval
rhiniti
among
children
burden
allerg
rhiniti
individu
patient
societi
often
underestim
gener
lack
data
risk
factor
phenotyp
rhiniti
childhood
diagnosi
allerg
rhiniti
diagnosi
allerg
rhiniti
base
upon
clinic
histori
includ
type
durat
frequenc
symptom
exacerb
children
teenag
rhiniti
experi
upper
respiratori
symptom
includ
nasal
blockag
itch
wateri
rhinorrhea
sneez
may
present
atyp
cough
snore
worth
note
despit
often
troublesom
symptom
rhiniti
often
ignor
minor
symptomat
children
appropri
diagnosi
manag
examin
nose
essenti
diagnosi
rhiniti
alway
carri
atop
sensit
ascertain
use
skin
prick
test
measur
serum
ige
howev
test
posit
absenc
symptom
posit
skin
test
ige
confirm
express
rhiniti
symptom
upon
allergen
exposur
rhiniti
symptom
seen
associ
allergen
data
demonstr
quantif
atop
sensit
use
titer
sige
antibodi
size
skin
prick
test
wheal
increas
specif
test
relat
presenc
sever
recent
year
chang
way
interpret
result
ige
skin
test
move
dichotom
positiveneg
test
quantif
ige
titer
skin
test
wheal
size
measur
sensit
allergen
compon
diagnost
may
inform
standard
test
use
whole
allergen
extract
howev
potenti
valu
compon
resolv
diagnosi
diagnosi
rhiniti
need
establish
consid
routin
use
clinic
investig
may
requir
evalu
possibl
diagnos
eg
measur
nasal
mucociliari
clearanc
nasal
nitric
oxid
nasal
endoscopi
acoust
rhinometri
etc
manag
manag
strategi
allerg
rhiniti
includ
avoid
relev
allergen
oral
intranas
antihistamin
intranas
corticosteroid
treatment
allerg
rhiniti
intranas
corticosteroid
greatest
efficaci
treatment
may
includ
oral
leukotrien
receptor
antagonist
intranas
patient
allerg
rhiniti
age
five
year
inadequ
control
use
standard
pharmacolog
treatment
immunotherapi
help
consid
allerg
rhiniti
asthma
presenc
sever
amongst
children
allerg
rhiniti
frequent
often
preced
asthma
mount
bodi
evid
patient
asthma
rhiniti
sever
lower
respiratori
symptom
compar
asthma
alon
exampl
amongst
adult
patient
asthma
comorbid
consider
poorer
qualiti
life
chronic
rhiniti
import
sever
similarli
children
asthma
allerg
rhiniti
advers
impact
asthma
addit
children
adolesc
moderatesever
asthma
treat
inhal
corticosteroid
concurr
allerg
increas
use
emerg
care
servic
compar
patient
without
among
children
asthma
recruit
hospit
asthma
clinic
presenc
allerg
rhiniti
shown
signific
advers
effect
asthma
control
even
asthma
consid
adequ
studi
demonstr
amongst
children
asthma
presenc
rhiniti
signific
advers
effect
asthma
among
asthmat
children
rhiniti
frequent
wheez
attack
increas
risk
sever
attack
wheez
associ
speech
limit
increas
risk
frequent
visit
famili
doctor
increas
risk
greater
school
absente
asthma
increas
risk
treatment
allerg
rhiniti
improv
asthma
control
studi
netherland
treatment
allerg
rhiniti
intranas
corticosteroid
reduc
advers
effect
rhiniti
asthma
sever
similarli
studi
describ
adjust
use
antihistamin
chang
associ
rhiniti
asthma
sever
adjust
use
intranas
corticosteroid
result
small
consist
reduct
observ
consist
find
retrospect
cohort
older
children
adult
show
among
patient
asthma
rhiniti
treat
allerg
rhiniti
significantli
less
like
visit
emerg
depart
hospit
result
studi
suggest
prove
amongst
children
asthma
rhiniti
appropri
treatment
rhiniti
intranas
corticosteroid
may
improv
asthma
control
definit
answer
obtain
appropri
design
random
control
trial
howev
yet
trial
children
howev
note
studi
among
children
mildmoder
asthma
intermitt
allerg
rhiniti
shown
intranas
corticosteroid
may
improv
contrast
random
trial
amongst
adult
asthma
persist
allerg
rhiniti
demonstr
steroid
spare
effect
ad
intranas
corticosteroid
low
dose
inhal
corticosteroid
lower
airway
recent
studi
assess
effect
intranas
corticosteroid
asthma
outcom
patient
allerg
comorbid
asthma
conclud
intranas
corticosteroid
may
improv
lower
airway
outcom
studi
need
confirm
role
intranas
corticosteroid
spray
therapi
asthma
conclus
allerg
rhiniti
common
import
childhood
asthma
children
asthma
assess
presenc
rhiniti
appropri
treat
allevi
upper
lower
respiratori
symptom
refer
n
pearc
n
anderson
hr
et
al
global
map
preval
symptom
rhinoconjunct
children
intern
studi
asthma
allergi
childhood
isaac
phase
three
allergi
robert
g
xatzipsalti
borrego
lm
et
al
paediatr
rhiniti
posit
paper
european
academi
allergi
clinic
immunolog
allergi
marinho
simpson
low
l
kissen
p
murray
c
custov
rhinoconjunct
children
birth
cohort
studi
allergi
marinho
simpson
soderstrom
l
woodcock
ahlstedt
custov
quantif
atopi
probabl
rhiniti
preschool
children
birth
cohort
studi
allergi
guerra
sherril
dl
martinez
fd
barbe
ra
rhiniti
independ
risk
factor
asthma
journal
allergi
clinic
immunolog
custov
johnston
sl
pavord
et
al
eaaci
posit
statement
asthma
exacerb
sever
asthma
allergi
de
groot
ep
nijkamp
duiverman
ej
brand
pl
allerg
rhiniti
associ
poor
asthma
control
children
asthma
thorax
lasmar
lm
camargo
pa
ordon
ab
gaspar
gr
campo
eg
ribeiro
ga
preval
allerg
rhiniti
impact
use
emerg
care
servic
group
children
adolesc
moder
sever
persist
asthma
jornal
de
pediatria
deliu
belgrav
simpson
murray
cs
kerri
g
custov
impact
rhiniti
asthma
sever
children
allergi
j
neslusan
c
crown
wh
torr
treat
allerg
rhiniti
patient
comorbid
asthma
risk
hospit
emerg
depart
visit
journal
allergi
clinic
immunolog
kersten
et
van
leeuwen
jc
brand
pl
et
al
effect
intranas
corticosteroid
exercis
induc
bronchoconstrict
asthmat
children
pediatr
pulmonolog
nair
vaidyanathan
cleari
k
williamson
p
meldrum
k
lipworth
bj
steroid
spare
effect
intranas
corticosteroid
asthma
allerg
rhiniti
allergi
lohia
schlosser
rj
soler
zm
impact
intranas
corticosteroid
asthma
outcom
allerg
rhiniti
allergi
asthma
diagnos
dr
louis
fleme
nation
heart
lung
institut
royal
brompton
hospit
london
uk
email
lfleme
imperialacuk
asthma
frequent
diagnos
chronic
condit
childhood
global
estim
million
peopl
given
frequenc
asthma
diagnosi
made
face
would
appear
diagnos
asthma
easi
howev
asthma
diagnos
made
basi
symptom
report
littl
object
evid
support
diagnosi
asthma
lead
diagnosi
asthma
delay
definit
diagnosi
condit
children
treatment
start
mani
littl
object
evid
whilst
symptom
report
clearli
start
point
suggest
possibl
asthma
symptom
insuffici
confirm
diagnosi
symptom
non
specif
cough
featur
normal
childhood
viral
infect
wheez
could
mean
respiratori
nois
upper
lower
airway
cultur
even
word
wheez
yet
great
weight
put
item
clinic
practic
epidemiolog
studi
object
test
asthma
singl
gold
standard
test
asthma
posit
neg
predict
valu
test
far
optim
howev
say
test
undertaken
rather
test
carri
suggest
histori
logic
fashion
demonstr
one
key
featur
character
asthma
chronic
inflammatori
diseas
variabl
airflow
obstruct
airway
object
test
includ
measur
peak
flow
peak
flow
variabl
spirometri
demonstr
revers
airflow
obstruct
exhal
nitric
oxid
feno
induc
sputum
test
airway
methacholin
histamin
challeng
test
may
avail
specialist
center
howev
abil
measur
peak
flow
assess
variabl
across
period
record
respons
short
act
beta
agonist
saba
avail
level
care
measur
feno
like
becom
increasingli
avail
absenc
variabl
airflow
obstruct
inflamm
realli
call
question
diagnosi
trial
treatment
may
help
case
provid
clearli
document
evid
respons
deterior
stop
accuraci
diagnosi
retrospect
review
dutch
children
diagnos
asthma
diagnosi
confirm
diagnosi
confirm
presenc
document
recurr
wheez
dyspnea
demonstr
revers
airflow
obstruct
spirometri
need
addit
test
histamin
challeng
percent
probabl
asthma
confirmatori
test
deem
remaind
never
diagnos
asthma
prescrib
inhal
anoth
unknown
reason
canadian
studi
recruit
children
diagnosi
asthma
control
carri
object
diagnosi
asthma
confirm
clinician
assess
plu
either
revers
bronchoconstrict
posit
methacholin
challeng
percent
case
overdiagnos
symptomat
control
underdiagnos
howev
emphas
studi
previous
state
singl
gold
standard
test
asthma
may
diagnosi
correct
made
child
grown
symptom
given
variabl
asthma
assess
singl
day
unlik
suffici
exclud
diagnosi
context
suggest
symptom
nonetheless
studi
highlight
infrequ
object
test
carri
import
review
diagnosi
matter
misdiagnosi
asthma
potenti
caus
harm
children
may
prescrib
unnecessari
potenti
harm
medic
altern
diagnosi
dose
inhal
corticosteroid
ic
may
relentlessli
increas
view
lack
symptomat
respons
howev
note
mani
children
diagnos
asthma
dutch
canadian
either
low
dose
ic
need
saba
impli
fact
children
symptom
receiv
diagnosi
asthma
rel
trivial
symptom
almost
half
children
diagnos
asthma
fact
healthi
children
reinforc
view
asthma
mild
diseas
highlight
nation
review
asthma
potenti
advers
outcom
includ
death
poorli
recogn
among
health
care
profess
complac
put
genuin
poorli
control
diseas
risk
correct
diagnosi
cornerston
good
asthma
manag
effort
made
ensur
diagnosi
underpin
object
test
global
asthma
report
http
wwwglobalasthmareportorgburdenburdenphp
access
fleme
l
diagnosi
manag
asthma
children
bmj
den
akker
karen
van
luijn
theo
verheij
overdiagnosi
asthma
children
primari
care
retrospect
analysi
br
j
gen
pract
cl
yan
e
simon
rg
foti
p
subbarao
sd
dell
misdiagnosi
asthma
schoolchildren
pediatr
pulmonolog
http
wwwrcplondonacukprojectsnationalreviewasthmadeath
relat
wheez
phenotyp
asthma
later
life
john
henderson
school
social
commun
medicin
faculti
health
scienc
univers
bristol
uk
email
ajhenderson
bristolacuk
mani
children
start
wheez
earli
childhood
outgrow
symptom
point
life
although
wheez
may
relaps
remit
life
cours
tempor
variat
frequenc
sever
wheez
asthma
first
year
life
heterogen
manifest
addit
tempor
variat
onset
progress
characterist
symptom
wheez
ill
vari
environment
trigger
factor
respons
treatment
associ
variabl
allerg
sensit
lung
function
observ
led
specul
wheez
ill
earli
childhood
may
repres
common
diseas
process
exist
sever
discret
wheez
phenotyp
underpin
differ
biolog
process
endotyp
greater
understand
phenotyp
heterogen
abil
discrimin
discret
phenotyp
earli
life
either
clinicopatholog
featur
biolog
marker
underli
process
could
advanc
opportun
stratifi
intervent
alter
natur
histori
asthma
wheez
across
life
cours
wheezi
bronchiti
asthma
earli
year
one
longest
run
studi
asthma
outcom
world
start
melbourn
report
follow
age
year
particip
recruit
childhood
age
recruit
children
classifi
categori
mild
wheezi
bronchiti
moder
wheezi
bronchiti
asthma
sever
asthma
success
follow
survey
sever
asthma
childhood
associ
greatest
risk
persist
frequent
asthma
adulthood
furthermor
sever
asthma
associ
lower
lung
function
establish
childhood
despit
acceler
rate
declin
adulthood
group
much
greater
risk
copd
life
subject
histori
asthma
wheez
similar
find
lung
function
deficit
exist
persist
adulthood
observ
dunedin
studi
associ
wheez
persist
throughout
tucson
children
respiratori
studi
semin
show
earli
childhood
phenotyp
base
tempor
pattern
wheez
relat
asthma
lung
function
outcom
later
life
prospect
follow
birth
cohort
show
earli
onset
wheez
becam
asymptomat
progress
asthma
associ
low
lung
function
soon
birth
subsequ
follow
up
birth
cohort
tucson
group
also
show
transient
earli
wheez
phenotyp
associ
persist
low
lung
function
adolesc
earli
earli
wheez
phenotyp
later
outcom
develop
tucson
paradigm
use
approach
analyz
parent
report
wheez
ill
age
year
larg
birth
cohort
uk
confirm
associ
transient
earli
wheez
low
lung
function
identifi
three
phenotyp
wheez
persist
character
age
sinc
replic
sever
time
independ
cohort
evid
extern
valid
comparison
phenotyp
base
clinic
observ
emerg
work
wheez
began
earli
within
first
month
birth
persist
strongest
associ
clinic
report
asthma
low
lung
function
compar
transient
phenotyp
insight
gain
analysi
manchest
asthma
allergi
studi
maa
link
individu
health
record
show
persist
wheez
phenotyp
could
stratifi
without
frequent
health
care
util
essenti
sever
form
persist
wheez
term
persist
troublesom
wheez
interestingli
genet
studi
suggest
persist
wheez
persist
troublesom
wheez
distinct
associ
genet
loci
share
phenotyp
recent
follow
earli
childhood
phenotyp
adolesc
confirm
persist
wheez
associ
asthma
low
lung
function
bronchodil
respons
increas
feno
adolesc
phenotyp
also
strongli
associ
allerg
sensit
cohort
maa
studi
longitudin
assess
sensit
model
atop
statu
indic
strongest
associ
hospit
wheezeasthma
poorer
lung
function
higher
airway
current
state
art
pool
resourc
combin
data
expertis
appli
sophist
statist
approach
data
interrog
enabl
us
reach
posit
target
phenotyp
intervent
almost
certainli
associ
earli
onset
troublesom
wheez
associ
evid
multipl
atop
sensit
juri
still
whether
phenotyp
identifi
latent
class
analysi
cluster
approach
repres
discret
biolog
entiti
differ
manifest
fundament
process
next
challeng
extend
analys
includ
triangul
detail
clinic
biomark
inform
fulli
understand
endotyp
associ
persist
allerg
asthma
target
intervent
pathway
prevent
modifi
long
term
morbid
condit
refer
william
h
mcnicol
kn
preval
natur
histori
relationship
wheezi
bronchiti
asthma
children
epidemiolog
studi
bmj
tai
tran
h
robert
clark
n
wilson
j
robertson
cf
associ
childhood
asthma
adult
chronic
obstruct
pulmonari
diseas
thorax
sear
mr
green
willan
ar
wiecek
em
taylor
dr
flanneri
em
cowan
jo
herbison
gp
silva
pa
poulton
r
longitudin
cohort
studi
childhood
asthma
follow
adulthood
n
engl
j
med
martinez
fd
wright
al
taussig
lm
holberg
cj
halonen
morgan
wj
asthma
wheez
first
six
year
life
group
health
medic
associ
n
engl
j
med
morgan
wj
stern
da
sherril
dl
guerra
holberg
cj
guilbert
tw
taussig
lm
wright
al
martinez
fd
outcom
asthma
wheez
first
year
life
adolesc
j
respir
crit
care
med
stern
da
morgan
wj
wright
al
guerra
martinez
fd
poor
airway
function
earli
infanc
lung
function
age
year
longitudin
cohort
studi
lancet
henderson
j
granel
r
heron
j
sherriff
simpson
woodcock
strachan
dp
shaheen
stern
ja
associ
wheez
phenotyp
first
year
life
atopi
lung
function
airway
respons
thorax
belgrav
dc
simpson
murray
cs
buchan
pickl
custov
joint
model
parent
report
wheez
identifi
children
persist
troublesom
wheez
j
allergi
clin
immunol
granel
r
henderson
aj
stern
ja
associ
wheez
phenotyp
late
asthma
outcom
avon
longitudin
studi
parent
children
birth
cohort
j
allergi
clin
immunol
simpson
tan
vy
winn
j
bishop
cm
heckerman
de
buchan
custov
beyond
atopi
multipl
pattern
sensit
relat
asthma
birth
cohort
studi
j
respir
crit
care
med
challeng
asthma
treatment
low
countri
paulo
pitrez
pucr
porto
alegr
brazil
email
pmpitrez
pucrsbr
sever
asthma
focu
research
discuss
worldwid
children
spectrum
diseas
result
import
impair
qualiti
life
involv
school
perform
leisur
emot
aspect
high
direct
indirect
cost
societi
mani
low
countri
lmic
high
preval
sever
asthma
children
particularli
latin
america
howev
studi
sever
childhood
asthma
countri
scarc
exampl
brazil
countri
south
america
hospitalizationsyear
asthma
approxim
deathsday
diseas
one
countri
highest
preval
sever
asthma
world
major
challeng
manag
sever
asthma
children
countri
usual
correct
diagnosi
clinic
present
profession
avail
referr
tertiari
center
difficulti
access
control
medic
higher
cost
mani
children
sever
asthma
problemat
asthma
percentag
children
resist
convent
pharmacolog
therapi
high
dose
corticosteroid
leukotrien
receptor
antagonist
repres
one
greatest
challeng
clinic
manag
asthma
type
sever
asthma
classifi
sever
asthma
stra
strongli
associ
atop
phenotyp
children
import
emphas
mani
patient
problemat
asthma
present
stra
often
anoth
diseas
inadequ
inhal
techniqu
problem
relev
environment
factor
comorbid
allerg
rhiniti
obes
sever
gastroesophag
reflux
among
other
lmic
popul
present
diseas
still
deserv
greater
understand
dissemin
moreov
child
uncontrol
asthma
use
inhal
corticosteroid
agonist
laba
deserv
care
evalu
clinic
least
month
specialist
area
adequ
diagnosi
manag
henc
due
complex
correct
diagnosi
problemat
asthma
children
profession
multidisciplinari
team
essenti
major
constraint
lmic
set
regard
pharmacolog
treatment
children
stra
step
gina
guidelin
indic
also
relat
higher
cost
treatment
lmic
anti
omalizumab
omalizumab
shown
signific
clinic
benefit
mani
children
stra
howev
high
cost
limit
countri
option
group
children
would
use
daili
system
corticosteroid
children
respond
treatment
use
associ
seriou
advers
event
conclus
burden
sever
asthma
children
high
larg
social
impact
lmic
review
guidelin
closer
look
discuss
effect
way
manag
sever
asthma
set
limit
econom
resourc
essenti
reduc
burden
diseas
children
asthma
lmic
refer
chung
kf
wenzel
se
brozek
jl
bush
castro
sterk
pj
adcock
im
bateman
ed
bel
eh
bleecker
er
et
al
intern
ersat
guidelin
definit
evalu
treatment
sever
asthma
eur
respir
j
lai
ck
beasley
r
crane
j
foliaki
shah
j
weiland
isaac
phase
three
studi
group
global
variat
preval
sever
asthma
symptom
phase
three
intern
studi
asthma
allergi
childhood
isaac
thorax
bush
zar
hj
univers
definit
sever
asthma
curr
opin
allergi
clin
immunol
datasu
da
brasil
http
tabnetdatasusgovbr
hedlin
g
bush
lodrup
carlsen
k
wennergren
g
de
benedicti
fm
e
paton
j
wilson
n
carlsen
problemat
sever
asthma
children
one
problem
mani
initi
eur
respir
j
global
initi
asthma
global
strategi
asthma
manag
prevent
updat
http
wwwginasthmaorg
roncada
c
oliveira
sg
cidad
sf
sarria
ee
mattiello
r
ojeda
bs
santo
brl
gustavo
pinto
la
jone
mh
et
al
burden
asthma
among
children
souther
brazil
j
asthma
rodrigu
roncada
c
santo
g
jp
souza
rg
varga
mhm
pinto
la
jone
mh
stein
rt
pitrez
pm
clinic
characterist
children
adolesc
sever
asthma
brazil
j
bra
pneumol
rodrigo
gj
neffen
h
systemat
review
use
omalizumab
treatment
sever
asthma
children
adolesc
ped
allergi
immunol
risk
factor
asthma
china
western
countri
gari
wong
depart
paediatr
princ
wale
hospit
shatin
nt
hong
kong
china
email
wingkinwong
cuhkeduhk
asthma
one
common
chronic
disord
childhood
mani
epidemiolog
studi
confirm
increas
trend
asthma
parallel
econom
develop
urban
research
around
world
tri
determin
factor
might
respons
induc
trend
factor
associ
asthma
atopi
air
pollut
exposur
tobacco
smoke
urban
dietari
chang
consumpt
fruit
veget
infect
includ
viral
bacteri
caus
person
factor
low
birth
weight
born
caesarean
section
determin
exact
mechan
factor
may
respons
asthma
difficult
task
one
thing
clear
one
two
factor
respons
increas
trend
asthma
western
world
studi
china
reveal
interest
find
may
help
us
understand
asthma
western
world
past
two
decad
extrem
rapid
econom
develop
unpreced
china
histori
parallel
rapid
increas
preval
childhood
asthma
document
data
guangzhou
standard
methodolog
although
sensit
factor
associ
asthma
high
rate
sensit
document
mani
year
rise
asthma
preval
level
air
pollut
high
mani
chines
citi
yet
preval
asthma
highli
pollut
citi
chongq
rel
low
perhap
strike
contrast
differ
asthma
allergi
urban
rural
environ
similar
rural
protect
asthma
found
western
countri
exposur
farm
anim
cow
consumpt
unpasteur
farm
milk
major
factor
rural
china
dairi
cow
consumpt
farm
milk
extrem
rare
last
studi
children
southern
china
exposur
domest
poultri
signific
factor
explain
rural
protect
furthermor
gene
express
studi
suggest
mark
variou
immun
regulatori
gene
rural
popul
environment
exposur
may
respons
differ
result
rural
protect
asthma
allergi
refer
asher
mi
montefort
b
lai
ck
strachan
dp
weiland
sk
william
h
worldwid
time
trend
preval
symptom
asthma
allerg
rhinoconjunct
eczema
childhood
isaac
phase
one
three
repeat
multicountri
survey
lancet
chen
wong
gw
li
j
environment
exposur
genet
predisposit
risk
factor
asthma
china
allergi
asthma
immunol
re
beasley
r
semprini
mitchel
ea
risk
factor
asthma
prevent
possibl
lancet
li
j
wang
h
chen
zheng
j
wong
gw
zhong
n
hous
dust
mite
sensit
main
risk
factor
increas
preval
wheez
schoolchildren
guangzhou
citi
china
clin
exp
allergi
feng
yang
z
pan
l
lai
x
xian
huang
x
chen
pc
roponen
schaub
b
wong
gw
li
j
associ
earli
life
exposur
environment
factor
asthma
among
children
rural
urban
area
guangdong
china
chest
barrier
treatment
develop
world
dr
louis
fleme
nation
heart
lung
institut
royal
brompton
hospit
london
uk
email
lfleme
imperialacuk
asthma
common
chronic
diseas
children
global
world
children
like
asthma
symptom
past
countri
develop
world
among
highest
preval
report
although
death
rate
highest
low
middl
incom
countri
death
rate
remain
high
develop
countri
exceed
mani
low
incom
therefor
greater
avail
resourc
financi
term
access
effect
asthma
medic
reflect
asthma
outcom
three
key
area
act
barrier
effect
asthma
treatment
develop
countri
lack
attent
basic
asthma
manag
diagnosi
asthma
children
base
symptom
report
rather
object
like
account
high
preval
seen
countri
lead
complac
appear
asthma
common
trivial
diseas
ineffect
risk
stratif
mean
appropri
resourc
direct
need
recent
year
larg
increas
number
gener
inhal
corticosteroid
ic
icslong
act
beta
agonist
laba
combin
inhal
devic
avail
prescrib
multipl
differ
devic
switch
devic
noth
improv
inhal
techniqu
organ
health
care
good
evid
coordin
nation
plan
asthma
involv
level
care
includ
commun
pharmaci
school
primari
secondari
tertiari
care
lead
improv
asthma
outcom
cost
howev
wide
replic
develop
countri
patchi
provis
specialist
care
poorli
defin
care
pathway
lack
effect
educ
patient
carer
includ
health
care
profession
block
pipelin
develop
new
drug
despit
legisl
aim
ensur
new
drug
test
appropri
pipelin
develop
new
drug
remain
particularli
slow
children
therapeut
target
novel
biolog
identifi
studi
adult
asthma
may
less
relev
pediatr
rel
small
number
children
usual
adolesc
recruit
phase
trial
result
children
rare
analyz
publish
separ
licens
novel
drug
children
often
lag
behind
adult
licens
restrict
access
drug
may
benefit
note
access
effect
treatment
healthcar
develop
countri
part
compar
low
middl
incom
countri
howev
differenti
avail
resourc
alway
reflect
outcom
need
done
ensur
resourc
squander
asthma
care
deliv
effect
refer
global
asthma
report
http
wwwglobalasthmareportorgburdenburdenphp
access
lai
ckw
beasley
r
crane
j
et
al
global
variat
preval
sever
asthma
symptom
phase
three
intern
studi
asthma
allergi
childhood
isaac
thorax
http
appswhointhealthinfostatisticsmortalitywhodpm
access
januari
ingrid
den
akker
karen
van
luijn
theo
verheij
overdiagnosi
asthma
children
primari
care
retrospect
analysi
br
j
gen
pract
haahtela
l
e
tuomisto
pietinalho
klaukka
erhola
kaila
nieminen
e
kontula
l
laitinen
year
programm
finland
major
chang
better
thorax
http
wwwemaeuropaeuemaindexjsp
lama
combin
product
select
glucocorticoid
receptor
agonist
pediatr
asthma
ricardo
fernand
depart
pediatr
santa
maria
hospit
lisbon
academ
medic
centr
clinic
pharmacolog
instituto
de
medicina
molecular
faculti
medicinetherapeut
univers
lisbon
portug
email
rmfernand
campusulpt
inhal
bronchodil
corticosteroid
cornerston
asthma
therapi
target
underli
inflamm
airway
obstruct
character
condit
use
revolution
manag
asthma
across
level
sever
mark
reduct
morbid
mortal
across
age
commonli
use
drug
group
commerci
avail
decad
consider
progress
made
improv
therapeut
ratio
reduc
advers
effect
ration
use
inhal
corticosteroid
ic
agonist
laba
support
better
understand
mechan
action
enhanc
drug
deliveri
adher
accumul
evid
efficaci
safeti
gap
current
treatment
option
remain
howev
recent
resurg
pharmacolog
research
field
fuel
increas
use
doubl
tripl
combin
therapi
focu
new
therapeut
target
eg
cholinerg
system
extens
research
bronchodil
copd
wealth
candid
drug
enter
asthma
pipelin
clinic
develop
includ
combin
ic
muscarin
receptor
antagonist
lama
alon
combin
select
glucocorticoid
receptor
agonist
segra
bifunct
drug
drug
hold
promis
overcom
pharmacokinet
pharmacodynam
limit
avail
molecul
may
also
allow
better
treat
patient
asthma
phenotyp
poorli
respons
current
manag
option
efficaci
come
expens
excess
burden
advers
effect
ic
prolong
durat
action
allow
dose
like
due
retent
within
cell
membran
persist
presenc
drug
near
adrenoreceptor
ar
use
asthma
limit
combin
therapi
ic
given
possibl
safeti
issu
monotherapi
indic
vilanterol
highli
select
partial
agonist
compound
current
molecul
approv
use
asthma
adolesc
combin
fluticason
furoat
ffvi
efficaci
safeti
demonstr
clinic
trial
includ
adolesc
adult
asthmat
patient
ic
ad
inhal
vi
well
compar
ffvi
placebo
current
use
ic
icslaba
activ
compar
adolesc
age
year
age
compris
asthma
popul
ffvi
clinic
develop
program
approv
age
rang
grant
european
medicin
agenc
ema
base
data
contrari
food
drug
administr
fda
consid
adequ
shown
data
earli
phase
trial
children
age
year
fail
show
signific
improv
lung
function
despit
good
toler
ffvi
combin
current
option
gina
step
onward
adolesc
countri
regulatori
approv
ff
cover
ic
categori
put
benefit
regard
treatment
adher
dose
although
recent
cochran
review
highlight
low
moder
qualiti
evid
ffvi
asthma
conclus
drawn
pediatr
popul
due
scarc
data
current
avail
studi
ongo
pediatr
clinic
develop
plan
asthma
data
earli
phase
trial
nearli
full
agonist
indacaterol
combin
mometason
avail
includ
adolesc
least
one
larg
trial
ongo
regulatori
submiss
other
focus
children
year
plan
data
pediatr
patient
avail
yet
offici
plan
olodaterol
abediterol
whose
product
develop
plan
combin
therapi
asthma
uncertain
preliminari
respect
whether
prone
safeti
issu
due
loss
bronchoprotect
effect
function
desensit
mechan
yet
uncertain
lama
rais
parasympathet
tone
provid
rational
use
antimuscarin
agent
asthma
tiotropium
administ
mist
inhal
subject
larg
clinic
develop
program
includ
children
adolesc
age
year
adult
evid
synthesi
shown
addit
tiotropium
icslaba
reduc
exacerb
use
replac
laba
lead
heterogen
result
differ
outcom
result
pediatr
trial
present
publish
throughout
earli
lead
recent
fda
approv
children
year
older
ema
approv
children
still
pend
result
suggest
children
adolesc
moder
andor
sever
asthma
use
tiotropium
ic
without
mainten
therapi
gener
safe
lung
function
paramet
gener
improv
reflect
efficaci
bronchodil
trial
primari
endpoint
achiev
across
age
rang
asthma
sever
observ
improv
measur
asthma
control
statist
signific
place
tiotropium
manag
pediatr
asthma
thu
still
unclear
gina
guidelin
suggest
use
therapi
adult
adolesc
patient
step
histori
exacerb
data
need
directli
compar
efficaci
tiotropium
versu
laba
identifi
predictor
eg
fix
airway
obstruct
clarifi
benefit
outcom
exacerb
establish
effect
airway
model
use
lama
adult
asthma
subject
earli
phase
trial
data
avail
yet
children
adolesc
segra
bifunct
drug
combin
therapi
combin
therapi
may
provid
synergi
drug
compon
well
enhanc
complianc
asid
previous
mention
combin
treatment
sever
doubl
labalama
tripl
icslabalama
combin
therapi
current
clinic
develop
also
grow
interest
develop
drug
two
differ
primari
pharmacolog
action
molecul
bifunct
drug
effort
obtain
efficaci
corticosteroid
fewer
advers
effect
focu
ligand
glucocorticoid
receptor
preferenti
induc
transrepress
littl
transactiv
activ
segra
dissoci
steroid
sever
compound
enter
clinic
develop
novelti
evid
practic
new
addit
therapeut
toolbox
greatli
welcom
mani
challeng
lie
ahead
drug
becom
valid
option
current
manag
pediatr
asthma
compani
develop
plan
pediatr
age
rang
plan
may
encount
trial
recruit
extrapol
issu
result
expect
within
decad
aspect
patient
caretak
prefer
type
devic
experi
implement
new
intervent
children
exist
treatment
must
consid
avail
drugdevic
combin
may
vari
around
world
due
regulatori
econom
motiv
need
solid
evid
efficaci
safeti
medicin
base
endpoint
across
differ
age
evalu
whether
ad
therapeut
valu
current
exist
option
includ
exist
soon
avail
biolog
would
allow
clarifi
role
current
stepwis
futur
treatment
approach
refer
billington
ck
penn
rb
hall
ip
agonist
page
cp
barn
pj
editor
pharmacolog
therapeut
asthma
copd
cham
springer
intern
publish
p
albertson
te
bullick
sw
schivo
sutter
spotlight
fluticason
furoatevilanterol
trifenat
treatment
asthma
design
develop
place
therapi
drug
design
develop
therapi
global
initi
asthma
global
strategi
asthma
manag
prevent
avail
http
wwwginasthmacom
dwan
k
milan
sj
bax
l
walter
n
powel
c
vilanterol
fluticason
furoat
asthma
cochran
databas
systemat
review
cazzola
rinaldi
b
luca
g
ora
j
olodaterol
treatment
asthma
expert
opinion
investig
drug
matera
mg
cazzola
muscarin
receptor
antagonist
page
cp
barn
pj
editor
pharmacolog
therapeut
asthma
copd
cham
springer
intern
publish
p
hamelmann
e
bernstein
ja
vandewalk
p
verri
unseld
et
al
randomis
control
trial
tiotropium
adolesc
sever
symptomat
asthma
european
respiratori
journal
szefler
sj
murphi
k
harper
boner
laki
engel
et
al
phase
iii
random
control
trial
tiotropium
therapi
children
sever
symptomat
asthma
journal
allergi
clinic
immunolog
page
c
cazzola
bifunct
drug
treatment
respiratori
diseas
page
cp
barn
pj
editor
pharmacolog
therapeut
asthma
copd
cham
springer
intern
publish
p
biolog
asthma
treatment
oliviero
sacco
antonino
capizzi
mariangela
tosca
giovanni
rossi
correspond
inform
giovanni
rossi
depart
pediatr
pulmonari
allergi
diseas
unit
cystic
fibrosi
center
g
gaslini
institut
genoa
itali
email
giovannirossi
gasliniorg
introduct
asthma
heterogen
diseas
airway
character
revers
airflow
obstruct
bronchial
hyperrespons
airway
inflamm
major
patient
current
treatment
base
inhal
glucocorticoid
ic
bronchodil
leukotrien
pathway
inhibitor
offer
good
control
diseas
howev
true
refractori
patient
popul
increas
risk
morbid
mortal
make
greater
asthma
econom
cost
base
cluster
analys
molecular
phenotyp
biomark
differenti
respons
therapi
last
decad
increas
appreci
heterogen
asthma
inde
substanti
divers
clinic
inflammatori
featur
diseas
sever
studi
identifi
cluster
patient
featur
correspond
atopicallerg
asthma
late
onset
atop
asthma
exercis
induc
asthma
asthma
asthma
associ
obes
etc
variou
phenotyp
character
differ
type
degre
inflammatori
immun
respons
approach
also
led
recognit
potenti
distinct
endotyp
type
helper
earli
onset
allerg
endotyp
late
onset
endotyp
interleukin
il
associ
eosinophil
endotyp
mast
cell
associ
endotyp
late
onset
obes
endotyp
neutrophil
andor
respons
endotyp
although
endotyp
character
asthmat
patient
area
activ
research
date
specif
pathway
target
biolog
agent
identifi
biolog
agent
also
term
biolog
biolog
therapeut
synthes
live
organ
direct
specif
determin
treatment
allerg
diseas
exampl
includ
agent
target
immunoglobulin
ig
e
b
lymphocyt
c
cytokin
cytokin
tumor
necrosi
factor
tnf
e
chemokin
receptor
f
lymphocyt
surfac
adhes
molecul
almost
biolog
current
avail
test
use
asthmat
patient
target
compon
like
asthma
endotyp
pathway
potenti
treatment
target
biolog
pathway
character
eosinophil
inflamm
driven
lymphocyt
respons
variou
agent
allergen
parasit
virus
produc
caus
shift
cell
differenti
cell
stimul
ige
product
upon
antigen
bind
ige
activ
mast
cell
eosinophil
releas
toxic
granul
cytokin
regul
eosinophil
matur
recruit
activ
act
local
eosinophil
mast
cell
whilst
induc
ige
synthesi
releas
mucu
product
epitheli
cell
favor
goblet
cell
metaplasia
eosinophil
inflamm
relat
allergi
sinc
patient
sever
asthma
eosinophil
inflamm
show
atop
sensit
normal
serum
ige
blocker
includ
receptor
human
monoclon
antibodi
hmab
first
cytokin
blocker
omalizumab
recombin
hmab
regist
treatment
patient
sever
persist
allerg
asthma
import
find
cochran
review
omalizumab
reduc
steroid
use
exacerb
improv
asthma
control
questionnair
acq
score
qualiti
life
score
treatment
efficaci
patient
howev
seem
relat
presenc
eosinophil
airway
inflamm
serum
ige
level
basophil
eosinophil
express
receptor
first
random
control
trial
patient
asthma
show
antagonist
mepolizumab
reduc
blood
eosinophil
count
prevent
blood
eosinophilia
respons
follow
allergen
challeng
effect
late
asthmat
respons
bronchial
hyperreact
howev
subsequ
trial
patient
eosinophil
asthma
demonstr
mepolizumab
treatment
reduc
asthma
attack
find
confirm
subsequ
studi
also
show
signific
oral
corticosteroid
spare
effect
trial
lebrikizumab
patient
asthma
show
improv
particularli
high
serum
periostin
concentr
high
feno
strong
trend
reduc
exacerb
receptor
blocker
close
link
exert
similar
function
bind
activ
receptor
subunit
thu
block
receptor
subunit
affect
signal
trial
antagonist
dupilumab
subgroup
patient
persist
asthma
blood
eosinophilia
show
signific
fewer
exacerb
withdrawn
long
act
agonist
inhal
corticosteroid
treatment
addit
forc
expiratori
volum
second
improv
significantli
acq
score
also
drop
treatment
group
also
show
reduct
fraction
exhal
nitric
oxid
feno
ige
thymu
chemokin
tarc
level
preliminari
data
asthma
endotyp
hope
provid
benefici
effect
azithromycin
patient
asthma
preliminari
data
efficaci
navarixin
sch
antagonist
whilst
posit
effect
report
treatment
brodalumab
hmab
asthmat
conclus
result
studi
show
like
disord
possibl
success
introduc
biolog
treatment
asthma
larg
depend
possibl
identifi
specif
patient
subgroup
select
measur
biomark
directli
influenc
treatment
refer
gina
global
strategi
asthma
manag
prevent
updat
http
wwwginasthmaorg
wenzel
se
complex
phenotyp
asthma
current
definit
pulm
pharmacol
ther
mccracken
jl
trippl
jw
calhoun
wj
biolog
therapi
manag
asthma
curr
opin
allergi
clin
immunol
boyman
kaegi
c
akdi
bavbek
bossio
chatzipetr
eiwegg
firinu
harr
knol
e
matucci
palomar
c
simon
hu
steiner
uc
vultaggio
akdi
ca
spertini
f
eaaci
ig
biolog
task
forc
paper
use
biolog
agent
allerg
disord
allergi
hilver
b
pavord
id
goe
must
come
biomark
novel
biolog
sever
asthma
clin
exp
allergi
normansel
r
walker
milan
sj
walter
eh
nair
p
omalizumab
asthma
adult
children
cochran
databas
syst
rev
lecki
mj
ten
brink
khan
j
diamant
z
oconnor
bj
wall
cm
mathur
ak
cowley
hc
chung
kf
djukanov
r
hansel
tt
holgat
st
sterk
pj
barn
pj
effect
block
monoclon
antibodi
eosinophil
airway
late
asthmat
respons
lancet
bel
e
wenzel
thompson
p
prazma
cm
keen
yancey
sw
ortega
hg
pavord
id
siriu
investig
oral
effect
mepolizumab
eosinophil
asthma
n
engl
j
med
corren
j
lemansk
rf
hanania
na
korenblat
pe
parsey
mv
arron
jr
harri
jm
scheeren
h
wu
lc
su
z
mosesova
eisner
md
bohen
sp
matthew
jg
lebrikizumab
treatment
adult
asthma
n
engl
j
med
wenzel
ford
l
pearlman
spector
sher
l
skobieranda
f
wang
l
kirkess
rocklin
r
bock
b
hamilton
j
ming
je
radin
stahl
n
yancopoulo
gd
graham
n
pirozzi
g
dupilumab
persist
asthma
elev
eosinophil
level
n
engl
j
med
diagnosi
treatment
pediatr
pulmonari
hypertens
rui
anjo
rato
nogueira
depart
pediatr
cardiolog
santa
cruz
hospit
centro
hospitalar
de
lisboa
ocident
lisbon
portug
email
ranjo
netcabopt
introduct
pediatr
pulmonari
hypertens
ph
rare
devast
diseas
may
present
pediatr
age
group
ph
pathophysiolog
disord
associ
multipl
clinic
condit
complic
major
cardiovascular
respiratori
diseas
associ
consider
morbid
mortal
pediatr
patient
preval
caus
ph
congenit
heart
diseas
idiopath
pulmonari
arteri
connect
tissu
diseas
portopulmonari
hypertens
hiv
infect
chronic
thromboembol
main
caus
ph
adult
much
less
frequent
pediatr
ph
distinct
adult
ph
sever
way
relat
lung
growth
develop
includ
prenat
earli
postnat
influenc
impair
function
structur
adapt
pulmonari
circul
transit
fetal
postnat
life
may
caus
neonat
ph
time
pulmonari
vascular
injuri
determin
subsequ
respons
develop
lung
hypoxia
hemodynam
stress
inflamm
normal
pulmonari
vascular
bed
essenti
normal
lung
structur
metabol
ga
exchang
toler
exercis
workload
perinat
factor
may
contribut
increas
risk
late
develop
ph
adulthood
adult
ph
pediatr
ph
differ
vascular
function
structur
genet
natur
histori
respons
right
ventricl
increas
load
ph
specif
definit
clinic
present
ph
defin
mean
pulmonari
arteri
pressur
mmhg
rest
month
age
measur
cardiac
nice
classif
categor
pulmonari
hypertens
ph
pulmonari
arteri
hypertens
ph
due
left
heart
diseas
ph
due
lung
diseas
andor
hypoxia
chronic
thromboembol
ph
ph
due
unclear
multifactori
mechan
pulmonari
arteri
hypertens
pah
describ
group
patient
ph
ph
normal
pulmonari
arteri
wedg
pressur
mmhg
pulmonari
vascular
resist
index
wood
unit
wu
pulmonari
vascular
research
institut
introduc
term
pediatr
pulmonari
hypertens
vascular
diseas
pphvd
approach
distinguish
ph
without
pulmonari
vascular
diseas
pvd
singl
biventricular
circul
patient
congenit
heart
diseas
chd
singl
ventricl
physiolog
often
meet
criteria
defin
may
benefit
similar
pharmacolog
strategi
patient
hemodynam
pulmonari
vascular
resist
pvr
index
wu
transpulmonari
gradient
mm
hg
suggest
definit
diagnosi
monitor
children
suspect
confirm
ph
refer
specialist
ph
pediatr
center
central
care
concentr
expertis
benefici
manag
patient
detail
medic
histori
care
physic
examin
essenti
diagnost
criteria
hemodynam
cardiac
pulmonari
arteri
catheter
gold
standard
establish
diagnosi
inde
method
direct
accur
measur
pulmonari
arteri
pressur
complement
acut
vasodil
test
inhal
nitric
ph
patient
complet
assess
hemodynam
use
echocardiographi
ecg
chest
function
test
lung
function
cardiopulmonari
exercis
abdomin
ultrasound
case
contrast
ct
angiographi
pulmonari
arteri
cardiac
mri
laboratori
evalu
includ
routin
biochemistri
hematolog
immunolog
hiv
test
thyroid
function
recommend
patient
pah
identifi
specif
associ
condit
echocardiogram
ecg
repeat
everi
month
frequent
clinic
deterior
pediatr
pulmonari
hypertens
treatment
manag
pulmonari
hypertens
evolv
dramat
last
year
mani
drug
approv
adult
pulmonari
hypertens
pediatr
age
group
therapi
frequent
use
adapt
adult
trial
clinic
trial
pediatr
popul
way
result
extrem
import
manag
children
ph
convent
therapi
gener
manag
ph
includ
treatment
right
ventricular
rv
failur
drug
loop
diuret
spironolacton
diuret
use
caution
patient
preload
clinician
use
digitali
improv
rv
function
sever
hypoxemia
treat
oxygen
therapi
use
anticoagul
controversi
suggest
children
rv
failur
physic
activ
encourag
strenuou
exercis
avoid
immun
plan
follow
strictli
particularli
avoid
respiratori
infect
target
therapi
develop
pulmonari
hypertens
involv
sever
pathway
lead
remodel
pulmonari
vascular
bed
target
current
pulmonari
hypertens
drug
includ
overexpress
endothelin
potent
vasoconstrictor
peptid
decreas
activ
vasodil
antiprolif
mediat
prostacyclin
nitric
oxid
calcium
channel
blocker
ccb
initi
target
therapi
patient
undergo
acut
vasodil
test
inhal
nitric
oxid
test
posit
fall
mean
pulmonari
arteri
pressur
increas
lack
decreas
cardiac
output
chang
decreas
ratio
pulmonari
vascular
system
vascular
lead
trial
ccb
nifedipin
amlodipin
diltiazem
ccb
caus
relax
vascular
smooth
muscl
use
caution
sever
ventricular
dysfunct
neg
inotrop
effect
may
decreas
cardiac
contractil
recommend
first
year
life
endothelin
receptor
antagonist
etra
endothelin
mediat
two
receptor
type
b
blockad
mechan
etra
bosentan
oral
dual
etra
approv
pediatr
use
caus
pap
pvr
decreas
improv
exercis
capac
seriou
side
effect
includ
liver
enzym
elev
anemia
impair
fertil
teratogen
regular
liver
function
test
recommend
children
receiv
ambrisentan
oral
et
antagonist
daili
formul
repercuss
liver
macitentan
novel
dual
etra
also
show
sign
hepat
toxic
fewer
drug
interact
phase
iii
trial
pediatr
patient
current
ongo
phosphodiesteras
type
inhibitor
sildenafil
current
approv
pediatr
use
act
prevent
breakdown
smooth
muscl
cell
cyclic
guanosin
monophosph
improv
pulmonari
vasodil
show
antiprolif
effect
oral
sildenafil
use
cautious
pediatr
popul
care
dose
accord
weight
frequent
assess
due
report
increas
mortal
patient
use
higher
side
effect
includ
headach
flush
noseble
hypotens
tadalafil
longer
durat
action
use
pediatr
popul
prostacyclin
analog
prostacyclin
act
increas
pulmonari
vasodil
inhibit
vascular
remodel
analog
includ
epoprostenol
treprostinil
iloprost
selexipag
first
two
deliv
continu
intraven
infus
treatment
choic
sever
pulmonari
hypertens
rv
epoprostenol
given
central
venou
line
place
patient
risk
advers
event
due
short
risk
rebound
ph
case
interrupt
administr
advers
side
effect
includ
bradycardia
hypotens
thrombocytopenia
treprostinil
longer
enabl
subcutan
infus
mini
pump
iloprost
administ
nebul
caus
acut
bronchospasm
patient
selexipag
oral
select
prostacyclin
receptor
agonist
promis
new
therapi
favor
side
effect
profil
show
signific
reduct
pvr
treatment
strategi
combin
therapi
treatment
pediatr
pulmonari
hypertens
aim
improv
surviv
qualiti
life
exercis
capac
hemodynam
reduc
overal
risk
improv
clinic
echocardiograph
hemodynam
risk
factor
goal
met
monotherapi
combin
therapi
use
combin
therapi
may
efficaci
address
multipl
pathophysiolog
pathway
simultan
whether
kind
strategi
initi
earli
use
two
drug
sequenti
ad
second
drug
previou
one
still
studi
high
risk
patient
inhal
intraven
prostacyclin
consid
deterior
occur
despit
maxim
therapi
techniqu
atrial
septostomi
shunt
appli
lung
transplant
last
therapeut
resort
figur
special
situat
congenit
heart
diseas
cardiac
lesion
like
ventricular
septal
defect
lead
ph
children
cyanot
congenit
heart
diseas
pulmonari
defect
highest
risk
patient
consid
oper
undergo
surgeri
earli
stage
follow
target
therapi
older
patient
increas
risk
develop
sever
form
ph
even
surviv
surgeri
suggest
surgeri
may
worsen
prognosi
acut
pulmonari
hypertens
crisi
character
sudden
increas
pap
pvr
pulmonari
hypertens
crisi
carri
high
risk
prevent
involv
maintain
adequ
oxygen
satur
acid
base
homeostasi
sedat
need
avoid
agit
inhal
nitric
oxid
standard
therapi
improv
pulmonari
vasodil
rv
function
cardiac
output
congenit
diaphragmat
hernia
increas
pvr
caus
vasoconstrict
decreas
vascular
growth
pulmonari
vascular
remodel
left
ventricular
dysfunct
treatment
involv
low
ventil
volum
permiss
hypercapnia
oscillatori
ventil
need
inhal
nitric
oxid
last
resort
extracorpor
membran
oxygen
surgic
repair
mandatori
gener
clinic
stabil
regular
echocardiographi
recommend
pulmonari
hypertens
may
cardiac
catheter
eventu
consid
sensibl
subtl
vascular
abnorm
pulmonari
diseas
chronic
diffus
lung
diseas
like
bronchopulmonari
dysplasia
lead
ph
echocardiographi
recommend
evalu
hypoxemia
avoid
persist
pulmonari
hypertens
newborn
defin
persist
physiolog
ph
fetu
birth
treatment
includ
oxygen
therapi
optim
lung
volum
cardiac
function
inhal
nitric
oxid
need
prognosi
pediatr
patient
reveal
registri
show
estim
surviv
rate
time
diagnosi
report
also
shown
improv
surviv
rate
pediatr
pah
patient
pah
repair
chd
address
care
may
present
unfavor
adult
classic
eisenmeng
hemodynam
better
surviv
patient
idiopath
pulmonari
arteri
hypertens
children
ipah
similar
mortal
surviv
report
conclus
ph
remain
major
challeng
signific
sourc
morbid
mortal
mani
childhood
diseas
although
random
pediatr
trial
treatment
strategi
children
improv
prognosi
past
decad
especi
introduct
new
therapeut
agent
refer
barst
rj
ertel
si
beghetti
ivi
dd
pulmonari
arteri
hypertens
comparison
children
adult
eur
respir
j
mar
berger
rm
beghetti
humpl
raskob
ge
ivi
dd
jing
zc
bonnet
barst
rj
clinic
featur
paediatr
pulmonari
hypertens
registri
studi
lancet
feb
barst
rj
mcgoon
md
elliott
cg
et
al
surviv
childhood
pulmonari
arteri
hypertens
insight
registri
evalu
earli
pulmonari
arteri
hypertens
diseas
manag
circul
abman
sh
ivi
dd
archer
sl
wilson
k
ahaat
joint
guidelin
pediatr
pulmonari
hypertens
committe
execut
summari
american
heart
associ
american
thorac
societi
joint
guidelin
pediatr
pulmonari
hypertens
j
respir
crit
care
med
oct
abman
sh
raj
u
toward
improv
care
children
pulmonari
hypertens
rational
develop
pediatr
pulmonari
hypertens
network
prog
pediatr
cardiol
simonneau
g
gatzouli
adatia
et
al
updat
clinic
classif
pulmonari
hypertens
j
coll
cardiol
cerro
mj
abman
diaz
g
et
al
consensu
approach
classif
pediatr
pulmonari
hypertens
vascular
diseas
report
pvri
pediatr
taskforc
panama
pulm
circ
lador
f
sekarski
n
beghetti
treat
pulmonari
hypertens
pediatr
expert
opin
pharmacoth
apr
mane
palazzini
leci
e
et
al
current
era
surviv
patient
pulmonari
arteri
hypertens
associ
congenit
heart
diseas
comparison
clinic
subgroup
eur
heart
j
ivi
dd
abman
sh
barst
rj
berger
rm
bonnet
fleme
tr
haworth
sg
raj
ju
rosenzweig
eb
schulz
neick
steinhorn
rh
beghetti
pediatr
pulmonari
hypertens
j
coll
cardiol
dec
suppl
figur
legend
algorithm
treatment
pulmonari
hypertens
adapt
ivi
ccb
calcium
channel
blocker
era
endothelin
receptor
antagonist
hpah
hereditari
pulmonari
arteri
hypertens
inh
inhal
ipah
idiopath
pulmonari
arteri
hypertens
iv
intraven
phosphodiesteras
inhibitor
sq
subcutan
lung
congenit
heart
diseas
paul
aurora
depart
paediatr
respiratori
medicin
cardiothorac
transplant
great
ormond
street
hospit
children
london
correspond
dr
paul
aurora
consult
paediatr
respiratori
medicin
lung
transplant
depart
paediatr
respiratori
medicin
great
ormond
street
hospit
children
great
ormond
street
london
email
paurora
uclacuk
word
count
exclud
titl
page
refer
keyword
congenit
heart
diseas
lung
diseas
children
introduct
cardiovascular
pulmonari
system
close
relat
health
diseas
mean
system
need
consid
evalu
symptom
cough
breathless
cardiac
diseas
affect
pulmonari
function
lung
diseas
affect
cardiac
function
addit
primari
ciliari
dyskinesia
caus
simultan
cardiac
pulmonari
diseas
propos
summar
understand
differ
area
diagnost
challeng
mani
children
present
respiratori
symptom
also
evalu
congenit
heart
diseas
chd
cardiac
diseas
summari
stridor
may
result
extrins
compress
airway
commonli
great
vessel
pulmonari
arteri
sling
dilat
left
atrium
ventriclewheez
andor
cough
may
consequ
pulmonari
edemareduc
exercis
toler
andor
hypoxia
result
cardiac
lesion
pulmonari
hypertens
mani
cardiac
condit
difficult
diagnos
histori
examin
target
investig
may
requir
particular
atrial
septal
defect
idiopath
pulmonari
arteri
hypertens
may
present
symptom
high
index
suspicion
requir
compress
airway
occur
due
abnorm
vessel
anatomi
increas
blood
flow
pulmonari
system
due
left
right
shunt
combin
two
fail
heart
cardiac
dilat
lead
common
caus
vascular
compress
abnorm
aortic
arch
congenit
correct
transposit
common
arteri
trunk
pulmonari
atresia
ventricular
septal
defect
condit
result
abnorm
locat
pulsatil
vessel
compress
major
airway
vascular
ring
trachea
esophagu
surround
vascular
structur
deriv
aorta
pulmonari
arteri
sling
rare
condit
left
pulmonari
arteri
aris
right
pulmonari
arteri
loop
back
lower
trachea
esophagu
congenit
absenc
pulmonari
valv
rare
condit
heterogen
present
sever
case
neonat
may
sever
pulmonari
regurgit
lead
grossli
dilat
pulmonari
vessel
compress
intrapulmonari
bronchi
due
increas
pulmonari
blood
flow
cardiac
failur
dilat
left
atrium
result
condit
caus
left
right
shunt
turn
compress
left
main
bronchu
left
lower
lobe
bronchu
consequ
also
seen
dilat
cardiomyopathi
dilat
left
ventricl
left
atrium
occur
post
cardiac
transplant
donor
larger
recipi
pulmonari
edema
pulmonari
edema
result
larg
left
right
shunt
also
condit
obstruct
pulmonari
venou
return
therefor
increas
pulmonari
venou
pressur
turn
increas
pressur
pulmonari
capillari
imbal
hydrostat
pressur
dictat
flow
water
across
alveolar
capillari
membran
result
accumul
water
pulmonari
interstitium
alveoli
physiolog
result
reduc
lung
complianc
impair
oxygen
transport
pulmonari
capillari
system
mani
children
patholog
also
engorg
peribronchi
vessel
show
bronchial
cuf
lung
imag
caus
compress
small
airway
cardiac
asthma
diuret
provid
effect
palliat
definit
therapi
possibl
condit
lead
reduc
pulmonari
blood
flow
fontan
circul
condit
produc
right
left
shunt
eg
arterioven
malform
tetralog
fallot
result
poor
match
total
volum
blood
pass
pulmonari
circul
reduc
pass
directli
caval
system
system
arteri
system
child
therefor
display
hypoxemia
either
without
mild
hypercarbia
fontan
procedur
commonest
situat
right
ventricl
bypass
absent
venou
blood
caval
system
directli
connect
pulmonari
arteri
case
volum
blood
pass
pulmonari
circul
normal
child
low
pressur
pulmonari
circul
depend
low
resist
mani
children
anatomi
develop
collater
system
venou
system
pulmonari
venou
system
lead
progress
cyanosi
anatomi
eg
pulmonari
valv
stenosi
system
arteri
pulmonari
arteri
collater
may
develop
mani
children
fontan
circul
pulmonari
hypoplasia
restrict
pattern
seen
lung
function
test
etiolog
fulli
understood
minor
children
fontan
circul
may
develop
plastic
bronchiti
particularli
fail
cardiac
function
condit
airway
becom
obstruct
mucoid
bronchial
cast
difficult
expector
may
grow
larg
enough
branch
pattern
manag
condit
challeng
mucolyt
agent
provid
littl
benefit
cardiac
transplant
immedi
cur
pulmonari
hypertens
pulmonari
arteri
hypertens
pah
defin
pulmonari
arteri
pressur
mmhg
rest
primari
term
idiopath
pulmonari
arteri
hypertens
ipah
secondari
cardiac
diseas
pulmonari
medic
manag
ipah
chang
dramat
last
decad
multipl
agent
avail
palli
relief
unfortun
disadvantag
none
cur
subject
eventu
proceed
lung
transplant
pah
secondari
cardiac
diseas
common
seen
adult
chd
patient
research
focus
sever
end
spectrum
also
known
eisenmeng
syndrom
pulmonari
arteri
pressur
suprasystem
lead
right
left
shunt
across
cardiac
commun
subsequ
hypoxemia
recent
attent
address
earlier
stage
diseas
particularli
investig
subject
prone
develop
secondari
pah
other
also
note
subject
respond
well
pah
therapi
trial
differ
combin
consid
primari
ciliari
dyskinesia
chd
increasingli
recogn
primari
ciliari
dyskinesia
pcd
result
situ
inversu
also
complex
organ
later
defect
includ
child
may
born
cardiac
isomer
dextrocardia
also
varieti
septal
defect
outflow
tract
abnorm
assum
embryon
nodal
cilia
base
embryon
node
play
role
establish
correct
organ
later
develop
embryo
genet
analysi
aspect
pcd
phenotyp
challeng
given
larg
number
gene
involv
howev
establish
genet
mutat
encod
outer
dynein
arm
inner
dynein
arm
protein
associ
chd
human
contrast
associ
found
mutat
encod
central
apparatu
radial
spike
protein
clinician
first
challeng
diagnosi
pulmonologist
care
child
pcd
must
low
threshold
detail
cardiac
evalu
cardiologist
care
child
known
chd
must
low
threshold
ciliari
studi
diagnosi
establish
treatment
chd
complet
standard
appropri
caution
children
bronchiectasi
abnorm
circul
cerebrospin
fluid
transplant
cardiac
diseas
pulmonari
hypertens
children
sever
ventricular
dysfunct
result
chd
cardiac
transplant
may
therapeut
long
term
surviv
follow
cardiac
transplant
children
excel
specif
challeng
children
chd
case
pulmonologist
may
ask
give
opinion
common
concern
relat
abnorm
vessel
anatomi
sometim
necessit
modifi
transplant
techniqu
previou
thorac
surgeri
hla
sensit
due
previou
transfus
presenc
system
pulmonari
collater
addit
children
pah
secondari
cardiac
diseas
pose
particular
challeng
current
consensu
pulmonari
vascular
resist
pvr
quantifi
right
heart
catheter
evalu
revers
pvr
measur
wood
unit
straightforward
cardiac
transplant
contraind
due
high
risk
right
heart
failur
previous
children
would
refer
transplant
shortag
donor
block
rel
poor
long
term
outcom
compar
cardiac
transplant
alon
result
center
advoc
cardiac
transplant
whilst
support
right
heart
right
ventricular
mechan
assist
devic
rvad
pre
post
transplant
result
encourag
pulmonari
hypertens
reced
pulmonari
blood
flow
normal
anoth
situat
pulmonologist
may
consult
children
fail
fontan
circul
mani
children
situat
protein
lose
enteropathi
also
may
plastic
bronchiti
term
protein
lose
bronchopathi
key
point
pulmonologist
contraind
transplant
multipl
report
condit
correct
rapidli
post
transplant
conclus
physiolog
heart
lung
close
intertwin
oblig
physician
alert
pulmonari
cardiac
diagnos
child
breathless
also
requir
pulmonologist
good
understand
impact
cardiac
diseas
upon
lung
upon
pulmonari
circul
close
commun
pulmonologist
cardiologist
essenti
refer
heali
f
b
hanna
r
zinman
pulmonari
complic
congenit
heart
diseas
paediatrrespirrev
rigbi
l
rosenth
cardiorespiratori
interact
paediatr
almost
alway
circul
stupid
paediatrrespirrev
gatzouli
beghetti
j
landzberg
n
gali
pulmonari
arteri
hypertens
associ
congenit
heart
diseas
recent
advanc
futur
direct
intjcardiol
harrison
j
j
shapiro
p
kennedi
congenit
heart
diseas
primari
ciliari
dyskinesia
paediatrrespirrev
houyel
l
n
leper
j
petit
r
roussin
ly
e
lebret
e
fadel
j
horer
hascoet
heart
transplant
adult
congenit
heart
diseas
archcardiovascdi
rossano
j
w
dipchand
l
b
edward
goldfarb
kucheryavaya
b
j
levvey
rn
l
h
lund
b
meiser
r
yusen
j
stehlik
registri
intern
societi
heart
lung
transplant
nineteenth
pediatr
heart
transplant
focu
theme
primari
diagnost
indic
transplant
jheart
lung
transplant
pulmonari
bleed
childhood
andrew
colin
correspond
inform
andrew
colin
md
univers
miami
batchelor
children
institut
depart
pediatr
divis
pediatr
pulmonolog
nw
ave
floor
miami
fl
email
acolin
medmiamiedu
phone
fax
comprehens
discuss
topic
lung
bleed
beyond
scope
present
previou
meet
cipp
updat
topic
offer
risk
repetit
updat
talk
present
focu
specif
clinic
etiolog
better
understand
natur
histori
idiopath
pulmonari
hemosiderosi
iph
use
flexibl
bronchoscopi
tool
improv
diagnosi
activ
intervent
pulmonari
bleed
definit
clinic
present
hemosiderosi
patholog
find
specif
diseas
etiolog
process
character
find
macrophag
hlm
alveolar
space
condit
may
variou
underli
primari
secondari
caus
episod
alveolar
hemorrhag
typic
present
triad
hemoptysi
anemia
diffus
radiolog
alveolar
infiltr
clinic
character
dyspnea
respiratori
distress
cough
vari
degre
hemoptysi
latter
frequent
absent
laboratori
featur
anemiaalveolar
often
fleet
opac
cxrin
advanc
stage
restrict
lung
diseas
becom
spirometr
featurepatholog
reveal
hlm
may
present
chronic
free
iron
pulmonari
tissu
subsequ
pulmonari
fibrosi
incid
caus
hemosiderosi
lung
bleed
rare
infanc
childhood
incid
vari
site
report
case
per
million
report
sweden
case
per
million
report
japan
low
incid
also
underli
pauciti
systemat
inform
causal
bleed
review
larg
referr
center
children
young
adult
report
cystic
fibrosi
cf
repres
congenit
heart
diseas
remain
infect
cf
neoplasm
caus
typic
classifi
idiopath
clinic
case
exemplifi
defin
caus
lung
bleed
discuss
present
includ
bleed
relat
cardiac
defect
case
cor
triatriatum
metabol
disord
exemplifi
syndrom
hemosiderosi
associ
celiac
diseas
syndrom
exemplifi
granulomatosi
polyangi
formerli
wegen
granulomatosi
classif
lung
bleed
readili
diagnos
relat
etiolog
describ
case
often
pose
signific
classif
challeng
systemat
approach
classif
dah
childhood
susarla
fan
separ
disord
without
pulmonari
capillar
one
without
cardiovascular
caus
disord
pulmonari
capillar
typic
carri
omin
prognosi
includ
idiopath
pulmonari
capillar
granulomatosi
polyangi
microscop
polyangi
system
lupu
erythematosu
goodpastur
syndrom
antiphospholipid
antibodi
syndrom
purpura
iga
nephropathi
polyarter
nodosa
behcet
syndrom
cryoglobulinemia
capillar
idiopath
syndrom
frequent
howev
attempt
defin
etiolog
fail
mani
hemorrhag
case
classifi
idiopath
pulmonari
hemosiderosi
iph
import
recogn
howev
iph
verit
diagnosi
includ
variabl
etiolog
still
requir
better
definit
recent
longitudin
french
studi
taytard
et
al
children
iph
gave
insight
featur
clinic
express
outcom
patient
expand
potenti
role
diseas
develop
also
contribut
point
rel
larg
number
patient
requir
immunosuppress
fail
univers
use
corticosteroid
studi
also
point
potenti
role
genet
factor
inde
recent
public
report
two
novel
missens
mutat
iron
transport
protein
transferrin
caus
hemosiderosi
athiyarath
et
al
definit
diagnosi
bleed
lung
patient
challeng
eventu
reli
bronchoscopi
detail
physic
examin
rang
subtl
tachypnea
dyspnea
variabl
crackl
wheez
pulmonari
hypertens
frank
respiratori
failur
fever
chest
discomfortpain
infrequ
observ
laboratori
work
beyond
anemia
suggest
radiograph
chang
rang
minim
infiltr
massiv
parenchym
involv
featur
separ
hemorrhag
process
infiltr
fleet
natur
howev
patient
small
frequent
episod
bleed
radiograph
may
reflect
chronic
diffus
interstiti
involv
chang
minim
acut
recurr
ct
scan
suggest
also
specif
mri
cite
offer
specif
presenc
blood
decreas
signal
imag
rare
recogn
radiologist
pulmonari
function
test
infrequ
avail
age
rang
discuss
howev
diffus
studi
dlco
may
result
unexpectedli
high
rapid
uptak
tracer
ga
hemoglobin
alveolar
space
acut
idiopath
pulmonari
hemorrhag
infanc
aiphi
center
diseas
control
cdc
classifi
aiph
nosolog
entiti
clinic
confirm
case
ill
previous
healthi
infant
age
year
gestat
age
week
histori
neonat
medic
problem
could
caus
pulmonari
hemorrhag
case
character
abrupt
onset
overt
bleed
evid
blood
airway
diffus
pulmonari
infiltr
chest
radiograph
diffus
alveolar
hemorrhag
dah
bronchoscopi
often
sever
present
lead
acut
respiratori
distress
failur
infantil
airway
bleed
uncommon
occurr
histor
emerg
cluster
greec
cleveland
massachusett
cleveland
outbreak
dearborn
et
al
mid
best
character
includ
case
aiph
mani
infant
came
geograph
area
male
sever
diseas
appear
benefici
affect
use
corticosteroid
reduc
high
mortal
recent
cluster
abl
find
five
infant
boston
area
mmwr
morb
mortal
wkli
rep
mortal
cluster
natur
present
appear
point
toward
common
underli
caus
bleed
inde
initi
associ
cleveland
seri
made
stachybotri
chartarum
atra
mold
may
found
home
ultim
associ
substanti
similarli
boston
seri
caus
assum
relat
underli
suscept
bleed
von
willebrand
diseas
vwd
ultim
propos
infant
underli
vulner
deem
underpin
bleed
would
precipit
injuri
lung
common
environment
caus
possibl
viral
infect
howev
sinc
direct
trigger
could
unifi
case
identifi
final
etiolog
identifi
public
emerg
seri
flexibl
bronchoscopi
pulmonari
hemorrhag
diagnosi
therapeut
intervent
flexibl
bronchoscopi
key
initi
diagnosi
identifi
sourc
bleed
lung
particular
defin
dah
latter
bronchoscopi
defin
bleed
absenc
overt
airway
bleed
bronchoalveolar
lavag
bal
result
persist
return
fluid
controversi
exist
role
repeat
bronchoscopi
defin
degre
bleed
howev
monitor
via
score
statu
bleed
therapeut
decis
wide
use
aiphi
seri
cleveland
wide
use
score
system
gold
score
finley
et
al
use
success
practic
use
flexibl
bronchoscopi
therapeut
intervent
bleed
limit
pediatr
practic
largest
report
seri
pediatr
patient
acut
pulmonari
hemorrhag
use
laser
bronchoscopi
laser
bronchoscopi
endoscop
balloon
occlus
lobe
main
bronchu
topic
airway
vasoconstrictor
endoscop
tumor
excis
recent
novel
bronchoscop
intervent
control
airway
bleed
dah
direct
instil
activ
recombin
factor
vii
rfviia
agent
previous
administ
system
control
recalcitr
bleed
lung
disappoint
result
howev
direct
instil
rfviia
airway
repeatedli
document
adult
children
group
report
case
reiter
et
al
recent
public
korea
report
case
park
kim
success
control
recalcitr
pulmonari
bleed
procedur
undertaken
intervent
last
resort
case
hemorrhag
visual
procedur
resolut
follow
treatment
immedi
unequivoc
definit
editori
follow
case
report
heslet
emphas
intervent
alveolu
constitut
key
advantag
direct
instil
advoc
earli
liber
use
intervent
dah
consid
remark
eas
efficaci
appar
absent
side
effect
prognosi
limit
inform
outcom
pulmonari
hemosiderosi
older
studi
suggest
overal
prognosi
may
favor
idiopath
case
howev
recent
larg
multicent
french
studi
promis
satisfactori
respiratori
outcom
patient
median
yr
taytard
et
al
clearli
case
requir
care
appropri
treatment
consist
corticosteroid
often
immunosuppress
therapi
importantli
case
dah
may
declar
later
life
autoimmun
diseas
infant
popul
aiph
discuss
like
reflect
differ
subclass
within
idiopath
group
individu
recurr
bleed
mortal
report
infect
diseas
mycobacteria
malena
pediatr
pulmonari
unit
univers
medic
center
jerusalem
israel
email
malena
hadassahorgil
dramat
increas
last
three
decad
total
number
mycobacteria
ntm
speci
mani
clinic
signific
chang
attribut
part
improv
cultur
techniqu
coupl
greater
diseas
awar
true
increas
diseas
preval
organ
ubiquit
readili
recov
environment
sourc
soil
water
plant
anim
ntm
may
caus
asymptomat
infect
symptomat
diseas
human
factor
predispos
infect
like
due
interact
host
defens
mechan
load
clinic
exposur
histor
differ
classif
system
propos
ntm
commonli
classifi
growth
slowli
grow
rapidli
grow
common
clinic
manifest
ntm
diseas
lung
diseas
lymphat
skinsoft
tissu
dissemin
diseas
also
diagnost
criteria
ntm
lung
diseas
accord
offici
atsidsa
statement
includ
typic
find
chest
radiograph
chest
comput
tomographi
hrct
scan
sputum
specimen
bacilli
analysi
exclus
disord
tuberculosi
lung
diseas
due
ntm
occur
commonli
patient
alreadi
structur
lung
diseas
chronic
obstruct
pulmonari
diseas
copd
bronchiectasi
cystic
fibrosi
cf
pneumoconiosi
prior
tb
pulmonari
alveolar
proteinosi
esophag
motil
disord
patient
await
undergon
lung
preval
ntm
isol
sputum
within
cf
popul
rise
due
increas
surviv
better
ntm
recognit
underli
structur
airway
diseas
alter
mucociliari
clearanc
may
predispos
factor
impact
ntm
posit
clinic
cours
cf
evalu
sever
studi
still
remain
nosocomi
spread
ntm
infect
cf
previous
consid
unlik
howev
recent
report
reveal
frequent
speci
diversif
ntm
within
cf
popul
appear
vari
geograph
distribut
unit
state
mycobacterium
avium
complex
mac
slow
grow
ntm
frequent
recogn
pulmonari
pathogen
europ
countri
howev
mycobacterium
abscessu
appear
major
pathogen
relationship
ntm
infect
aspergillu
infect
without
abpa
found
might
associ
specif
immun
dysregul
involv
subgroup
cf
addit
corticosteroid
itraconazol
treatment
also
found
associ
increas
incid
ntm
cf
treatment
ntm
pulmonari
diseas
least
month
involv
multipl
antibiot
patient
ntm
isol
may
meet
at
criteria
diseas
requir
close
monitor
clinic
statu
serial
ct
scan
sputumbronchoalveolar
lavag
surveil
research
requir
improv
identif
ntm
cf
respiratori
sampl
understand
pathophysiolog
ntm
infect
within
cf
lung
develop
effect
drug
regimen
pulmonari
diseas
refer
obrien
rj
geiter
lj
snider
de
epidemiolog
nontubercul
mycobacteri
diseas
unit
state
result
nation
survey
rev
respir
di
olivi
kn
weber
dj
wallac
rj
jr
faiz
ar
lee
jh
zhang
ba
handler
wilson
rw
schechter
ms
et
al
nontubercul
mycobacteria
cystic
fibrosi
studi
group
nontubercul
mycobacteria
multicent
preval
studi
cystic
fibrosi
j
respir
crit
care
med
griffith
de
girard
wm
wallac
rj
jr
clinic
featur
pulmonari
diseas
caus
rapidli
grow
mycobacteria
analysi
patient
rev
respir
di
esther
cr
henri
mm
molina
pl
leigh
mw
nontubercul
mycobacteri
infect
young
children
cystic
fibrosi
pediatr
pulmonol
qvist
waldmann
e
olesen
hv
hansen
cr
mathiesen
ih
et
al
compar
harm
effect
nontubercul
mycobacteria
gram
neg
bacteria
lung
function
patient
cystic
fibrosi
j
cyst
fibro
caval
quitteri
reynaud
romain
bricca
durupt
philipp
reix
mari
percev
de
montclo
lina
isabel
durieu
high
incid
cultur
among
adolesc
cystic
fibrosi
j
cyst
fibro
feb
pii
doi
epub
ahead
print
bryant
jm
grogono
dm
greav
fowerak
j
roddick
inn
et
al
sequenc
identifi
transmiss
mycobacterium
abscessu
patient
cystic
fibrosi
retrospect
cohort
studi
lancet
mussaffi
h
prai
steuer
g
stafler
p
hananya
blau
h
increas
nontubercul
mycobacteria
infect
cystic
fibrosi
journal
cystic
fibrosi
roux
al
catherinot
e
ripol
f
soismier
n
machera
e
ravilli
et
al
multicent
studi
preval
nontubercul
mycobacteria
patient
cystic
fibrosi
franc
j
clin
microbiol
mussaffi
h
rivlin
j
shalit
ephro
blau
h
nontubercul
mycobacteria
cystic
fibrosi
associ
allerg
bronchopulmonari
aspergillosi
steroid
therapi
eur
respir
j
protract
bacteri
bronchiti
chronic
wet
cough
petr
pohunek
tamara
correspond
inform
petr
pohunek
pediatr
pulmonolog
pediatr
depart
faculti
medicin
univers
hospit
motol
pragu
czech
republ
email
petrpohunek
lfmotolcunicz
introduct
protract
bacteri
bronchiti
pbb
defin
condit
isol
wet
cough
last
four
week
evid
specif
caus
cough
resolv
fulli
prolong
antibiot
consid
rather
benign
condit
properli
treat
may
advanc
chronic
suppur
lung
diseas
csld
affect
mainli
younger
children
half
patient
age
year
one
third
year
old
older
year
etiolog
lead
pathogen
involv
pbb
nontyp
haemophilu
influenza
approx
follow
streptococcu
pneumonia
moraxella
catarrhali
approx
combin
pathogen
infect
pseudomona
aeruginosa
resist
pathogen
occur
simpl
pbb
found
child
chronic
cough
search
underli
etiolog
undertaken
eg
cystic
fibrosi
primari
ciliari
dyskinesia
immunodefici
risk
factor
main
risk
factor
protract
bacteri
bronchiti
reduc
mucociliari
clearanc
viral
respiratori
infect
lack
reconvalesc
viral
bronchiti
may
lead
impair
airway
clearanc
secondari
ciliari
dyskinesia
persist
bronchial
inflamm
facilit
secondari
bacteri
infect
airway
stabil
disord
tracheobronchomalacia
detect
children
pbb
often
gener
popul
one
studi
evalu
children
pbb
age
month
author
found
laryngomalacia
tracheomalacia
anoth
studi
found
tracheomalacia
young
children
far
malacia
caus
factor
extent
instabl
airway
may
secondari
prolong
infect
protract
cough
remain
studi
immunodefici
disord
humor
immun
associ
insuffici
protect
may
facilit
bacteri
growth
airway
environment
burden
import
environment
risk
develop
pbb
environment
tobacco
smoke
et
mani
countri
frequenc
smoke
famili
children
high
local
heat
use
wood
coal
describ
signific
risk
factor
pediatr
industri
pollut
industri
pollut
shown
risk
factor
respiratori
infect
children
import
part
industri
emiss
small
particl
particul
matter
whose
concentr
may
rise
local
advers
climat
condit
correl
exposur
increas
respiratori
symptom
repeatedli
pathogenesi
pbb
usual
develop
consequ
insult
impair
airway
defens
risk
factor
may
start
gradual
base
continu
damag
mucosa
eg
recurr
aspir
environment
trigger
ger
appar
initi
acut
event
high
enzymat
activ
neutrophil
enhanc
process
studi
fraction
neutrophil
bal
high
bacteri
infect
retent
mucu
high
proteolyt
activ
neutrophil
lead
csld
damag
bronchial
wall
gradual
develop
bronchiectasi
diagnos
earli
process
interrupt
antibiot
treatment
even
develop
mild
bronchiectasi
revers
pathogen
interfer
defens
mechan
form
biofilm
cleav
immunoglobulin
clinic
present
main
symptom
bacteri
bronchiti
wet
cough
without
sputum
product
wet
sound
cough
suggest
intrabronchi
secret
variou
qualiti
consist
abil
produc
sputum
age
train
depend
infant
young
children
abl
spit
sputum
howev
success
train
physiotherapist
earli
third
year
life
cough
usual
present
day
night
often
pronounc
morn
secret
accumul
overnight
cough
may
worsen
physic
exercis
occasion
patient
may
wheez
base
obstruct
mucu
transient
variabl
chang
cough
recurr
wheez
may
signal
bronchial
hyperrespons
rais
suspicion
asthma
pbb
fever
gener
absent
infect
limit
bronchial
tree
lead
system
inflammatori
respons
fever
elev
acut
phase
protein
associ
acut
exacerb
sever
affect
lung
parenchyma
pneumonia
diagnosi
children
protract
wet
cough
diagnos
earli
gener
practic
gener
practition
detect
analyz
symptom
differenti
blood
count
crp
erythrocyt
sediment
rate
belong
standard
investig
gp
also
trace
possibl
environment
risk
smoke
local
heat
local
risk
household
detail
investig
import
mainli
children
recurr
pbb
chest
sweat
test
assess
clinic
risk
primari
ciliari
dyskinesia
help
exclud
sever
underli
condit
cooper
children
pulmonari
function
test
loop
done
revers
test
use
inhal
rapid
act
agonist
child
abl
produc
sputum
sampl
sent
cultur
microscop
evalu
antibiot
would
administ
treat
child
stop
antibiot
least
hour
may
increas
yield
analysi
child
deep
suction
hypopharynx
morn
physiotherapi
may
help
effect
method
microbiolog
sampl
bronchoscopi
indic
children
singl
episod
pbb
even
children
recurr
pbb
usual
necessari
expector
suffici
howev
bronchoscopi
may
exclud
underli
patholog
flexibl
bronchoscopi
perform
spontan
breath
allow
visual
assess
airway
anatomi
exclud
aspir
foreign
bodi
also
help
assess
mucos
inflamm
observ
stabil
airway
breath
cough
perform
bronchial
toilett
remov
mucu
plug
directli
sampl
mucu
addit
standard
bronchoalveolar
lavag
perform
specimen
sent
microbiolog
differenti
cytolog
stain
macrophag
anaerob
mycot
cultur
also
consid
addit
examin
must
includ
detail
ent
assess
exclud
focal
infect
upper
airway
area
adenoid
sinus
immunolog
test
mainli
check
humor
immun
includ
concentr
vaccin
specif
antibodi
total
serum
ige
allerg
sensit
test
context
symptom
histori
develop
bronchiectasi
suspect
diagnost
method
choic
high
resolut
computer
tomographi
hrct
treatment
prognosi
uncompl
pbb
easili
treat
howev
untreat
persist
bacteri
infect
accompani
inflamm
associ
risk
develop
csld
bronchiectasi
antibiot
treatment
base
expect
confirm
microbi
etiolog
mostli
broad
spectrum
antibiot
target
hemophillu
spp
pneumococcu
moraxella
use
product
penicillinas
respect
select
antibiot
uncompl
pbb
resolv
two
week
cours
appropri
antibiot
also
shown
random
control
trial
analyz
cours
placebo
children
activ
arm
show
significantli
higher
resolut
rate
children
placebo
good
effect
antibiot
confirm
also
systemat
even
though
consist
data
effect
physiotherapi
pbb
use
use
least
basic
techniqu
airway
clearanc
techniqu
especi
young
children
even
though
antibiot
usual
effect
relaps
occur
case
good
effect
repeat
antibiot
child
high
frequenc
recurr
prolong
cours
antibiot
may
consid
underli
condit
found
critic
treat
patholog
togeth
treatment
bronchiti
conclus
protract
bacteri
bronchiti
condit
suspect
children
protract
wet
cough
quick
diagnosi
earli
initi
proper
treatment
lead
complet
resolut
prevent
sever
sequela
chronic
suppur
lung
diseas
bronchiectasi
refer
chang
ab
red
gj
everard
ml
chronic
wet
cough
protract
bronchiti
chronic
suppur
lung
diseas
bronchiectasi
pediatr
pulmonol
chang
ab
byrn
ca
everard
ml
diagnos
prevent
chronic
suppur
lung
diseas
csld
bronchiectasi
paediatr
respir
rev
kompar
weinberg
protract
bacteri
bronchiti
young
children
associ
airway
malacia
j
pediatr
zgherea
pagala
mendiratta
marcu
mg
shelov
sp
kazachkov
bronchoscop
find
children
chronic
wet
cough
pediatr
qian
z
q
kong
l
xu
f
wei
f
chapman
rs
chen
w
edward
rd
bascom
r
respiratori
respons
divers
indoor
combust
air
pollut
sourc
indoor
air
hoek
g
pattenden
willer
antova
fabianova
e
c
forastier
f
gehr
u
h
grize
l
et
al
children
respiratori
symptom
lung
function
pati
studi
eur
respir
j
marchant
j
master
ib
champion
petski
h
chang
ab
randomis
control
trial
amoxycillin
clavulan
children
chronic
wet
cough
thorax
biali
l
domino
fj
chang
ab
thomson
becker
l
cochran
librari
chronic
cough
children
umbrella
review
child
heal
cochran
rev
j
complic
pneumonia
differ
type
clinic
cours
outcom
eitan
kerem
depart
pediatr
cf
center
hadassah
univers
hospit
jerusalem
israel
email
ek
mailhujiacil
pneumonia
cap
lead
caus
morbid
mortal
especi
children
year
age
complic
associ
pneumococc
pneumonia
includ
develop
pleural
effus
pleural
empyema
necrot
pneumonia
lung
abscess
increas
incid
pleural
empyema
report
mani
studi
unit
state
europ
although
incid
invas
pneumococc
diseas
decreas
sinc
use
pneumococc
conjug
vaccin
pcv
develop
countri
seen
emerg
empyema
necrot
pneumonia
episod
caus
nonvaccin
serotyp
rate
pleural
empyema
steadili
rose
per
million
pediatr
hospit
admiss
uk
preval
parapneumon
empyema
shown
increas
amongst
pneumonia
case
caus
pneumonia
eight
american
hospit
case
pleural
empyema
occur
pediatr
hospit
cincinnati
case
caus
pneumonia
studi
jerusalem
found
incid
empyema
necrot
pneumonia
doubl
year
almost
case
caus
pneumonia
seventi
percent
case
occur
age
year
mani
author
also
report
increas
lung
abscess
cavit
reason
increas
preval
suppur
complic
children
pneumonia
clearli
identifi
suppur
complic
associ
age
recent
chicken
pox
infect
pneumonia
especi
serotyp
therapi
antibiot
drug
nsaid
prior
hospit
admiss
accumul
fluid
pleural
space
may
follow
develop
pneumonia
mani
children
success
manag
may
either
repres
parapneumon
effus
contamin
leukocyt
fibrin
form
empyema
crucial
compon
overal
care
patient
controversi
exist
regard
appropri
manag
strategi
empyema
complic
parapneumon
effus
children
current
option
includ
primari
chest
tube
placement
either
open
radiolog
guidanc
thoracoscop
surgeri
vat
remov
pleural
fluid
exud
primari
chest
tube
drainag
may
favor
clinician
perceiv
advantag
radiograph
drainag
local
fluid
collect
avoid
gener
anesthesia
smaller
thoracostomi
tube
use
howev
fibrin
pleural
fluid
set
empyema
often
clog
small
drain
result
inadequ
drainag
intrapleur
administr
fibrinolyt
may
augment
drainag
although
measur
help
case
open
placement
may
lead
suboptim
placement
tip
tube
shortcom
led
use
primari
drainag
pleural
space
pediatr
patient
empyema
parapneumon
effus
approach
offer
potenti
better
lung
expans
remov
pleural
debri
exud
excel
magnifi
vision
optim
locat
chest
tube
reduc
chest
wall
muscl
trauma
compar
tradit
thoracotomi
necrot
pneumonia
also
term
massiv
pulmonari
gangren
sequela
pneumonia
lung
tissu
becom
necrot
recent
attent
focus
pneumonia
major
caus
agent
children
limit
intervent
prognosi
good
surgic
intervent
may
lead
bronchopleur
fistula
prolong
cours
sever
case
death
associ
vat
report
manag
children
pneumonia
gener
base
age
patient
clinic
present
initi
antibacteri
therapi
cap
usual
empir
cultur
antibacteri
sensit
test
result
rare
avail
initi
diagnosi
agent
select
empir
therapi
good
activ
pathogen
commonli
associ
cap
favor
toler
profil
administ
simpl
dosag
regimen
good
complianc
pneumonia
common
bacteri
caus
pneumonia
associ
complic
current
guidelin
antibacteri
cam
recommend
initi
treatment
direct
erad
microorgan
antibiot
advoc
first
instanc
inappropri
use
antibiot
result
treatment
failur
advers
drug
reaction
contribut
emerg
pathogen
resist
consider
drug
pharmacodynam
pharmacokinet
properti
also
import
agent
low
maximum
plasma
tissu
concentr
long
may
like
expos
bacteria
concentr
strategi
administr
also
import
low
dose
long
treatment
durat
risk
factor
carriag
pneumococci
penicillin
wherea
therapi
minim
risk
conveni
toler
also
essenti
consider
pediatr
pneumonia
oral
amoxicillin
antibacteri
choic
low
failur
rate
report
random
control
trial
children
develop
develop
countri
show
previous
well
children
oral
amoxicillin
iv
benzyl
penicillin
equival
efficaci
treatment
pneumonia
success
cure
children
cap
pneumococc
isol
suscept
penicillin
cephalosporin
well
describ
vitro
rate
report
worldwid
surveil
signific
geograph
variat
high
rate
spain
franc
part
southeast
asia
usa
furthermor
macrolid
resist
also
problem
commun
main
mechan
resist
via
alter
protein
overcom
achiev
adequ
local
drug
level
ie
decreas
sensit
rather
absolut
resist
yet
evid
clinic
treatment
failur
infect
outsid
central
nervou
system
use
penicillin
sinc
pneumococci
remain
sensit
antibacteri
amoxicillin
penicillin
remain
antibiot
choic
pneumococc
pneumonia
emerg
spread
resist
commonli
use
antibiot
challeng
manag
cap
multipl
set
cap
guidelin
publish
address
continu
chang
complex
diseas
sever
ill
children
tradit
treat
parenter
antibacteri
shown
penicillin
resist
pneumococci
associ
sever
diseas
shown
penicillin
resist
factor
outcom
invas
pneumonia
pneumonia
pneumococc
macrolid
resist
mediat
via
alter
ribosom
bind
site
therebi
prevent
bind
subsequ
inhibit
bacteri
protein
synthesi
second
mechan
via
presenc
efflux
pump
antibiot
often
associ
penicillin
rate
usag
resist
newer
macrolid
substanti
increas
recent
time
vari
geograph
region
report
treatment
failur
pneumococc
diseas
use
macrolid
alon
thu
approach
recommend
parenter
therapi
requir
pneumococcu
like
pathogen
benzylpenicillin
aminopenicillin
use
agent
addit
benefit
sever
unwel
toxic
child
without
effus
rarer
pathogen
possibl
rare
scenario
high
pneumococc
penicillin
resist
mean
inhibitori
concentr
mgl
therapi
includ
cephalosporin
eg
ceftriaxon
macrolid
atyp
agent
potenti
pathogen
eg
oxacillin
vancomycin
staphylococcu
aureu
mrsa
infect
like
howev
treat
children
cam
antibiot
may
chang
micrflora
pneumonia
caus
bacteria
increas
rate
infect
less
common
resist
microorgan
viral
bronchiol
children
oliviero
sacco
antonino
capizzi
roberta
olces
donata
girosi
giovanni
rossi
depart
pediatr
pulmonari
allergi
diseas
unit
cystic
fibrosi
center
istituto
g
gaslini
institut
genoa
itali
email
giovannirossi
gasliniorg
introduct
bronchiol
first
common
acut
lower
respiratori
tract
viral
infect
infant
less
month
age
lead
caus
hospit
age
group
although
children
mild
symptom
infant
month
old
hospit
diagnosi
bronchiol
usa
account
hospit
annual
extrem
elev
hospit
charg
care
relat
disord
addit
hospit
infant
requir
admiss
intens
care
unit
impair
gener
condit
recurr
apnea
episod
respiratori
failur
requir
mechan
ventil
bronchiol
also
associ
disproportion
number
death
among
children
younger
year
age
nation
number
much
lower
industri
countri
death
bronchiol
show
incid
nine
time
higher
influenza
viru
infect
larg
epidemiolog
studi
also
demonstr
clear
relationship
bronchiol
earli
infanc
subsequ
bronchial
hyperreact
childhood
adulthood
viral
also
host
factor
establish
magnitud
structur
function
damag
respiratori
structur
ultim
extent
sever
durat
first
infect
later
consequ
etiolog
bronchiol
pathogen
frequent
caus
bronchiol
infant
respiratori
syncyti
viru
rsv
follow
human
rhinoviru
hrv
respiratori
virus
metapneumoviru
mpv
human
bocaviru
hbov
enteroviru
ev
adenoviru
adv
influenza
viru
iv
human
coronaviru
hcov
parainfluenza
viru
piv
also
implic
bacteri
rare
describ
infant
bronchiol
except
hrv
infect
peak
spring
fall
epidemiolog
report
shown
gener
season
bronchiol
epidem
peak
decemb
march
everi
year
differ
clinic
present
bronchiol
due
variou
virus
report
exampl
shown
bronchiol
may
result
shorter
hospit
length
bronchiol
attribut
rsv
consist
rsv
infect
seem
caus
sever
diseas
addit
one
constant
characterist
infant
hospit
bronchiol
tendenc
younger
hospit
virus
final
although
differ
respons
medic
intervent
identifi
consist
suggest
infant
hospit
hrv
rsv
may
distinct
respons
therapi
treatment
system
corticosteroid
seem
like
reduc
recurr
wheez
infant
rv
bronchiol
oppos
rsv
bronchiol
differ
probabl
reflect
involv
differ
pathogenet
mechan
risk
factor
sever
rsv
bronchiol
number
risk
factor
sever
rsv
bronchiol
identifi
varieti
epidemiolog
studi
immatur
innat
acquir
immun
respons
incomplet
develop
respiratori
system
surpris
risk
factor
includ
prematur
low
birth
weight
young
chronolog
age
environment
factor
also
rais
risk
hospit
admiss
rate
number
sibl
live
perman
child
household
day
care
attend
tobacco
smoke
exposur
risk
factor
male
gender
presenc
chronic
pulmonari
diseas
infanc
congenit
heart
diseas
structur
function
airway
abnorm
neuromuscular
syndrom
immunodefici
cystic
fibrosi
syndrom
howev
epidemiolog
data
show
vast
major
infant
hospit
condit
belong
risk
group
suggest
viral
host
factor
includ
classic
risk
factor
may
account
diseas
sever
play
put
role
magnitud
subsequ
respiratori
morbid
bronchiol
recurr
wheez
later
life
infect
induc
sever
respiratori
symptom
almost
exclus
young
children
patient
infant
bronchiol
symptom
sever
enough
warrant
hospit
increas
risk
develop
recurr
wheez
asthma
childhood
also
adult
life
mechan
explain
higher
incid
wheez
sever
bronchiol
unclear
sinc
known
whether
viral
bronchiol
simpli
identifi
infant
increas
risk
subsequ
wheez
inform
come
rsv
hrv
infect
besid
direct
cytopath
effect
local
host
inflammatori
respons
rsv
play
primari
role
develop
sign
symptom
character
diseas
combin
effect
viru
inflammatori
respons
lead
epitheli
damag
slough
epithelium
mucu
product
ultim
airway
obstruct
inde
infant
sever
diseas
cytopath
effect
induc
rsv
amplifi
presenc
potent
inflammatori
reaction
mediat
activ
polymorphonuclear
leukocyt
natur
killer
cell
first
innat
respons
associ
defect
host
adapt
immun
respons
character
reaction
lead
ineffici
stimul
cytotox
ineffect
clear
viru
poorli
stimul
macrophag
phagocyt
activ
endors
dead
cell
clearanc
persist
airway
hyperreact
rsv
infect
may
relat
least
part
abnorm
neural
control
airway
smooth
muscl
tone
induc
rsv
upregul
nerv
growth
factor
ngf
trka
neurokinin
receptor
function
promot
acetylcholin
releas
signal
molecul
induc
product
neurokinin
substanc
p
mediat
involv
pathogenesi
neurogen
inflamm
bronchomotor
tone
addit
persist
latent
viral
infect
site
bone
marrow
cell
could
maintain
constant
stimul
immun
system
explain
respiratori
sequela
bronchiol
contrast
rsv
hrv
affect
peopl
age
induc
minim
airway
cell
cytotox
cytopath
effect
airway
structur
inflammatori
cell
associ
inflammatori
reaction
releas
mediat
lead
predispos
individu
recurr
persist
bronchial
hyperreact
current
hypothesi
hrv
infect
may
favor
allerg
sensit
bia
characterist
immun
respons
allergen
atop
individu
may
modifi
host
antimicrobi
defens
thu
attenu
abil
fight
viral
infect
via
immun
deviat
addit
releas
cytokin
chemokin
could
result
amplif
inflammatori
respons
infect
present
cold
asthma
exacerb
compar
children
rsv
infect
hrv
infect
present
often
atop
dermat
blood
eosinophilia
acut
viral
infect
causal
role
allerg
sensit
favor
sever
ill
support
demonstr
allerg
sensit
may
preced
wheez
may
lead
increas
risk
wheez
ill
caus
hrv
rsv
thu
rsv
seem
act
induc
subsequ
airway
hyperreact
first
infect
character
extens
airway
damag
induct
neurogen
inflamm
latter
possibl
respons
bronchial
hyperreact
contrast
hrv
seem
act
trigger
induc
extens
releas
mediat
lead
recurr
persist
bronchial
hyperreact
allerg
patient
individu
predispos
atop
sensit
manag
bronchiol
infant
prevent
bronchiol
includ
environment
prophylaxi
decreas
transmiss
respiratori
infect
b
pharmacolog
prophylaxi
specif
rsv
bronchiol
administr
human
monoclon
antibodi
palivizumab
epidem
season
particular
risk
categori
despit
decad
research
licens
rsv
vaccin
effect
therapeut
agent
market
current
larg
number
candid
evalu
preclin
phase
undergo
clinic
trial
still
controversi
regard
best
therapeut
approach
bronchiol
support
treatment
approach
recommend
recent
intern
guidelin
reli
mainli
oxygen
therapi
hydrat
develop
tool
manag
rsv
infect
recent
larg
focus
three
major
target
area
viral
entri
machineri
viral
complex
viral
compon
assembl
mani
rsv
inhibitor
describ
recent
year
none
complet
phase
clinic
trial
conclus
comprehens
knowledg
bronchiol
pathogenesi
induc
differ
virus
interact
host
defens
hope
allow
produc
newli
design
effect
vaccin
antivir
therapi
prevent
control
infect
major
respiratori
pathogen
refer
meissner
hc
viral
bronchiol
children
n
engl
j
med
nicolai
ferrara
schiavariello
c
gentil
f
grand
alessandroni
c
midulla
f
viral
bronchiol
children
common
condit
therapeut
option
earli
hum
dev
suppl
eugenio
baraldi
marcello
lanari
paolo
manzoni
giovanni
rossi
silvia
vandini
alessandro
rimini
costantino
romagnoli
pierluigi
colonna
andrea
biondi
paolo
biban
giampietro
chiamenti
roberto
bernardini
marina
picca
marco
cappa
giusepp
carlo
catassi
antonio
francesco
urbino
luigi
memo
gianpaolo
donzelli
carlo
minetti
francesco
paravati
giusepp
di
mauro
filippo
festini
susanna
esposito
giovanni
corsello
consensu
document
treatment
prevent
bronchiol
newborn
infant
ital
j
pediatr
singh
moor
pe
gern
je
lemansk
rf
jr
hartert
tv
bronchiol
asthma
review
call
studi
interact
asthma
causat
ajrccm
rossi
ga
colin
aa
infantil
respiratori
syncyti
viru
human
rhinoviru
infect
respect
role
incept
persist
wheez
eur
respir
j
jartti
korppi
bronchiol
asthma
develop
pediatr
allergi
immunol
piedimont
g
neural
mechan
respiratori
syncyti
inflamm
prevent
respiratori
syncyti
viru
sequela
j
respir
crit
care
med
jackson
dj
evan
md
gangnon
tisler
cj
pappa
te
lee
wm
gern
je
lemansk
rf
jr
evid
causal
relationship
allerg
sensit
rhinoviru
wheez
earli
life
j
respir
crit
care
med
american
academi
pediatr
committe
infecti
diseas
american
academi
pediatr
bronchiol
guid
line
committe
updat
guidanc
palivizumab
prophylaxi
among
infant
young
children
increas
risk
hospit
respiratori
syncyti
viru
infect
pediatr
esposito
pietro
gd
respiratori
syncyti
viru
vaccin
updat
immedi
pipelin
futur
microbiol
drakenstein
child
health
studi
new
insight
childhood
pneumonia
heather
j
zar
depart
paediatr
child
health
red
cross
war
memori
children
hospit
mrc
unit
child
adolesc
health
univers
cape
town
cape
town
south
africa
correspond
heatherzar
uctacza
childhood
pneumonia
predomin
caus
death
ill
children
year
outsid
neonat
asthma
commonest
diseas
children
occur
approxim
adolesc
although
africa
childhood
popul
constitut
around
global
childhood
popul
incid
childhood
pneumonia
death
disproportion
high
account
almost
death
preval
asthma
african
adolesc
higher
report
global
impact
earli
respiratori
ill
child
health
well
studi
african
children
despit
high
preval
risk
factor
sever
diseas
high
incid
drakenstein
child
health
studi
uniqu
multidisciplinari
south
african
birth
cohort
investig
impact
antenat
earli
life
exposur
child
health
core
focu
studi
incid
risk
factor
etiolog
long
term
impact
earli
lower
respiratori
tract
infect
lrti
pneumonia
child
studi
investig
role
interact
potenti
risk
factor
cover
area
environment
infecti
nutrit
genet
psychosoci
matern
immunolog
risk
factor
may
impact
child
method
pregnant
women
poor
commun
south
africa
high
exposur
infecti
diseas
environment
risk
factor
enrol
second
trimest
clinic
tc
newman
serv
mix
ancestri
popul
mbekweni
serv
black
african
popul
women
follow
pregnanc
child
birth
paarl
hospit
pair
follow
children
least
year
biomed
environment
psychosoci
demograph
risk
factor
longitudin
measur
environment
exposur
carbon
monoxid
particul
matter
dust
microbiom
volatil
organ
compound
measur
use
monitor
place
home
tobacco
smoke
exposur
investig
use
urin
cotinin
measur
children
synchron
routin
primari
care
visit
studi
visit
conduct
paarl
hospit
tc
newman
mbekweni
clinic
provid
strong
primari
health
care
program
includ
strong
hiv
prevent
treatment
program
nation
immun
program
includ
pneumococc
conjug
vaccin
given
week
month
activ
surveil
pneumonia
done
microbiolog
investig
includ
multiplex
pcr
perform
longitudin
nasopharyng
specimen
pneumonia
episod
lung
function
tidal
breath
measur
multipl
breath
washout
test
tidal
exhal
nitric
oxid
respiratori
function
use
forc
oscil
techniqu
fot
measur
children
week
annual
lrti
result
pair
enrol
children
complet
year
child
year
accru
high
cohort
retent
popul
poor
mbekweni
popul
rel
poorer
tc
newman
mostli
singl
mother
mother
rate
tobacco
smoke
exposur
high
approxim
third
pregnant
women
activ
birth
neonat
cotinin
level
indic
exposur
level
activ
immun
coverag
epi
schedul
includ
pneumococc
conjug
vaccin
given
week
month
feb
pneumonia
case
ambulatori
hospit
pneumonia
incid
episod
per
child
year
eci
highest
incid
occur
children
month
age
use
case
control
analysi
rsv
influenza
viru
b
pertussi
strongli
associ
pneumonia
bocaviru
parainfluenza
viru
adenoviru
cmv
less
strongli
associ
rsv
commonest
pathogen
identifi
occur
case
howev
sever
organ
identifi
time
lrti
median
organ
detect
np
swab
longitudin
analysi
np
specimen
show
high
rate
carriag
pneumonia
cattarrhali
aureu
well
sever
potenti
organ
interact
month
prior
pneumonia
lung
function
show
track
first
year
life
lrti
infanc
impair
lung
function
year
pneumonia
case
fatal
rate
conclus
pneumonia
common
cohort
despit
high
rate
immun
rsv
predomin
pathogen
sever
pathogen
occur
concurr
dysbiosi
np
microbiom
preced
develop
pneumonia
earli
life
lrti
impact
lung
health
reduc
lung
function
infanc
earli
life
exposur
may
predispos
acut
lrti
result
long
term
chronic
diseas
life
cours
new
intervent
need
prevent
earli
life
lrti
promot
long
term
health
refer
global
burden
diseas
pediatr
c
kyu
hh
pinho
c
et
al
global
nation
burden
diseas
injuri
among
children
adolesc
find
global
burden
diseas
studi
jama
pediatr
liu
l
oza
hogan
et
al
global
region
nation
caus
child
mortal
project
inform
prioriti
updat
systemat
analysi
lancet
pearc
n
n
beasley
r
et
al
worldwid
trend
preval
asthma
symptom
phase
iii
intern
studi
asthma
allergi
childhood
isaac
thorax
n
odhiambo
j
pearc
n
et
al
preval
symptom
asthma
rhiniti
eczema
children
africa
intern
studi
asthma
allergi
childhood
phase
iii
allergi
zar
hj
ferkol
tw
global
burden
respiratori
child
health
pediatr
pulmonolog
zar
hj
barnett
w
myer
l
stein
dj
nicol
mp
investig
determin
ill
africa
drakenstein
child
health
studi
thorax
stein
dj
koen
n
donald
ka
et
al
investig
psychosoci
determin
child
health
africa
drakenstein
child
health
studi
journal
neurosci
method
zar
hj
barnett
w
myer
l
nicol
mp
childhood
pneumonia
drakenstein
child
health
studi
south
african
medic
journal
tydskrif
vir
geneeskund
vanker
barnett
w
nduru
pm
gie
rp
sli
pd
zar
hj
home
environ
indoor
air
pollut
exposur
african
birth
cohort
studi
scienc
total
environ
gray
willems
l
visagi
et
al
lung
function
exhal
nitric
oxid
healthi
unsed
african
infant
respirolog
vanker
barnett
w
brittain
k
et
al
antenat
earli
life
tobacco
smoke
exposur
african
birth
cohort
studi
intern
journal
tuberculosi
lung
diseas
offici
journal
intern
union
tuberculosi
lung
diseas
le
roux
dm
myer
l
nicol
mp
zar
hj
incid
sever
childhood
pneumonia
first
year
life
south
african
birth
cohort
drakenstein
child
health
studi
lancet
global
health
zar
hj
barnett
w
stadler
myer
l
nicol
mp
aetiolog
childhood
pneumonia
well
vaccin
south
african
birth
cohort
nest
studi
drakenstein
child
health
studi
lancet
respiratori
medicin
gray
dm
turkov
l
willems
l
et
al
lung
function
african
infant
drakenstein
child
health
studi
impact
lower
respiratori
tract
ill
american
journal
respiratori
critic
care
medicin
treatment
altern
rsv
diseas
infant
fernando
p
polack
professor
depart
pediatr
vanderbilt
univers
scientif
director
infant
foundat
bueno
air
argentina
email
fernandoppolack
vanderbiltedu
respiratori
syncyti
viru
rsv
main
caus
hospit
infant
industri
develop
countri
million
children
hospit
estim
die
everi
year
worldwid
due
rsv
diseas
addit
rsv
causal
link
recurr
wheez
associ
pediatr
asthma
recognit
acut
chronic
burden
rsv
lower
respiratori
tract
infect
lrti
spark
wave
initi
develop
prevent
therapeut
product
pathogen
recent
year
promis
strategi
evalu
prevent
sever
rsv
diseas
immun
pregnant
women
viru
matern
immun
aim
elicit
high
level
protect
antibodi
pregnant
women
foster
transplacent
acquir
protect
infant
first
month
life
interest
approach
rsv
prevent
infant
studi
includ
limit
passiv
prophylaxi
monoclon
antibodi
neutral
epitop
rsv
fusion
f
protein
immun
recombin
live
attenu
rsv
vaccin
surg
old
novel
approach
prevent
rsv
suggest
may
wit
signific
chang
landscap
respiratori
infect
near
futur
main
caus
infant
hospit
worldwid
tame
burden
rsv
diseas
may
decreas
predict
magnitud
chang
prematur
yet
numer
import
lesson
emerg
worldwid
effort
first
rsv
respons
signific
proport
infant
hospit
worldwid
second
decreas
impact
may
affect
acut
chronic
consequ
rsv
infect
secondari
bacteri
infect
mortal
recurr
wheez
asthma
final
rsv
prevent
may
inform
factor
influenc
health
human
milk
protect
andor
acut
effect
respiratori
ill
pregnanc
present
intend
address
question
may
emerg
rsv
prevent
refer
hall
cb
respiratori
syncyti
viru
young
children
lancet
p
nair
h
et
al
global
burden
acut
lower
respiratori
infect
due
respiratori
syncyti
viru
young
children
systemat
review
lancet
p
blanken
mo
et
al
respiratori
syncyti
viru
recurr
wheez
healthi
preterm
infant
n
engl
j
med
p
stein
rt
et
al
respiratori
syncyti
viru
earli
life
risk
wheez
allergi
age
year
lancet
p
wu
p
et
al
evid
causal
role
winter
viru
infect
infanc
earli
childhood
asthma
j
respir
crit
care
med
p
madhi
sa
mc
nune
cl
cutland
influenza
vaccin
pregnant
women
protect
infant
n
engl
j
med
p
steinhoff
mc
et
al
influenza
immun
respons
mother
infant
n
engl
j
med
p
amirthalingam
g
et
al
effect
matern
pertussi
vaccin
england
observ
studi
lancet
revis
indic
use
palivizumab
respiratori
syncyti
viru
immun
globulin
intraven
prevent
respiratori
syncyti
viru
infect
pediatr
pt
p
johnson
et
al
direct
comparison
activ
two
human
respiratori
syncyti
viru
monoclon
antibodi
j
infect
di
p
ciliopathi
syndrom
current
diagnost
approach
manag
thoma
ferkol
washington
univers
school
medicin
pediatr
allergi
pulmonari
medicin
st
loui
missouri
unit
state
email
ferkolt
wustledu
ciliopathi
grow
genet
heterogen
collect
disord
relat
cilia
dysfunct
first
ciliopathi
describ
human
primari
ciliari
dyskinesia
mim
inherit
disord
character
impair
motor
ciliari
function
frequenc
primari
ciliari
dyskinesia
roughli
live
birth
base
popul
survey
valu
like
underestim
incid
gener
popul
famili
diseas
transmit
pattern
inherit
though
rare
instanc
inherit
pattern
report
primari
ciliari
dyskinesia
appar
racial
gender
predilect
primari
ciliari
dyskinesia
sever
characterist
featur
neonat
respiratori
distress
common
featur
affect
newborn
develop
increas
work
breath
tachypnea
upper
middl
lobe
atelectasi
chest
radiograph
often
diagnos
transient
tachypnea
neonat
pneumonia
infant
frequent
requir
supplement
oxygen
flow
ventil
support
day
week
daili
product
wet
cough
begin
infanc
common
clinic
manifest
primari
ciliari
dyskinesia
persist
nasal
congest
rhiniti
present
earli
infanc
typic
chronic
otiti
media
present
patient
primari
ciliari
dyskinesia
middl
ear
find
may
help
distinguish
primari
ciliari
dyskinesia
chronic
lung
diseas
although
primari
ciliari
dyskinesia
consid
rare
lung
diseas
preval
children
chronic
respiratori
infect
estim
high
extrapulmonari
manifest
includ
later
defect
often
situ
inversu
totali
occur
nearli
patient
primari
ciliari
dyskinesia
respiratori
ciliari
dysfunct
also
found
patient
heterotaxi
congenit
heart
defect
demonstr
import
cilia
function
normal
cardiac
develop
male
infertil
common
due
impair
sperm
motil
ultrastructur
defect
ciliat
cell
line
fallopian
tube
led
specul
subfertil
ectop
pregnanc
occur
women
associ
conclus
establish
histor
diagnosi
primari
ciliari
dyskinesia
base
compat
clinic
phenotyp
specif
ultrastructur
defect
ciliari
axonem
unfortun
ultrastructur
examin
cilia
diagnost
test
primari
ciliari
dyskinesia
signific
drawback
ciliari
defect
acquir
nonspecif
chang
may
seen
relat
exposur
environment
pollut
infect
normal
ciliari
ultrastructur
exclud
primari
ciliari
dyskinesia
found
approxim
affect
individu
newer
test
measur
ciliari
beat
pattern
use
videomicroscopi
nasal
nitric
oxid
measur
increasingli
use
diagnost
screen
tool
immunofluoresc
stain
ciliari
protein
anoth
approach
hold
promis
may
address
limit
transmiss
electron
microscopi
genet
test
becom
power
diagnost
tool
primari
ciliari
dyskinesia
collabor
intern
research
effort
gene
link
diseas
patient
test
biallel
mutat
gene
gene
discoveri
continu
percentag
rise
mani
mutat
gene
link
specif
ultrastructur
defect
ciliari
dysmotil
includ
gene
encod
compon
outer
dynein
arm
inner
dynein
arm
dynein
regulatori
complex
nexin
radial
spoke
central
apparatu
recent
mutat
gene
code
sever
cytoplasm
protein
found
appear
import
role
cilia
assembl
protein
transport
genet
provid
unexpect
insight
phenotyp
primari
ciliari
dyskinesia
instanc
biallel
mutat
dynein
axonem
heavi
chain
gene
encod
outer
dynein
arm
protein
clearli
lead
diseas
associ
ultrastructur
defect
cilia
normal
rapid
beat
frequenc
sever
patient
mutat
cyclin
ccno
multicili
differenti
dna
synthesi
associ
cell
cycl
protein
mcida
found
symptom
consist
primari
ciliari
dyskinesia
rare
cilia
epitheli
surfac
mutat
protein
regulatori
complex
act
ruler
determin
precis
repetit
structur
protein
along
axonem
yield
inconsist
ultrastructur
abnorm
character
absent
inner
dynein
arm
axonem
misplac
radial
spoke
microtubular
disorgan
cilia
studi
show
children
microtubular
disorgan
primarili
due
biallel
mutat
sever
lung
diseas
contrast
individu
biallel
mutat
milder
respiratori
phenotyp
contrast
motor
cilia
primari
sensori
cilia
solitari
immotil
organel
locat
surfac
nondivid
cell
origin
consid
vestigi
remnant
structur
special
sensori
function
genet
defect
lead
divers
syndrom
condit
polycyst
kidney
diseas
syndrom
syndrom
creveld
syndrom
retin
pigmentosia
variou
skelet
dysplasia
primari
ciliopathi
found
clinic
featur
suggest
motil
sensori
cilia
dysfunct
suggest
overlap
date
therapi
shown
correct
ciliari
dysfunct
manag
focus
aggress
mucociliari
clearanc
treatment
bacteri
infect
hope
futur
advanc
cilia
genet
biolog
identifi
therapeut
target
could
restor
ciliari
structur
function
refer
afzeliu
ba
human
syndrom
caus
immotil
cilia
scienc
behan
l
dimitrov
bd
kuehni
ce
hogg
c
carrol
evan
hj
goutaki
harri
packham
walker
wt
luca
js
picadar
diagnost
predict
tool
primari
ciliari
dyskinesia
eur
respir
j
davi
sd
ferkol
tw
rosenfeld
et
al
clinic
featur
childhood
primari
ciliari
dyskinesia
genotyp
ultrastructur
phenotyp
j
respir
crit
care
med
horani
h
ferkol
tw
dutcher
brodi
sl
genet
primari
ciliari
dyskinesia
paediatr
respir
rev
horani
ferkol
tw
primari
ciliari
dyskinesia
associ
sensori
ciliopathi
expert
rev
respir
med
knowl
mr
leigh
mw
carson
jl
et
al
mutat
patient
primari
ciliari
dyskinesia
normal
ciliari
ultrastructur
thorax
knowl
mr
daniel
la
davi
sd
et
al
primari
ciliari
dyskinesia
recent
advanc
diagnost
genet
character
clinic
diseas
j
respir
crit
care
med
leigh
mw
ferkol
tw
davi
sd
et
al
clinic
featur
associ
likelihood
primari
ciliari
dyskinesia
children
adolesc
ann
thorac
soc
luca
js
barbato
collin
sa
et
al
european
respiratori
societi
guidelin
diagnosi
primari
ciliari
dyskinesia
shapiro
aj
zariwala
ferkol
et
al
diagnosi
monitor
treatment
primari
ciliari
dyskinesia
pcd
foundat
consensu
recommend
base
state
art
review
pediatr
pulmonol
bronchiectasi
averag
patient
catherin
byrn
associ
professor
depart
paediatr
univers
auckland
paediatr
respiratori
starship
children
hospitalspecialist
auckland
new
zealand
email
cbyrn
aucklandacnz
unfortun
child
fibrosi
cf
bronchiectasi
becom
common
incid
preval
pediatr
adult
bronchiectasi
increas
develop
countri
especi
socioeconom
depriv
indigen
popul
may
due
true
increas
diseas
associ
reduc
antibiot
use
commun
encourag
antimicrobi
stewardship
improv
recognit
andor
increas
use
chest
ct
scan
enabl
diagnosi
bronchiectasi
preval
difficult
ascertain
develop
countri
children
hospit
pneumonia
suspect
develop
bronchiectasi
overcrowd
poor
hous
smoke
exposur
cigarett
cook
fire
also
increas
risk
combin
poor
access
healthcar
bronchiectasi
like
high
preval
certainli
probabl
common
enough
lose
orphan
diseas
statu
differ
associ
report
studi
across
countri
eg
nearli
secondari
tb
china
mostli
india
associ
high
rate
hiv
south
africa
access
investig
also
issu
present
children
bronchiectasi
commonli
present
chronic
wet
cough
recurr
respiratori
infect
wheezeasthma
report
persist
chest
abnorm
follow
respiratori
infect
particularli
focal
chang
anoth
common
pathway
earli
pneumonia
key
risk
factor
chang
persist
high
risk
children
one
year
singl
admiss
diagnosi
often
signific
delay
onset
symptom
definit
diagnosi
current
diagnost
guidelin
suggest
referr
week
wet
cough
episod
product
wet
cough
per
year
howev
differ
studi
children
mean
two
hospit
admiss
four
infect
first
year
life
mean
two
year
chronic
cough
mean
five
chest
rang
chest
ct
scan
request
suggest
commun
health
practition
awar
bronchiectasi
still
low
signific
barrier
earli
diagnosi
exist
particularli
ct
scan
access
due
economicgeograph
constraint
concern
regard
radiat
dose
gener
anesthet
treatment
commenc
base
suspici
histori
delay
obtain
definit
diagnosi
etiolog
pediatr
popul
describ
literatur
etiolog
idiopath
also
like
main
major
caus
number
underli
disord
variabl
eg
aspir
immunodefici
primari
ciliari
dyskinesia
presenc
foreign
bodi
seen
studi
involv
children
combin
avail
guidelin
suggest
rang
appropri
investig
individu
histori
examin
inform
common
infect
organ
children
haemophilu
influenza
streptococc
pneumonia
moraxella
catarrhali
frequent
cultur
pseudomona
aeruginosa
rare
new
zealand
clinic
seen
sever
diseas
chronic
aspir
presenc
staphylococcu
aureu
indic
need
exclud
cystic
fibrosi
bronchiectasi
pathogenesi
involv
complex
interact
host
microb
environ
initi
infect
impair
mucociliari
clearanc
dysregul
inflamm
ultim
result
destruct
airway
wall
mucu
retent
increas
suscept
infect
inflamm
result
progress
airway
damag
respiratori
secret
bal
sputum
show
neutrophil
inflamm
high
level
mediat
neutrophil
chemoattract
factor
addit
inflammatori
recent
suggest
impair
respons
haemophilu
influenza
reduc
macrophag
activ
treatment
airway
clearanc
chest
physiotherapi
exercis
mainstay
bronchiectasi
manag
infect
exacerb
treat
longer
usual
cours
week
antibiot
prolong
cours
antibiot
oral
azithromycin
nebul
gentamicin
month
shown
reduc
infect
reduc
hospit
admiss
improv
cough
score
issu
increas
bacteri
resist
importantli
resist
seen
less
better
adher
recent
cochran
review
intervent
bronchiectasi
indic
pauciti
data
base
manag
trial
children
nebul
hyperton
salin
inconclus
nebul
rhdnase
increas
exacerb
therefor
must
avoid
small
possibl
question
clinic
relev
respons
lung
function
dyspnea
day
report
inhal
corticosteroid
alon
long
act
beta
agonist
particip
singl
studi
suggest
benefit
nebul
indomethacin
agent
nebul
antibiot
amikacin
ciprofloxacin
triall
adher
seriou
issu
one
adult
studi
report
adher
prognosi
children
long
term
outcom
seem
depend
sever
diagnosi
subsequ
rate
exacerb
howev
unlik
adult
diseas
improv
even
revers
associ
pediatr
bronchiectasi
earli
referr
diagnosi
essenti
futur
knowledg
true
preval
etiolog
pathogenesi
manag
bronchiectasi
lag
behind
respiratori
diseas
burst
research
last
decad
certainli
new
develop
databas
europ
uk
usa
australia
websit
list
increas
intern
collabor
add
new
insight
alreadi
cluster
research
determin
differ
phenotyp
group
sever
score
bronchiectasi
sever
index
face
score
develop
use
paramet
irrelev
children
signific
differ
children
adult
bronchiectasi
diseas
progress
treatment
trial
children
essenti
littl
evid
manag
new
drug
use
better
alreadi
develop
pediatr
databas
sever
score
would
help
evolut
organ
websit
would
power
step
forward
probabl
signific
burden
diseas
exit
develop
world
lack
access
diagnost
facil
avail
therapi
major
concern
registri
person
bronchiectasi
embarc
europ
http
wwwbronchiectasiseu
unit
kingdom
http
wwwbronchacuk
unit
state
america
http
wwwcopdfoundationorgresearchbronchiectasisresearchregistri
australia
bronchiectasi
toolkit
http
bronchiectasiscomau
http
lungfoundationcomauhealthprofession
refer
chang
ab
bell
sc
torzillo
pj
king
pt
maguir
gp
byrn
ca
et
al
chronic
suppur
lung
diseas
bronchiectasi
children
adult
australia
new
zealand
thorac
societi
australia
new
zealand
guidelin
med
j
aust
pasteur
mc
bilton
hill
british
thorac
societi
guidelin
bronchiectasi
thorax
suppl
singleton
rj
valeri
pc
morri
p
byrn
ca
grimwood
k
red
g
et
al
indigen
children
three
countri
fibrosi
chronic
suppur
lung
diseasebronchiectasi
pediatr
pulmonolog
edmond
k
scott
korczak
v
ward
c
sanderson
c
theodorat
e
et
al
long
term
sequela
childhood
pneumonia
systemat
review
plo
one
red
gj
carter
er
chronic
suppur
lung
diseas
children
definit
spectrum
diseas
frontier
pediatr
trenholm
aa
byrn
ca
mcbride
c
lennon
dr
f
vogel
et
al
respiratori
health
outcom
year
admiss
sever
lower
respiratori
tract
infect
pediatr
pulmonol
brower
ks
del
vecchio
mt
aronoff
sc
etiolog
bronchiectasi
childhood
systemat
review
subject
bmc
pediatr
goyal
v
grimwood
k
marchant
j
master
ib
chang
ab
pediatr
bronchiectasi
longer
orphan
diseas
pediatr
pulmonol
welsh
ej
evan
dj
fowler
sj
spencer
intervent
bronchiectasi
overview
cochran
systemat
review
cochran
databas
syst
rev
mc
cullough
ryan
cj
bradley
j
oneil
b
elborn
hugh
cm
intervent
enhanc
adher
treatment
adult
bronchiectasi
protocol
cochran
review
kapur
n
master
ib
chang
ab
longitudin
growth
lung
function
pediatr
fibrosi
bronchiectasi
influenc
lung
function
stabil
chest
twiss
j
stewart
aw
byrn
ca
longitudin
pulmonari
function
childhood
bronchiectasi
comparison
cystic
fibrosi
thorax
allerg
bronchopulmonari
aspergillosi
abpa
malena
pediatr
pulmonari
unit
univers
medic
center
jerusalem
israel
email
malena
hadassahorgil
allerg
bronchopulmonari
aspergillosi
abpa
lung
hypersensit
diseas
mediat
allerg
immun
respons
specif
antigen
aspergillu
fumigatu
af
character
clinic
deterior
associ
elev
serum
ige
precipitin
level
evid
immedi
cutan
reactiv
af
abpa
occur
almost
exclus
asthma
cystic
fibrosi
cf
patient
preval
abpa
patient
cf
report
rang
increas
patient
age
immun
mediat
mechan
lung
destruct
abpa
complet
understood
aspergillu
fumigatu
antigen
stimul
polyclon
antibodi
respons
essenti
respons
elev
level
total
ige
well
antibodi
increas
interleukin
il
product
due
cellular
immunolog
respons
suggest
immunocompet
genet
risk
factor
includ
express
genotyp
wherea
protect
diagnosi
abpa
includ
set
minim
essenti
criteria
includ
asthma
immedi
cutan
reactiv
af
total
serum
ige
ngml
elev
specif
central
bronchiectasi
absenc
distal
bronchiectasi
truli
minim
set
diagnost
criteria
propos
includ
item
aforement
minim
essenti
sinc
cf
share
similar
symptom
radiolog
find
abpa
epidemiolog
studi
cystic
fibrosi
escf
adapt
set
less
strict
criteria
diagnosi
acut
abpa
patient
includ
presenc
follow
immedi
skin
reactiv
af
antigen
precipit
antibodi
af
antigen
total
serum
ige
iuml
least
follow
bronchoconstrict
peripher
blood
eosinophilia
histori
pulmonari
infiltr
elev
specif
af
sputum
smear
cultur
respons
steroid
howev
later
abpa
cf
consensu
criteria
state
serum
ige
iuml
consid
cf
lung
abpa
caus
acut
deterior
pulmonari
function
suspicion
rais
clinic
respons
convent
antibiot
therapi
symptom
may
includ
increas
wheez
fever
malais
thick
sputum
brown
black
bronchial
cast
high
level
clinic
suspicion
necessari
earli
recognit
specif
treatment
abpa
immedi
start
order
prevent
lung
damag
corticosteroid
effect
drug
treat
abpa
dose
schedul
durat
therapi
remain
poorli
defin
patient
cf
abpa
often
requir
prolong
therapi
oral
corticosteroid
associ
sever
side
effect
monthli
puls
iv
methylprednisolon
therapi
mgkgday
consecut
day
shown
effect
treatment
cf
patient
abpa
induc
significantli
less
side
effect
compar
convent
oral
therapi
furthermor
patient
treat
puls
iv
methylprednisolon
seem
respond
faster
antifung
oral
treatment
eg
itraconazol
voriconazol
propos
adjunct
therapi
patient
abpa
advers
exact
role
antifung
agent
treatment
abpa
still
debat
decreas
fungal
load
antifung
agent
help
control
antigen
stimulu
thu
diminish
inflammatori
respons
howev
definit
evid
exist
regard
efficaci
patient
cf
abpa
omalizumab
monoclon
antibodi
ige
also
tri
manag
abpa
signific
clinic
improv
reduct
hospit
exacerb
patient
concomit
cf
abpa
could
benefici
steroid
spare
therapi
howev
data
requir
clarifi
role
omalizumab
expens
therapi
recommend
treatment
approach
refer
zander
ds
allerg
bronchopulmonari
aspergillosi
overview
arch
pathol
lab
med
sambatak
h
pravica
v
hutchinson
iv
den
dw
cytokin
profil
pulmonari
aspergillosi
int
j
immunogenet
chauhan
b
santiago
l
hutcheson
ps
schwartz
hj
spitznagel
e
castro
et
al
evid
involv
two
differ
mhc
class
ii
region
suscept
protect
allerg
bronchopulmonari
aspergillosi
j
allergi
clin
immunol
greenberg
pa
suspect
work
allerg
bronchopulmonari
aspergillosi
ann
allergi
asthma
immunol
geller
de
kaplowitz
h
light
mj
colin
aa
allerg
bronchopulmonari
aspergillosi
cystic
fibrosi
report
preval
region
distribut
patient
characterist
scientif
advisori
group
investig
coordin
epidemiolog
studi
cystic
fibrosi
chest
steven
da
moss
rb
kurup
vp
knutsen
ap
greenberg
p
judson
et
al
allerg
bronchopulmonari
aspergillosi
cystic
art
cystic
fibrosi
foundat
consensu
confer
clin
infect
di
suppl
blau
h
shoseyov
efrati
armoni
kerem
e
intraven
monthli
puls
methylprednisolon
treatment
abpa
patient
cystic
fibrosi
journal
cystic
fibrosi
hilliard
edward
buchdahl
r
franci
j
rosenth
bush
davi
j
voriconazol
therapi
children
cystic
fibrosi
j
cyst
fibro
van
der
ent
ck
hoekstra
h
rijker
gt
success
treatment
allerg
bronchopulmonari
aspergillosi
recombin
antiig
antibodi
thorax
raphael
soazic
grard
lila
auzou
philipp
reix
md
marlen
francoi
bremont
benyebka
mammar
laurent
meli
dominiqu
hubert
isabel
durieu
burgel
case
seri
omalizumab
allerg
bronchopulmonari
aspergillosi
cystic
fibrosi
patient
pediatr
pulmonolog
role
nutrit
chronic
lung
diseas
childhood
manuel
e
pediatr
pulmonologist
clinic
epidemiologist
respiratori
depart
hospit
nacion
de
nation
hospit
san
costa
rica
email
msotom
hnnsacr
quiquesoto
gmailcom
introduct
chronic
lung
diseas
asthma
copd
affect
million
peopl
major
caus
prematur
death
children
adult
worldwid
gener
accept
mani
chronic
lung
diseas
result
complex
genet
environment
interact
therefor
increas
attent
given
mani
environment
lifestyl
factor
air
pollut
smoke
physic
activ
diet
research
show
earli
nutrit
play
critic
role
healthi
lung
develop
underpin
increas
propens
mani
respiratori
diseas
diet
may
import
modifi
risk
factor
develop
progress
manag
chronic
lung
diseas
children
adult
eg
bronchopulmonari
dysplasia
bpd
asthma
cystic
fibrosi
cf
copd
may
signific
effect
pulmonari
function
poor
growth
risk
chronic
lung
diseas
earli
life
malnutrit
relat
impair
immun
result
frequent
sever
respiratori
infect
addit
nutrit
deplet
common
problem
patient
sever
chronic
lung
diseas
bpd
cf
other
hypermetabol
malabsorpt
deplet
fat
free
mass
associ
increas
morbid
signific
impair
health
statu
obes
also
relat
poor
lung
function
increas
preval
asthma
asthma
sever
addit
sever
nutrit
defici
rare
occur
isol
dietari
intervent
potenti
role
reduc
acut
respiratori
ill
relat
morbid
mortal
especi
develop
countri
chronic
lung
diseas
nutrit
intervent
proven
effect
prevent
improv
outcom
evid
scarc
other
macronutri
relat
chronic
respiratori
diseas
pregnant
women
henc
babi
children
year
age
particularli
vulner
micronutri
defici
increas
suscept
acut
chronic
lung
diseas
childhood
addit
multipl
micronutri
defici
coexist
individu
vitamin
defici
relat
impair
immun
function
cell
differenti
zinc
defici
associ
higher
incid
acut
respiratori
infect
major
caus
death
children
year
develop
countri
instead
nutrit
intervent
diet
rich
fruit
veget
seem
protect
recent
effect
childhood
nutrient
intak
risk
develop
wheez
asthma
show
evid
protect
effect
vitamin
e
zinc
fruit
veget
mediterranean
diet
develop
asthma
also
saadeh
et
al
show
fruit
green
veget
intak
associ
low
preval
wheez
asthma
school
children
age
year
old
adequ
dietari
vitamin
c
intak
also
relat
reduc
wheez
observ
studi
children
vitamin
extens
investig
last
year
immunomodulatori
effect
within
lung
epidemiolog
studi
show
signific
associ
vitamin
sever
acut
chronic
lung
diseas
asthma
evid
role
vitamin
defici
diseas
onset
progress
exacerb
respiratori
infect
asthma
copd
sever
observ
studi
shown
associ
asthma
high
intak
long
chain
polyunsatur
fatti
acid
lcpufa
wherea
lcpufa
shown
decreas
inflammatori
cell
product
prostaglandin
leukotrien
activ
nuclear
matern
dietari
intak
oili
fish
found
protect
asthma
children
year
age
born
mother
asthma
systemat
review
fatti
acid
supplement
studi
women
pregnanc
found
risk
asthma
develop
children
reduc
ci
asthma
variou
dietari
pattern
link
risk
respiratori
diseas
asthma
dietari
exposur
nutrient
diet
period
introduct
antenat
childhood
relev
diseas
pathogenesi
sever
cohort
studi
suggest
link
reduc
matern
consumpt
micronutri
childhood
asthma
systemat
review
note
higher
matern
intak
vitamin
vitamin
e
zinc
associ
lower
odd
wheez
childhood
relat
dietari
pattern
mediterranean
diet
high
intak
minim
process
plant
food
low
intak
dairi
food
fish
poultri
minim
intak
red
meat
found
protect
effect
allerg
respiratori
diseas
sever
epidemiolog
studi
contrari
western
dietari
pattern
character
high
consumpt
refin
grain
cure
red
meat
dessert
sweet
french
fri
dairi
product
associ
obes
increas
risk
asthma
children
observ
studi
vitamin
children
asthma
shown
strong
relationship
low
level
vitamin
lower
lung
function
increas
corticosteroid
use
asthma
exacerb
result
obes
clearli
link
respiratori
diseas
particularli
asthma
obes
children
asthma
decreas
lung
function
reduc
respons
inhal
corticosteroid
lower
qualiti
life
higher
morbid
recent
forno
et
al
report
obes
associ
airway
dysanapsi
associ
sever
diseas
exacerb
obes
children
asthma
obes
state
sever
causal
mechanist
pathway
report
anatom
chang
airway
circul
free
fatti
acid
activ
immun
respons
lead
increas
inflamm
product
adipokin
higher
concentr
circul
leptin
epigenet
also
microbiom
chronic
lung
diseas
prematur
cldp
bronchopulmonari
dysplasia
inadequ
growth
weight
gain
malnutrit
complic
bpd
given
fact
nutrit
play
import
role
lung
develop
matur
specif
nutrit
defici
combin
risk
factor
may
aggrav
pulmonari
injuri
involv
bpd
factor
bpd
develop
includ
oxygen
toxic
immatur
mechan
ventil
infect
inadequ
nutrit
support
infant
bpd
low
energi
intak
increas
energi
util
compar
term
infant
result
neg
energi
balanc
lead
malnutrit
follow
discharg
infant
bpd
high
risk
persist
growth
failur
possibl
explan
includ
increas
energi
expenditur
poor
oral
feed
skill
toler
concomit
dysfunct
organ
recurr
infect
hospit
therefor
adequ
nutrit
intervent
essenti
match
increas
energi
requir
infant
risk
bpd
although
consensu
regard
optim
nutrit
manag
bpd
mani
suggest
specif
nutrient
supplement
eg
glutamin
selenium
lcpufa
cystein
inositol
vitamin
e
c
other
prevent
treat
bpd
theoret
nutrient
may
curb
injuri
improv
alveolar
develop
howev
evid
supplement
still
controversi
effect
bpd
need
studi
current
evid
show
supplement
vitamin
lcpufa
effect
prevent
bpd
cystic
fibrosi
cf
intim
close
relationship
nutrit
statu
cf
prognosi
earli
nutrit
intervent
monitor
respiratori
diseas
infant
preschool
cf
prioriti
improv
outcom
poor
nutrit
lead
poor
lung
function
increas
number
infect
poor
lung
function
also
caus
increas
energi
util
growth
failur
end
unsatisfactori
outcom
cf
patient
pancreat
insuffici
approxim
one
third
patient
percentil
weight
age
sever
studi
shown
malnutrit
earli
life
relat
impart
lung
function
childhood
micronutri
defici
also
occur
cf
patient
pancreat
insuffici
secondari
malabsorpt
vitamin
e
defici
well
zinc
magnesium
may
present
either
intak
nutrient
absorpt
inadequ
defici
may
also
increas
suscept
respiratori
infect
malnutrit
normal
growth
patient
cf
associ
improv
pulmonari
function
surviv
yen
et
al
show
better
nutrit
statu
age
year
children
cystic
fibrosi
associ
better
lung
function
fewer
complic
greater
surviv
oral
supplement
use
conflict
evid
therefor
consid
nutrit
behavior
approach
gastrostomi
tube
feed
shown
improv
weight
studi
pulmonari
function
also
poor
adher
pancreat
enzym
relat
difficulti
correct
malabsorpt
henc
worst
nutrit
outcom
conclus
nutrit
play
import
role
develop
manag
chronic
lung
diseas
childhood
mani
epidemiolog
studi
shown
malnutrit
well
obes
may
deleteri
consequ
term
lung
function
probabl
surviv
time
nutrit
intervent
beyond
gener
principl
balanc
diet
alway
recommend
part
comprehens
approach
children
chronic
lung
diseas
refer
bailey
rl
kp
west
black
epidemiolog
global
micronutri
defici
ann
nutr
metab
suppl
p
nurmatov
u
g
devereux
sheikh
nutrient
food
primari
prevent
asthma
allergi
systemat
review
j
allergi
clin
immunol
p
saadeh
et
al
diet
allerg
diseas
among
popul
age
year
myth
realiti
nutrient
p
foong
gr
zoski
vitamin
defici
lung
diseas
initi
diseas
modifi
nutrient
p
klemen
cm
dr
berman
el
mozurkewich
effect
perinat
fatti
acid
supplement
inflammatori
marker
allerg
diseas
systemat
review
bjog
p
beckhau
aa
et
al
matern
nutrit
pregnanc
risk
asthma
wheez
atop
diseas
childhood
systemat
review
allergi
p
barro
r
et
al
adher
mediterranean
diet
fresh
fruit
intak
associ
improv
asthma
control
allergi
p
brehm
jm
et
al
serum
vitamin
level
marker
sever
childhood
asthma
costa
rica
j
respir
crit
care
med
p
egan
kb
etting
mb
bracken
childhood
bodi
mass
index
subsequ
asthma
systemat
review
prospect
cohort
studi
bmc
pediatr
p
forno
e
et
al
obes
airway
dysanapsi
children
without
asthma
j
respir
crit
care
med
p
wilson
dc
g
mcclure
energi
requir
sick
preterm
babi
acta
paediatr
suppl
p
zhang
p
et
al
polyunsatur
fatti
acid
extrem
preterm
infant
systemat
review
pediatr
p
konstan
mw
et
al
growth
nutrit
index
earli
life
predict
pulmonari
function
cystic
fibrosi
j
pediatr
p
yen
eh
h
quinton
borowitz
better
nutrit
statu
earli
childhood
associ
improv
clinic
outcom
surviv
patient
cystic
fibrosi
j
pediatr
p
preterm
epidem
lmic
impact
respiratori
morbid
renato
stein
school
medicin
pontificia
universidad
rg
porto
alegr
brazil
email
rstein
pucrsbrrstein
pucrsbr
preterm
birth
ptb
signific
impact
public
health
global
associ
increas
morbid
mortal
affect
seri
variabl
frequenc
ptb
rang
recent
report
associ
ptb
death
neonat
period
addit
death
children
age
one
five
year
repres
lead
caus
neonat
childhood
mortal
impact
ptb
affect
surviv
prematur
infant
increas
risk
cerebr
palsi
impair
learn
visual
disord
chronicrecurr
respiratori
diseas
start
earli
year
specif
subgroup
affect
life
great
major
ptb
occur
poor
region
world
africa
south
asia
current
infant
born
weight
g
surviv
close
born
week
gestat
age
tertiari
center
surviv
year
age
cohort
main
featur
chronic
lung
diseas
mean
babi
surviv
neonat
period
present
later
morbid
mortal
due
sequela
prematur
bronchopulmonari
dysplasia
bpd
anoth
seri
preterm
infant
born
less
week
gestat
age
show
hospit
first
two
year
life
seri
interven
variabl
play
affect
immatur
pulmonari
system
preterm
newborn
babi
influenc
normal
develop
respiratori
tract
consequ
process
alveolar
growth
format
adequ
pulmonari
microvasculatur
risk
respiratori
morbid
invers
associ
birth
weight
depend
gestat
age
birth
long
list
pulmonari
find
children
born
preterm
includ
increas
incid
pneumonia
bronchiol
frequent
respiratori
diseas
chronic
recurr
cough
wheez
bronchial
hyperreact
pulmonari
function
abnorm
chang
present
first
month
year
life
children
born
less
week
gestat
signific
burden
respiratori
diseas
structur
abnorm
lung
function
lower
children
born
preterm
associ
increas
structur
lung
damag
recent
million
children
worldwid
analyz
chanc
wheez
first
year
life
preterm
birth
found
independ
associ
variabl
higher
risk
subgroup
low
birth
weight
vlbw
risk
three
time
greater
rsv
lower
respiratori
tract
ill
lrti
signific
infecti
agent
associ
respiratori
morbid
possibl
earli
life
intervent
may
attenu
sever
sever
case
may
recent
advent
monoclon
antibodi
specif
rsv
recent
trial
shown
treatment
palivizumab
shown
reduct
total
wheez
day
first
year
life
healthi
preterm
infant
born
wg
approach
serv
fascin
proof
concept
block
sever
event
caus
rsv
earli
life
last
protect
least
first
year
life
recurr
wheez
common
set
babi
born
prematur
also
interest
perspect
new
vaccin
monoclon
antibodi
alreadi
test
pipelin
target
rsv
may
complet
chang
current
sceneri
today
conserv
sinc
effect
therapeut
option
chang
cours
acut
recurr
wheez
popul
popul
lmic
benefit
greatli
new
approach
sinc
burden
diseas
commun
seem
even
greater
observ
affluent
societi
refer
nour
n
preterm
deliveri
millennium
develop
goal
rev
obstet
gynecol
world
health
organ
newborn
reduc
mortal
http
access
march
doyl
l
outcom
year
age
children
week
gestat
refin
prognosi
pediatr
ralser
e
mueller
w
haberland
c
et
al
rehospit
first
year
life
children
born
preterm
acta
paediatr
stahlman
hedval
g
dolanski
e
faxeliu
g
burko
h
kirk
v
clinic
hyalin
membran
diseas
pediatr
clin
north
mcleod
ross
p
mitchel
tay
hunter
paton
j
et
al
respiratori
health
total
low
birthweight
cohort
classroom
control
arch
di
child
pelkonen
hakulinen
turpeinen
bronchial
abil
respons
school
children
born
preterm
j
respir
crit
care
med
stock
j
godfrey
role
artifici
ventil
cpap
pathogenesi
lung
damag
neonat
assess
serial
measur
lung
function
pediatr
simpson
sj
logi
km
ca
banton
gl
murray
c
wilson
ac
pillow
jj
hall
gl
alter
lung
structur
function
survivor
preterm
birth
thorax
jv
lugtenbergmj
smet
e
et
al
pretermbirth
childhood
wheez
disord
systemat
review
plo
med
blanken
mo
rover
mm
molenaar
jm
et
al
dutch
rsv
neonat
network
respiratori
syncyti
viru
recurr
wheez
healthi
preterm
infant
n
engl
j
med
advanc
diagnosi
pulmonari
tuberculosi
ptb
children
heather
j
zar
depart
paediatr
child
health
red
cross
war
memori
children
hospit
mrc
unit
child
adolesc
health
univers
cape
town
south
africa
correspond
prof
heather
j
zar
dept
paediatr
child
health
floor
ich
build
red
cross
war
memori
children
hospit
cape
town
south
africa
tel
fax
email
heatherzar
uctacza
pulmonari
tuberculosi
ptb
commonest
form
childhood
tb
global
time
accur
diagnosi
essenti
promot
effect
treatment
includ
therapi
drug
resist
tb
delin
burden
childhood
tb
prevent
complic
dissemin
progress
diseas
clinic
score
system
radiolog
find
tuberculin
skin
test
usual
method
diagnosi
hamper
poor
interobserv
agreement
low
sensit
specif
especi
context
hiv
result
well
potenti
ptb
remain
challeng
children
live
high
tb
burden
countri
howev
sever
diagnost
advanc
occur
last
year
improv
microbiolog
confirm
support
strategi
promot
better
specimen
collect
includ
induc
sputum
realiz
repeat
specimen
need
children
better
rapid
molecular
diagnost
test
particularli
gene
xpert
xpert
mtbrif
enabl
rapid
diagnosi
simultan
detect
resist
rifampicin
singl
induc
sputum
provid
similar
cultur
yield
gastric
lavag
sequenti
second
specimen
increas
yield
cultur
approxim
primari
care
set
sputum
induct
also
effect
increas
diagnost
yield
ptb
report
pool
sensit
specif
xpert
mtbrif
singl
respect
compar
cultur
children
perform
xpert
gastric
lavag
similar
xpert
test
repeat
specimen
provid
higher
yield
specimen
detect
approxim
children
cultur
confirm
diseas
almost
fold
tanzanian
studi
older
children
report
similar
sensit
xpert
sputum
specimen
increment
increas
subsequ
specimen
studi
focus
hospit
children
xpert
respiratori
secret
report
use
diagnosi
children
suspect
ptb
present
mild
diseas
primari
care
health
facil
although
microbiolog
yield
cultur
xpert
much
lower
obtain
hospit
world
health
organ
recommend
xpert
replac
smear
first
line
investig
children
live
area
high
hiv
preval
drug
resist
tb
concern
xpert
attract
test
perform
specimen
less
invas
collect
south
african
studi
report
xpert
sequenti
npa
use
microbiolog
confirm
hospit
children
provid
similar
sensit
repeat
xpert
test
howev
npa
provid
lower
yield
specimen
cultur
xpert
stool
specimen
may
offer
promis
strategi
particularli
children
studi
xpert
mtbrif
ultra
ultra
detect
diseas
fewer
bacilli
xpert
may
offer
improv
rapid
diagnost
childhood
ptb
paucibacillari
studi
children
underway
diagnost
test
includ
urin
lipoarabinomannan
lam
host
genom
express
profil
improv
immunolog
assay
lam
low
sensit
specif
children
includ
children
make
unsuit
host
genom
signatur
associ
tb
children
work
develop
avail
diagnost
test
need
serolog
test
success
gamma
interferon
test
provid
major
advantag
tuberculin
skin
test
distinguish
infect
diseas
cell
activ
marker
test
novel
immunodiagnost
test
distinguish
activ
diseas
infect
reli
predomin
effector
memori
cell
phenotyp
studi
tanzania
assay
show
good
diagnost
perform
children
studi
need
refer
nicol
mp
zar
hj
new
specimen
laboratori
diagnost
childhood
pulmonari
tb
progress
prospect
paediatr
respiratori
review
zar
hj
hanslo
apol
p
swingler
g
hussey
g
induc
sputum
versu
gastric
lavag
microbiolog
confirm
pulmonari
tuberculosi
infant
young
children
prospect
studi
lancet
moor
ha
apol
p
de
villier
pj
zar
hj
sputum
induct
microbiolog
diagnosi
childhood
pulmonari
tuberculosi
commun
set
intern
journal
tuberculosi
lung
diseas
detjen
ak
dinardo
ar
leyden
j
et
al
xpert
mtbrif
assay
diagnosi
pulmonari
tuberculosi
children
systemat
review
lancet
respiratori
medicin
nicol
mp
workman
l
isaac
w
et
al
accuraci
xpert
mtbrif
test
diagnosi
pulmonari
tuberculosi
children
admit
hospit
cape
town
south
africa
descript
studi
lancet
infecti
diseas
zar
hj
workman
l
isaac
w
dheda
k
zemanay
w
nicol
mp
rapid
diagnosi
pulmonari
tuberculosi
african
children
primari
care
set
use
xpert
mtbrif
respiratori
specimen
prospect
studi
lancet
global
health
zar
hj
workman
l
isaac
w
et
al
rapid
molecular
diagnosi
pulmonari
tuberculosi
children
use
nasopharyng
specimen
clinic
infecti
diseas
nicol
mp
spier
k
workman
l
et
al
xpert
mtbrif
test
stool
sampl
diagnosi
pulmonari
tuberculosi
children
clinic
infecti
diseas
nicol
mp
allen
v
workman
l
et
al
urin
lipoarabinomannan
test
diagnosi
pulmonari
tuberculosi
children
prospect
studi
lancet
global
health
anderson
st
kafor
brent
aj
et
al
diagnosi
childhood
tuberculosi
host
rna
express
africa
new
england
journal
medicin
noninvas
ventil
pediatr
clinic
indic
experi
brigitt
fauroux
pediatr
noninvas
ventil
sleep
unit
necker
pari
pari
descart
faculti
pari
franc
research
unit
inserm
u
team
franc
correspond
pr
brigitt
fauroux
pediatr
noninvas
ventil
sleep
unit
necker
rue
de
pari
franc
tel
fax
email
brigittefauroux
aphpfr
introduct
noninvas
ventil
niv
involv
deliveri
ventilatori
assist
noninvas
interfac
oppos
invas
ventil
via
tracheostomi
number
children
treat
home
type
respiratori
support
expand
exponenti
around
world
increas
pediatr
condit
may
benefit
long
term
niv
howev
indic
benefit
valid
reli
mainli
recommend
clinic
experi
diseas
may
benefit
noninvas
ventil
support
niv
compris
continu
posit
airway
pressur
cpap
util
deliveri
constant
posit
pressur
airway
aim
maintain
airway
patenc
throughout
entir
breath
cycl
biphas
posit
airway
pressur
bipap
aim
assist
breath
patient
deliv
supplement
higher
posit
pressur
inspir
niv
indic
disord
caus
disequilibrium
respiratori
balanc
compris
load
impos
respiratori
system
capac
respiratori
muscl
central
drive
healthi
subject
respiratori
load
ie
effort
subject
perform
gener
breath
low
capac
respiratori
muscl
normal
central
drive
appropri
command
respiratori
muscl
disord
character
increas
respiratori
load
weak
respiratori
muscl
central
drive
increas
demand
respiratori
muscl
howev
imbal
exce
certain
threshold
hypoventil
defin
hypercapnia
hypoxemia
occur
sever
upper
airway
obstruct
airway
malacia
cystic
fibrosi
bronchopulmonari
dysplasia
bronchiol
obliteran
may
respons
excess
respiratori
load
neuromuscular
diseas
involv
motor
neuron
peripher
nerv
neuromuscular
junction
muscl
may
caus
excess
respiratori
muscl
weak
disord
central
drive
rare
may
congenit
ondin
curs
congenit
central
hypoventil
syndrom
acquir
due
compress
injuri
brainstem
disord
involv
impair
two
compon
achondroplasia
mucopolysaccharidos
may
caus
upper
airway
obstruct
brain
stem
compress
choic
type
niv
depend
pathophysiolog
respiratori
failur
cpap
simplest
type
noninvas
respiratori
support
indic
case
isol
obstruct
upper
lower
airway
bipap
indic
two
compon
respiratori
balanc
impair
ie
central
drive
andor
respiratori
muscl
lung
diseas
associ
increas
respiratori
load
aim
niv
unload
respiratori
muscl
patient
normal
central
nervou
system
preserv
respiratori
muscl
capac
ventilatori
assist
preserv
patient
breath
pattern
allow
patient
trigger
assist
breath
appropri
comfort
convers
patient
weak
respiratori
muscl
role
bipap
replac
respiratori
muscl
deliv
posit
pressur
inspir
control
mode
rate
ie
minim
number
breath
deliv
per
minut
ventil
close
normal
respiratori
rate
sleep
age
thu
recommend
cpap
thu
clearli
treatment
breath
patient
neuromuscular
diseas
final
case
abnorm
central
drive
ventil
abl
take
command
respiratori
muscl
mean
control
mode
indic
benefit
niv
valid
criteria
start
long
term
niv
children
clinic
practic
niv
may
initi
acut
set
niv
wean
failur
pediatr
intens
care
unit
picu
abnorm
nocturn
ga
exchang
alon
associ
high
index
ahi
polysomnographi
main
challeng
difficulti
niv
initi
children
time
type
investig
polysomnographi
polygraphi
overnight
ga
exchang
record
perform
niv
initi
valu
threshold
paramet
retain
niv
initi
oxygen
andor
carbon
dioxid
level
andor
ahi
assumpt
correct
associ
benefit
niv
difficulti
due
lack
marker
morbid
associ
breath
chronic
respiratori
failur
children
neurocognit
dysfunct
behavior
disturb
common
sever
consequ
obstruct
sleep
apnea
osa
children
deleteri
effect
highli
variabl
one
child
anoth
sleep
studi
part
routin
evalu
child
osa
polysomnographi
repres
gold
standard
polygraphi
continu
monitor
nocturn
ga
exchang
may
use
altern
full
polysomnographi
avail
usual
indic
cpap
residu
osa
adenotonsillectomi
defin
ahi
eventsh
osa
relat
obes
craniofaci
abnorm
practic
cpap
prescrib
children
complex
osa
due
anatom
structur
abnorm
upper
airway
craniofaci
malform
syndrom
prader
willi
syndrom
morbid
obes
bipap
indic
nocturn
hypoventil
persist
despit
optim
cpap
cpap
associ
improv
sleep
paramet
ahi
ga
exchang
attent
deficit
behavior
sleepi
qualiti
life
less
consensu
regard
type
investig
criteria
bipap
initi
children
neuromuscular
diseas
first
bipap
may
justifi
without
sleep
studi
child
present
episod
acut
respiratori
failur
trigger
respiratori
infect
anesthet
procedur
event
marker
insuffici
respiratori
reserv
concern
time
sleep
studi
lack
valid
recommend
may
partial
explain
heterogen
neuromuscular
disord
children
symptom
suggest
breath
use
predictor
marker
nocturn
hypoventil
differ
neuromuscular
children
without
document
nocturn
hypoventil
concern
predict
valu
lung
function
respiratori
paramet
larg
prospect
studi
children
neuromuscular
disord
identifi
sensit
specif
daytim
lung
function
respiratori
muscl
test
associ
predict
nocturn
hypoxemia
hypercapnia
type
neuromuscular
disord
thu
taken
account
nocturn
hypoventil
occur
preferenti
disord
character
promin
diaphragmat
weak
children
myopathi
thu
screen
systemat
sleep
disord
breath
priorit
screen
also
recommend
infant
young
children
congenit
myopathi
rapidli
progress
neuromuscular
diseas
children
neuromuscular
diseas
document
nocturn
hypoventil
mean
polysomnographi
recommend
essenti
prior
start
bipap
isol
abnorm
nocturn
ga
exchang
may
suffici
inde
patient
neuromuscular
diseas
thorac
deform
isol
nocturn
hypercapnia
without
daytim
hypercapnia
progress
overt
daytim
respiratori
failur
within
period
year
moreov
presenc
abnorm
overnight
ga
exchang
record
full
polysomnographi
criteria
use
defin
nocturn
hypoventil
highli
variabl
practic
consequ
long
term
niv
indic
reli
upon
hypoventil
detect
score
polysomnographi
patient
neuromuscular
diseas
requir
specif
expertis
inde
instead
apneic
hypopn
event
patient
may
present
progress
simultan
decreas
airflow
thorac
abdomin
movement
accompani
chang
ga
exchang
suggest
global
inspiratori
muscl
weak
paradox
breath
opposit
phase
thorac
abdomin
belt
may
consequ
diaphragmat
dysfunct
weak
intercost
muscl
fals
interpret
obstruct
event
clinic
practic
period
reduc
ventil
paradox
breath
obstruct
andor
central
especi
movement
sleep
associ
puls
oximetri
andor
transcutan
carbon
dioxid
valu
mmhg
indic
insuffici
respiratori
muscl
perform
justifi
long
term
bipap
children
neuromuscular
diseas
clinic
practic
howev
mani
children
progress
neuromuscular
diseas
spinal
muscular
atrophi
duchenn
muscular
dystrophi
start
niv
empir
inde
limit
access
sleep
studi
delay
access
patient
effect
treatment
import
requisit
patient
follow
pediatr
team
expertis
niv
consensu
regard
clinic
situat
criteria
justifi
initi
bipap
children
cystic
fibrosi
like
adult
patient
chronic
obstruct
pulmonari
diseas
bipap
recommend
first
line
treatment
acut
hypercapn
respiratori
exacerb
without
evid
prospect
random
studi
bipap
also
larg
prescrib
patient
lung
transplant
list
insuffici
improv
oxygen
therapi
contrast
recent
cochran
review
conclud
improv
nocturn
ga
exchang
less
oxygen
desatur
respiratori
muscl
fatigu
chest
physiotherapi
proven
benefit
bipap
cystic
fibrosi
conclus
screen
least
overnight
ga
exchang
record
detect
nocturn
hypoxemia
andor
hypercapnia
possibl
complet
sleep
studi
prioriti
children
upper
airway
obstruct
type
neuromuscular
lung
diseas
may
associ
nocturn
hypoventil
symptom
breath
insuffici
sensit
specif
tend
appear
late
cours
differ
diseas
poor
sleep
qualiti
associ
neurocognit
dysfunct
abnorm
behavior
decreas
qualiti
life
trial
one
three
month
niv
thorough
evalu
niv
period
seem
reason
option
conclus
long
term
niv
extrem
efficaci
respiratori
support
transform
scope
chronic
respiratori
failur
sever
breath
children
avoid
tracheotomi
allow
child
live
home
good
qualiti
life
child
famili
tremend
heterogen
disord
age
prognosi
outcom
patient
underlin
necess
manag
experienc
multidisciplinari
center
technic
compet
pediatr
niv
expertis
sleep
studi
therapeut
educ
refer
paulid
fm
fb
den
oudenrijn
lp
van
gestel
jp
kampelmach
mj
thirti
year
home
mechan
ventil
children
escal
need
pediatr
intens
care
bed
intens
care
med
mcdougal
cm
adderley
rj
wensley
df
seear
md
ventil
children
longitudin
trend
outcom
arch
di
child
pavon
verrillo
e
caldarelli
v
ullmann
n
cutrera
r
posit
pressur
ventil
children
earli
hum
dev
fauroux
b
pigeot
j
polkey
mi
roger
g
lofaso
f
chronic
stridor
caus
laryngomalacia
children
work
breath
effect
noninvas
ventilatori
assist
j
respir
crit
care
med
fauroux
b
pigeot
j
isabey
harf
lofaso
f
vivo
physiolog
comparison
two
ventil
use
domiciliari
ventil
children
cystic
fibrosi
crit
care
med
fauroux
b
nicot
f
essouri
hart
n
polkey
mi
lofaso
f
set
pressur
support
young
patient
cystic
fibrosi
eur
resp
j
essouri
nicot
f
garabedian
roger
g
lofaso
f
fauroux
b
noninvas
posit
pressur
ventil
infant
upper
airway
obstruct
comparison
continu
bilevel
posit
pressur
intens
care
medicin
hart
n
polkey
mi
moxham
j
lofaso
f
fauroux
b
chang
pulmonari
mechan
increas
diseas
sever
children
young
adult
cystic
fibrosi
j
respir
crit
care
med
l
khirani
thouvenin
g
ramirez
fauroux
b
work
breath
optim
noninvas
ventil
bronchiol
obliteran
intens
care
medicin
khirani
ramirez
aloui
leboulang
n
picard
fauroux
b
cpap
titrat
infant
sever
airway
obstruct
crit
care
fauroux
b
loui
b
hart
n
essouri
leroux
k
clement
polkey
mi
lofaso
f
effect
rate
ventil
young
patient
cystic
fibrosi
intens
care
med
l
khirani
thouvenin
g
ramirez
fauroux
b
work
breath
optim
noninvas
ventil
bronchiol
obliteran
intens
care
med
amaddeo
moreau
j
frapin
khirani
felix
ramirez
fauroux
b
long
term
continu
posit
airway
pressur
cpap
noninvas
ventil
niv
children
initi
criteria
real
life
pediatr
pulmonol
marcu
cl
brook
lj
draper
ka
gozal
halbow
ac
jone
j
schechter
ms
ward
sd
sheldon
sh
shiffman
rn
et
al
diagnosi
manag
childhood
obstruct
sleep
apnea
syndrom
pediatr
kaditi
ag
alonso
alvarez
ml
boudewyn
alexopoulo
ei
ersu
r
joosten
k
larramona
h
miano
narang
trang
h
et
al
obstruct
sleep
disord
breath
children
diagnosi
manag
eur
respir
j
marcu
cl
radcliff
j
konstantinopoul
beck
se
cornaglia
traylor
j
difeo
n
karamessini
lr
gallagh
pr
meltzer
lj
effect
posit
airway
pressur
therapi
neurobehavior
outcom
children
obstruct
sleep
apnea
j
respir
crit
care
med
girbal
ic
c
nune
ferreira
r
pereira
l
saianda
bandeira
ventil
complex
obstruct
sleep
apnea
year
experi
pediatr
tertiari
center
rev
port
pneumol
amaddeo
caldarelli
v
moreau
j
ramirez
khirani
fauroux
b
polygraph
respiratori
event
sleep
children
treat
home
continu
posit
airway
pressur
descript
clinic
consequ
sleep
med
hull
j
aniapravan
r
chan
e
chatwin
forton
j
callagh
j
gibson
n
gordon
j
hugh
mc
culloch
r
et
al
respiratori
manag
children
neuromuscular
weak
guidelin
group
behalf
british
thorac
societi
standard
care
committe
thorax
khirani
colella
caldarelli
v
aubertin
g
forin
v
ramirez
fauroux
b
longitudin
cours
lung
function
respiratori
muscl
strength
spinal
muscular
atrophi
type
eur
j
paediatr
neurol
foley
ar
collin
j
straub
v
mccallum
deconinck
n
mercuri
e
pane
damico
bertini
e
et
al
natur
histori
pulmonari
function
collagen
myopathi
brain
katz
sl
gabouri
keilti
k
banwel
b
vajsar
j
anderson
p
ni
macluski
nocturn
hypoventil
predictor
outcom
childhood
progress
neuromuscular
diseas
arch
di
child
bersanini
c
khirani
ramirez
lofaso
f
aubertin
g
beydon
n
mayer
maincent
k
fauroux
b
nocturn
hypoxemia
hypercapnia
children
neuromuscular
disord
eur
respir
j
khirani
colella
ramirez
aloui
wehbi
de
becdelievr
carlier
ry
allamand
v
richard
p
et
al
diaphragmat
dysfunct
collagen
vi
myopathi
neuromuscular
disord
rutkowski
chatwin
koumbourli
fauroux
b
simond
consortium
crp
enmc
intern
workshop
respiratori
pathophysiolog
congenit
muscl
disord
implic
care
clinic
research
decemb
naarden
netherland
neuromuscul
disord
ward
chatwin
heather
simond
ak
randomis
control
trial
ventil
niv
nocturn
hypoventil
neuromuscular
chest
wall
diseas
patient
daytim
normocapnia
thorax
ogna
quera
salva
prigent
h
mroue
g
vaugier
annan
lofaso
f
orlikowski
nocturn
hypoventil
neuromuscular
diseas
preval
accord
differ
definit
issu
literatur
sleep
breath
sep
epub
ahead
print
griffon
l
amaddeo
mortamet
g
barneria
c
abadi
v
olmo
arroyo
j
de
sancti
l
r
fauroux
b
sleep
studi
diagnost
tool
unexplain
respiratori
failur
infant
hospit
picu
j
crit
care
accept
public
white
je
drinnan
mj
smithson
aj
griffith
cj
gibson
gj
respiratori
muscl
activ
oxygen
sleep
patient
muscl
weak
eur
respir
j
steier
j
jolley
cj
seymour
j
kaul
luo
ym
rafferti
gf
hart
n
polkey
mi
j
breath
unilater
diaphragm
paralysi
sever
weak
eur
respir
j
sood
n
paradowski
lj
yankaska
jr
outcom
intens
care
unit
care
adult
cystic
fibrosi
j
respir
crit
care
med
ellaffi
vinsonneau
c
cost
j
hubert
burgel
pr
dhainaut
jf
dusser
outcom
sever
pulmonari
exacerb
adult
cystic
fibrosi
j
respir
crit
care
med
texereau
j
jamal
choukroun
g
burgel
pr
diehl
jl
rabbat
loirat
p
parrot
duguet
cost
j
et
al
determin
mortal
adult
cystic
fibrosi
admit
intens
care
unit
multicent
studi
respir
re
fauroux
b
burgel
pr
boell
py
cracowski
c
r
stremler
n
derlich
l
giovanetti
p
practic
noninvas
ventil
cystic
fibrosi
nationwid
survey
franc
respir
care
moran
f
bradley
jm
piper
aj
ventil
cystic
fibrosi
cochran
databas
syst
rev
apr
controversi
updat
non
invas
ventil
nicu
amir
kugelman
depart
neonatolog
rambam
medic
center
ruth
children
hospit
b
r
rappaport
faculti
medicin
technion
haifa
israel
email
amirkug
gmailcom
debat
non
invas
ventil
niv
prefer
mode
modern
neonatolog
treatment
respiratori
distress
syndrom
rd
yet
controversi
mode
niv
use
differ
condit
niv
role
initi
treatment
rd
aim
decreas
rate
endotrach
ventil
incid
chronic
lung
diseas
cld
niv
also
use
post
extub
order
decreas
need
reintub
resolut
rd
treat
apnea
avail
option
niv
includ
nasal
continu
posit
airway
pressur
ncpap
nasal
intermitt
posit
pressur
ventil
nippv
high
flow
heat
humidifi
nasal
cannula
hfnc
ncpap
common
modal
niv
larg
random
control
trial
rct
conclud
earli
ncpap
safe
altern
immedi
intub
even
extrem
low
birth
weight
elbw
initi
treatment
rd
center
use
ncpap
escal
nippv
intub
use
nippv
initi
mode
non
invas
support
recent
includ
ten
trial
enrol
total
infant
show
significantli
reduc
risk
meet
respiratori
failur
criteria
risk
ratio
rr
confid
interv
ci
need
intub
typic
rr
ci
among
infant
treat
earli
nippv
compar
earli
ncpap
demonstr
reduct
risk
cld
among
infant
random
nippv
typic
rr
ci
evid
harm
author
conclud
earli
nippv
appear
superior
ncpap
alon
decreas
respiratori
failur
need
intub
endotrach
tube
ventil
among
preterm
infant
rd
synchron
nippv
vs
ncpap
later
use
post
extub
rd
resolut
bridg
spontan
unsupport
breath
shown
effect
ncpap
updat
show
nippv
reduc
incid
extub
failur
need
within
hour
one
week
effect
ncpap
howev
effect
cld
mortal
synchron
may
import
deliv
effect
nippv
devic
use
deliv
nippv
may
import
howev
data
insuffici
support
strong
conclus
synchron
nippv
may
effect
ncpap
also
apnea
regard
apnea
prematur
suggest
synchron
nippv
efficaci
apnea
frequent
sever
howev
studi
perform
address
outcom
could
address
properli
rate
reintub
thu
studi
need
recommend
synchron
nippv
standard
care
apnea
prematur
possibl
addit
effect
nippv
compar
ncpap
relat
synchron
debat
one
studi
stabl
prematur
infant
find
benefit
synchron
yet
infant
stabl
expos
studi
mode
short
time
neutral
adjust
ventil
assist
nava
might
answer
question
nava
new
mode
synchron
nippv
util
chang
electr
activ
diaphragm
edi
trigger
ventil
current
larg
rct
compar
non
synchron
nippv
recent
hfnc
frequent
use
mode
niv
high
flow
result
washout
anatom
physiolog
dead
space
contribut
improv
fraction
alveolar
gase
respect
carbon
dioxid
well
oxygen
decreas
work
breath
energi
cost
ga
condit
hfnc
probabl
creat
posit
end
expiratori
pressur
peep
may
contribut
benefici
effect
peep
usual
lower
peep
administ
via
ncpap
nippv
peep
monitor
hfnc
rais
concern
regard
safeti
hfnc
term
air
leak
cochran
conclud
hfnc
similar
rate
efficaci
form
respiratori
support
preterm
infant
prevent
treatment
failur
death
chronic
lung
diseas
evid
avail
use
hfnc
support
follow
extub
hfnc
associ
less
nasal
trauma
may
associ
reduc
pneumothorax
compar
ncpap
yet
studi
especi
initi
treatment
rd
elbw
infant
need
adopt
hfnc
altern
mode
niv
condit
follow
cochran
intern
hipster
multicent
random
noninferior
preterm
infant
gestat
age
week
day
earli
respiratori
distress
receiv
surfact
replac
assign
treatment
either
hfnc
ncpap
primari
outcom
treatment
failur
within
hour
random
treatment
failur
occur
infant
group
infant
cpap
group
risk
differ
percentag
point
confid
interv
ci
p
rate
intub
within
hour
differ
significantli
cpap
group
respect
risk
differ
percentag
point
ci
p
rate
advers
event
conclud
use
primari
support
preterm
infant
rd
therapi
result
significantli
higher
rate
treatment
failur
ncpap
post
extub
preterm
infant
manley
et
multicent
random
noninferior
trial
assign
preterm
infant
receiv
treatment
either
hfnc
ncpap
primari
outcom
treatment
failur
within
day
use
hfnc
noninferior
use
ncpap
treatment
failur
occur
infant
hfnc
group
infant
ncpap
group
almost
half
infant
treatment
hfnc
fail
success
treat
ncpap
without
reintub
ventil
probabl
safe
success
depend
gestat
age
data
indic
surfact
may
still
signific
role
treatment
rd
especi
elbw
infant
recent
studi
report
intub
rate
ncpap
group
elbw
lead
us
non
less
invas
mode
surfact
administr
may
allow
infant
benefit
surfact
niv
includ
intub
surfact
extub
insur
approach
minim
invas
surfact
therapi
mist
use
mist
surfact
appli
trachea
without
endotrach
intub
use
thin
cathet
spontan
breath
preterm
infant
receiv
ncpap
techniqu
report
reduc
need
mechan
ongo
trial
inhal
surfact
consensu
yet
mode
non
invas
surfact
administr
superior
best
time
applic
mode
infant
niv
summar
ncpap
still
common
mode
non
invas
respiratori
support
world
avail
evid
support
prefer
earli
later
use
nippvsnippv
compar
ncpap
minim
use
length
endotrach
new
mode
niv
nava
nasal
high
frequenc
ventil
need
studi
conclud
benefit
short
long
term
outcom
prematur
infant
less
invas
mode
surfact
administr
may
enhanc
impact
niv
aim
reduc
cld
refer
sweet
dg
carnielli
v
greisen
g
hallman
ozek
e
plavka
r
saugstad
od
simeoni
u
speer
cp
vento
et
al
european
consensu
guidelin
manag
respiratori
distress
syndrom
updat
neonatolog
kugelman
durand
comprehens
approach
prevent
bronchopulmonari
dysplasia
ped
pulmonol
support
studi
group
eunic
kennedi
shriver
nichd
neonat
research
network
finer
nn
carlo
wa
walsh
mc
rich
w
gantz
mg
laptook
ar
yoder
ba
faix
rg
da
pool
wk
et
al
earli
cpap
versu
surfact
extrem
preterm
infant
n
engl
j
med
morley
cj
davi
pg
doyl
lw
brion
lp
hascoet
jm
carlin
jb
coin
trial
investig
nasal
cpap
intub
birth
preterm
infant
n
engl
j
med
lemyr
b
laughon
bose
c
davi
pg
earli
nasal
intermitt
posit
pressur
ventil
nippv
versu
earli
nasal
continu
posit
airway
pressur
ncpap
preterm
infant
cochran
databas
syst
rev
lemyr
b
davi
pg
de
paoli
ag
kirpalani
h
nasal
intermitt
posit
pressur
ventil
nippv
versu
nasal
continu
posit
airway
pressur
ncpap
preterm
neonat
extub
cochran
databas
syst
rev
doi
epub
ahead
print
wilkinson
andersen
c
odonnel
cp
de
paoli
ag
manley
bj
high
flow
nasal
cannula
respiratori
support
preterm
infant
cochran
databas
syst
rev
robert
ct
owen
ls
manley
bj
dh
donath
sm
dalziel
km
pritchard
cartwright
dw
collin
cl
malhotra
et
al
hipster
trial
investig
nasal
therapi
primari
respiratori
support
preterm
infant
n
engl
j
med
manley
bj
owen
ls
doyl
lw
andersen
cc
cartwright
dw
pritchard
donath
sm
davi
pg
nasal
cannula
preterm
infant
extub
n
engl
j
med
w
krib
ziegler
laux
r
hoehn
wieg
c
siegel
j
avenariu
von
der
wens
vochem
et
al
german
neonat
network
avoid
mechan
ventil
surfact
treatment
spontan
breath
preterm
infant
amv
random
control
trial
lancet
ventil
pediatr
updat
praud
pediatr
pulmonolog
divis
univers
sherbrook
qc
canada
email
jeanpaulpraud
usherbrookeca
respiratori
support
increasingli
use
age
extrem
preterm
hisher
adapt
life
elderli
patient
dyspnea
relief
respiratori
support
encompass
number
modal
nasal
cannula
continu
posit
airway
pressur
cpap
ventil
niv
abstract
highlight
recent
public
focus
niv
use
pediatr
acut
well
chronic
respiratori
failur
acut
ventil
acut
niv
neonat
cochran
examin
risk
benefit
earli
niv
versu
earli
nasal
cpap
preterm
infant
risk
respiratori
distress
within
first
hour
birth
ten
trial
enrol
total
infant
met
criteria
inclus
analysi
author
conclud
earli
niv
appear
superior
nasal
cpap
decreas
respiratori
failur
need
intub
endotrach
tube
ventil
preterm
infant
respiratori
distress
syndrom
larger
trial
howev
need
confirm
result
assess
safeti
niv
compar
nasal
cpap
anoth
cochran
team
focus
use
niv
deliv
nasal
prong
nasopharyng
tube
extub
preterm
newborn
ten
random
trial
enrol
total
infant
includ
analysi
author
conclud
overal
evid
indic
niv
reduc
incid
extub
failur
need
within
first
week
effect
nasal
cpap
addit
use
synchron
form
niv
may
import
although
necessit
confirm
larger
trial
similarli
use
mechan
ventil
deliv
niv
appear
effici
bilevel
devic
although
larger
trial
need
confirm
final
differ
niv
nasal
cpap
rate
bronchopulmonari
dysplasia
death
necrot
enterocol
two
public
two
differ
team
summar
data
anim
model
investig
clinic
observ
use
nasal
high
frequenc
oscillatori
ventil
nhfov
neonat
nasal
hfov
advantag
ventil
need
synchron
high
efficaci
remov
nasal
cpap
interfac
improv
oxygen
via
increas
function
residu
capac
data
preterm
lamb
suggest
nhfov
decreas
incid
bronchopulmonari
dysplasia
addit
report
sever
case
seri
shown
nhfov
use
human
neonat
appar
benefit
compar
niv
modal
author
underlin
sever
survey
report
nhfov
increasingli
attempt
neonatolog
center
random
control
studi
rapidli
need
confirm
nhfov
truli
benefici
human
neonat
acut
niv
children
mortamet
et
al
assess
avail
interfac
deliv
niv
children
acut
respiratori
failur
given
niv
acut
set
must
initi
rapidli
use
around
clock
sever
day
choic
optim
interfac
crucial
often
make
differ
niv
success
failur
author
summar
advantag
limit
variou
interfac
avail
children
includ
approach
choos
optim
interfac
monitor
toler
cochran
examin
use
niv
acut
asthma
children
two
trial
enrol
total
children
elig
includ
analysi
bipap
devic
compar
standard
care
use
nasal
cpap
howev
two
studi
asthma
symptom
score
significantli
decreas
low
number
children
high
risk
bia
studi
allow
confirm
reject
benefici
effect
niv
children
acut
asthma
chronic
ventil
clinic
updat
home
ventil
home
niv
focu
two
excel
comprehens
updat
home
niv
may
indic
central
respiratori
drive
anomali
respiratori
musclethorac
wall
dysfunct
upper
airway
obstruct
andor
primari
bronchopulmonari
disord
markedli
disabl
basi
amen
cpap
therapi
articl
underlin
contrast
exponenti
use
niv
children
age
worldwid
lack
valid
criteria
especi
initi
titrat
monitor
treatment
challeng
face
home
niv
infant
children
numer
success
depend
highli
special
multidisciplinari
center
among
other
choic
interfac
patient
mechan
ventil
crucial
factor
addit
train
caregiv
well
avail
dedic
personnel
basi
support
caregiv
essenti
interfac
ventil
children
alreadi
allud
choos
interfac
ventil
patient
one
challeng
aspect
niv
pediatr
especi
infant
recent
articl
address
problem
optim
interfac
use
innov
technolog
subject
mean
age
year
technolog
studi
includ
imag
assess
fit
particular
mask
patient
face
measur
skin
hydrat
interfac
high
definit
color
photographi
visual
earli
skin
compromis
present
studi
patient
skin
injuri
shown
reduc
use
silicon
foam
dress
interpos
plastic
mask
skin
sign
injuri
observ
water
cloth
mask
use
accompani
editori
underlin
need
intens
research
focus
ideal
niv
interfac
comfort
adapt
wide
rang
facial
shape
ii
prevent
overhydr
skin
iii
prevent
unintent
leak
increas
dead
space
asynchroni
ventil
reflux
lesson
newborn
ovin
model
esophag
insuffl
ga
niv
lead
gastric
dilat
latter
turn
increas
reflux
via
transient
relax
inferior
esophag
sphincter
previous
report
nasal
cpap
virtual
abolish
reflux
newborn
lamb
report
acut
niv
either
form
pressur
support
ventilatori
assist
also
inhibit
reflux
note
gastric
dilat
observ
pressur
use
explain
mechan
current
investig
refer
lemyr
b
laughon
bose
c
davi
pg
earli
nasal
intermitt
posit
pressur
ventil
nippv
versu
earli
nasal
continu
posit
airway
pressur
ncpap
preterm
infant
cochran
databas
syst
rev
lemyr
b
davi
pg
de
paoli
ag
kirpalani
h
nasal
intermitt
posit
pressur
ventil
nippv
versu
nasal
continu
posit
airway
pressur
ncpap
preterm
neonat
extub
cochran
databas
syst
rev
yoder
ba
albertin
kh
null
dm
jr
ventil
respiratori
support
neonat
semin
fetal
neonat
med
de
luca
dellorto
v
oscillatori
ventil
neonat
review
physiolog
biolog
clinic
data
arch
di
child
fetal
neonat
ed
press
mortamet
g
amaddeo
essouri
renolleau
emeriaud
g
fauroux
b
interfac
noninvas
ventil
acut
set
children
paediatr
respir
rev
press
korang
sk
feinberg
j
wetterslev
j
jakobsen
jc
posit
pressur
ventil
acut
asthma
children
cochran
databas
syst
rev
amin
r
narang
domiciliari
noninvas
posit
airway
pressur
therapi
children
pediatr
pulmonol
amaddeo
frapin
fauroux
b
ventil
children
lancet
respir
med
visscher
mo
white
cc
jone
jm
cahil
jone
dc
pan
bs
face
mask
noninvas
ventil
fit
excess
skin
hydrat
pressur
ulcer
respir
care
cantin
djeddi
v
samson
n
nault
jia
wl
beck
j
praud
jp
inhibitori
effect
nasal
intermitt
posit
pressur
ventil
gastroesophag
reflux
plo
one
cystic
fibrosi
diagnosi
unclear
jane
c
davi
imperi
colleg
london
royal
brompton
harefield
nh
trust
london
uk
email
jcdavi
imperialacuk
cf
caus
mutat
gene
encod
cf
transmembran
conduct
regul
cftr
protein
anion
channel
situat
apic
surfac
epitheli
cell
control
flux
chlorid
bicarbon
sodium
therebi
regul
airway
surfac
hydrat
patient
lack
normal
cftr
function
impair
mucociliari
clearanc
prone
earli
infect
inflamm
airway
cftr
also
express
sweat
gland
reabsorb
chlorid
sweat
patient
cf
thu
rais
level
sweat
chlorid
earli
observ
fact
led
develop
diagnost
sweat
test
diagnost
establish
mmol
cf
mmol
healthi
popul
intermedi
area
gene
respons
cf
first
identifi
common
mutat
describ
present
least
one
allel
cf
patient
worldwid
around
patient
homozyg
mutat
describ
mani
extrem
rare
yet
fulli
understood
project
aid
progress
rapidli
assign
report
cftr
mutat
variabl
clinic
consequ
categori
http
clinic
manifest
cf
includ
earli
onset
failur
thrive
diarrhea
due
pancreat
exocrin
dysfunct
respiratori
symptom
chronic
moist
cough
bacteri
infect
upper
airway
complic
includ
sinus
nasal
polyp
liver
diseas
later
complic
diabet
mellitu
arthropathi
cf
babi
born
gut
obstruct
due
inspiss
meconium
diagnosi
may
even
suspect
prenat
echogen
bowel
vast
major
case
cf
easi
diagnos
constel
suggest
clinic
phenotyp
rais
sweat
chlorid
mmoll
two
recogn
mutat
allow
diagnosi
confirm
treatment
initi
screen
offer
close
famili
member
mani
part
world
newborn
screen
program
case
diagnos
earli
infanc
commonli
base
find
rais
immunoreact
trypsinogen
irt
follow
cftr
genotyp
repeat
irt
number
differ
algorithm
exist
howev
later
life
newborn
period
diagnost
dilemma
aris
addit
test
may
need
exampl
case
provid
use
framework
illustr
issu
case
old
man
present
primari
care
seek
fertil
test
found
azosperm
question
well
throughout
childhood
suffer
prolong
bout
bronchiti
whilst
travel
gap
year
asia
admit
unhealthi
behavior
includ
smoke
tobacco
marijuana
trip
sinc
persist
smoker
cough
despit
given
report
produc
small
amount
clear
phlegm
day
could
unwel
prescrib
cours
antibiot
last
year
normal
bowel
habit
report
signific
abdomin
pain
ct
scan
reveal
moder
bilater
upper
lobe
bronchiectasi
diagnosi
cf
sensibl
consid
repeat
sweat
test
reveal
chlorid
mmoll
first
line
genet
test
show
heterozyg
mutat
underw
nasal
potenti
differ
test
reveal
normal
basal
pd
almost
complet
absenc
chlorid
secret
upon
stimul
combin
ringer
camp
agonist
isoprenalin
sensit
test
cftr
function
airway
epithelium
subsequ
found
possess
addit
mutat
allel
mutat
variabl
clinic
signific
often
found
associ
diseas
one
organ
normal
borderlin
sweat
test
patient
constel
sign
test
consid
support
diagnosi
cf
case
well
old
babi
girl
refer
follow
posit
newborn
screen
cf
follow
rais
irt
genotyp
confirm
latter
mutat
ci
lead
residu
variabl
cftr
function
togeth
mutat
may
lead
cf
albeit
usual
milder
phenotyp
may
also
found
complet
healthi
individu
babi
normal
stool
parent
concern
sweat
chlorid
mmoll
well
upper
limit
normal
rang
mmoll
consensu
europ
babi
term
cf
spid
screen
posit
indetermin
diagnosi
cystic
fibrosi
develop
lung
complic
later
life
degre
follow
advis
consensu
guidelin
group
babi
detail
present
babi
underw
repeat
sweat
test
first
two
year
life
remain
normal
clinic
concern
evolv
cf
therefor
diseas
consid
learn
cftr
recogn
much
remain
unknown
mani
cftr
mutat
lead
variabl
consequ
may
addit
factor
environ
behavior
aspect
genet
make
modifi
gene
determin
whether
peopl
remain
healthi
display
manifest
diseas
nasal
potenti
differ
test
assay
cftr
function
short
circuit
current
rectal
biopsi
recent
cultur
organoid
latter
may
prove
use
diagnost
aid
case
borderlin
diagnost
test
context
singl
organ
diseas
nasal
polyp
term
disord
diagnost
understand
evolv
new
term
cfspid
requir
cohort
patient
describ
diseas
actual
mutat
investig
consid
case
refer
de
boeck
k
wilschanski
castellani
c
et
al
cystic
fibrosi
terminolog
diagnost
algorithm
thorax
munck
mayel
sj
winter
v
et
al
cystic
fibrosi
screen
posit
inconclus
diagnosi
cfspid
new
design
manag
recommend
infant
inconclus
diagnosi
follow
newborn
screen
j
cyst
fibro
dekker
jf
wiegerinck
cl
de
jong
hr
et
al
function
cftr
assay
use
primari
cystic
fibrosi
intestin
organoid
nat
med
fajac
viel
gaitch
n
et
al
combin
enac
cftr
mutat
may
predispos
cystic
diseas
eur
respir
j
therapi
cystic
fibrosi
judith
voynow
edwin
l
kendig
jr
professor
pediatr
pulmonari
medicin
children
hospit
richmond
vcu
richmond
va
usa
email
judithvoynow
vcuhealthorg
cystic
fibrosi
cf
lung
diseas
mark
recurr
exacerb
bronchiti
opportunist
organ
neutrophil
domin
inflamm
relentless
cycl
infect
inflamm
result
airway
injuri
bronchiectasi
lead
ultim
respiratori
failur
common
caus
death
semin
featur
cf
lung
diseas
excess
unoppos
neutrophil
mediat
degrad
innat
immun
function
promot
mucu
obstruct
airway
airway
epitheli
cell
immun
cell
play
critic
role
initi
progress
cf
lung
diseas
primari
caus
cf
lung
diseas
loss
function
cystic
fibrosi
transmembran
conduct
regul
cftr
howev
debat
concern
whether
loss
cftr
caus
inher
hyperinflammatori
state
whether
loss
cftr
promot
persist
lung
infect
local
innat
immun
failur
secondari
hyperinflammatori
state
new
insight
pig
ferret
recapitul
patholog
featur
human
cf
lung
diseas
reveal
airway
inflamm
newborn
anim
absenc
infect
howev
grow
bodi
evid
cftr
defici
impair
critic
innat
immun
function
enabl
lung
infect
cftr
directli
affect
airway
innat
immun
via
function
regul
anion
channel
cftr
regul
chlorid
efflux
also
bicarbon
thiocyan
efflux
cftr
defici
result
loss
bicarbon
acid
airway
surfac
milieu
chang
statu
inhibit
antimicrobi
peptid
includ
cathelicidin
hinder
normal
phagocyt
cell
clearanc
bacteria
affect
mucin
biochem
biophys
properti
result
failur
normal
mucociliari
clearanc
microb
thiocyan
critic
epitheli
gener
hypothiocyan
import
factor
loss
cftr
apic
chlorid
channel
result
unoppos
epitheli
sodium
channel
activ
airway
surfac
dehydr
loss
airway
surfac
liquid
homeostasi
increas
mucu
viscos
prevent
mucociliari
clearanc
microb
addit
caus
aberr
ion
water
homeostasi
loss
cftr
associ
deplet
protect
factor
airway
epithelium
includ
cytokin
ii
ino
requir
factor
upregul
interferon
factor
iii
glutathion
major
antioxid
furthermor
loss
cftr
also
affect
balanc
lipid
result
state
airway
patient
cf
increas
arachidon
acid
decreas
docosahexano
acid
compar
healthi
control
subject
arachidon
acid
precursor
inflammatori
lipid
leukotrien
thromboxan
prostaglandin
docosahexano
acid
precursor
lipid
resolvin
protectin
blunt
neutrophil
infiltr
sphingolipid
lung
also
alter
cf
conflict
inform
concern
impact
loss
cftr
ceramid
level
macrophag
epitheli
cell
either
excess
defici
ceramid
level
observ
differ
mice
importantli
homeostasi
ceramid
disturb
either
direct
mice
suscept
increas
inflamm
furthermor
sphingolipid
sphingosin
play
import
role
respons
microb
lung
ceramid
affect
cell
membran
lipid
raft
composit
receptor
cluster
cell
signal
ceramid
also
increas
epitheli
cell
permeabl
induc
apoptosi
patient
cf
long
chain
ceramid
increas
sphingosin
decreas
respiratori
epitheli
cell
either
inhibit
ceramid
accumul
augment
sphingosin
analog
rescu
mice
p
aeruginosa
pneumonia
cf
immun
cell
also
dysregul
respons
shift
differenti
cf
cell
cf
alveolar
macrophag
fail
clear
infect
yet
exagger
inflammatori
respons
stimuli
cf
neutrophil
overexuber
respons
infect
releas
reactiv
oxygen
speci
damag
protein
lipid
dna
releas
neutrophil
elastas
via
neutrophil
extracellular
trap
necrosi
neutrophil
elastas
ne
activ
cascad
event
airway
promot
infect
impair
bacteri
phagocytosi
kill
ne
upregul
mucin
express
secret
injur
cilia
caus
failur
mucociliari
clearanc
ne
cleav
opsonin
receptor
macrophag
prevent
bacteri
clearanc
efferocytosi
apoptot
neutrophil
ne
upregul
neutrophil
chemokin
aggrav
neutrophil
inflamm
ne
cleav
tissu
inhibitor
matrix
metalloproteas
increas
releas
activ
proteas
invers
relat
ne
also
induc
releas
high
mobil
group
box
cytokin
alarmin
activ
rage
receptor
significantli
inhibit
macrophag
phagocytosi
bacteri
kill
pseudomona
pneumonia
mous
model
furthermor
alarmin
calgranulin
releas
neutrophil
activ
rage
signal
via
activ
ne
degrad
iron
contain
protein
lactoferrin
airway
releas
iron
requir
bacteri
growth
biofilm
format
also
taken
epitheli
cell
gener
oxid
stress
larg
number
inflammatori
target
lead
sustain
infect
inflamm
enorm
challeng
develop
therapi
patient
cf
great
hope
drug
correct
andor
potenti
normal
cftr
function
abrog
cycl
infect
inflamm
start
earli
life
howev
although
ivacaftor
therapi
patient
mutat
significantli
improv
lung
function
weight
gain
sweat
chlorid
level
decreas
airway
inflammatori
mediat
result
may
due
initi
therapi
bronchiectasi
establish
patient
ivacaftor
approv
infant
concept
test
correct
cftr
prevent
infect
inflamm
importantli
earli
prospect
random
doubl
blind
studi
use
oral
glucocorticoid
everi
day
year
patient
cf
provid
proof
principl
therapi
improv
lung
function
cf
patient
howev
side
effect
chronic
glucocorticoid
therapi
prevent
use
routin
agent
approv
therapi
cf
current
high
dose
ibuprofen
azithromycin
although
ibuprofen
slow
lung
function
declin
random
control
prospect
trial
year
particularli
patient
chronic
p
aeruginosa
infect
wide
accept
due
difficulti
obtain
level
monitor
therapi
potenti
side
effect
thrice
weekli
azithromycin
therapi
chronic
p
aeruginosa
wide
accept
therapi
reveal
modest
improv
decreas
risk
pulmonari
exacerb
decreas
serum
inflammatori
marker
chronic
azithromycin
therapi
patient
cf
infect
p
aeruginosa
also
decreas
frequenc
pulmonari
exacerb
cough
improv
sinc
approv
ibuprofen
azithromycin
sever
trial
therapi
patient
cf
target
specif
inflammatori
mediat
proteas
reactiv
oxygen
speci
neutrophil
chemoattract
abnorm
intracellular
signal
abnorm
lipid
date
none
drug
move
forward
phase
trial
addit
target
therapi
global
medic
approv
use
inflammatori
diseas
test
efficaci
patient
cf
cff
therapeut
develop
network
shepherd
drug
test
confirm
safeti
efficaci
sever
challeng
met
first
import
character
inflammatori
biomark
follow
trial
although
airway
biomark
detect
sputum
bronchoalveolar
lavag
direct
measur
airway
inflamm
healthi
young
subject
expector
would
requir
sputum
induct
bal
invas
easili
access
research
purpos
children
therefor
identif
circul
inflammatori
biomark
would
facilit
determin
efficaci
vivo
second
confirm
safeti
critic
earli
process
sinc
medic
may
unpredict
side
effect
increas
suscept
infect
third
import
select
correct
popul
like
respond
person
medicin
approach
therapi
differ
class
cftr
mutat
respons
specif
cftr
correctorpotenti
therapi
possibl
patient
inflammatori
profil
use
clinician
determin
best
choic
medic
overcom
challeng
forg
path
effect
safe
therapi
break
viciou
cycl
infect
inflamm
prevent
cf
lung
diseas
progress
refer
bruscia
em
bonfield
tl
innat
adapt
immun
cystic
fibrosi
clin
chest
med
aur
schiumarini
loberto
n
bassi
r
tamanini
mancini
g
tironi
munari
cabrini
g
dechecchi
mc
et
al
unravel
role
sphingolipid
cystic
fibrosi
lung
diseas
chem
phi
lipid
torphi
tj
allen
j
cantin
konstan
mw
accurso
fj
joseloff
e
ratjen
fa
chmiel
jf
antiinflammatori
therapi
work
g
consider
conduct
clinic
trial
antiinflammatori
agent
cystic
fibrosi
cystic
fibrosi
foundat
workshop
report
ann
thorac
soc
cantin
hartl
konstan
mw
chmiel
jf
inflamm
cystic
fibrosi
lung
diseas
pathogenesi
therapi
j
cyst
fibro
nichol
dp
chmiel
jf
inflamm
genesi
cystic
fibrosi
pediatr
pulmonol
suppl
kerem
e
ferkol
elizur
airway
inflamm
cystic
fibrosi
molecular
mechan
clinic
implic
thorax
freedman
sd
blanco
pg
zaman
mm
shea
jc
ollero
hopper
ik
weed
da
gelrud
regan
mm
laposata
alvarez
jg
osullivan
bp
associ
cystic
fibrosi
abnorm
fatti
acid
metabol
n
engl
j
med
voynow
ja
fischer
bm
zheng
proteas
cystic
fibrosi
int
j
biochem
cell
biol
treat
resist
bacteria
aureu
p
aeruginosa
other
matthia
gries
hauner
children
hospit
univers
munich
lindwurmstr
tel
fax
email
matthiasgries
medunimuenchend
cours
frequent
autosom
recess
disord
caucasian
cystic
fibrosi
cf
strongli
influenc
presenc
respiratori
pathogen
last
decad
care
cf
patient
becom
challeng
due
select
bacteria
well
novel
techniqu
identifi
pathogen
present
lung
regard
staphylococcu
aureu
mrsa
establish
assess
success
erad
scheme
introduc
newli
colon
patient
center
intens
therapi
ie
iv
oral
combin
mrsa
erad
patient
subject
stabl
clinic
cours
mean
one
year
mrsa
year
mrsa
pseudomona
aeruginosa
p
ae
detect
studi
burn
et
al
combin
bronchoalveolar
lavag
serolog
result
high
rate
even
children
younger
three
year
age
indic
p
aeruginosa
infect
occur
earli
may
intermitt
undetect
cultur
secondari
prevent
ie
intervent
diagnosi
airway
colon
establish
usual
approach
interest
variou
studi
success
rate
depend
primarili
definit
erad
time
point
least
better
year
first
detect
use
get
reliabl
result
also
includ
measur
serum
ae
antibodi
chronic
p
ae
infect
necessit
regular
suppress
therapi
antimicrobi
order
prevent
deterior
lung
function
qvist
et
al
identifi
infect
signific
impact
rate
declin
pseudomona
aeruginosa
alon
neg
impact
ci
mycobacterium
abscessu
complex
led
loss
point
per
year
ci
burkholderia
cepacia
complex
ci
achromobact
xylosoxidan
ci
common
approach
address
microbacteria
discuss
studi
qvist
clear
abscessu
complex
associ
chang
slower
declin
similar
magnitud
slope
multitud
bacteria
cf
airway
detect
base
techniqu
given
patient
dosag
pharmacodynam
interact
drug
appli
comprehens
treatment
includ
airway
clearanc
upper
airway
reservoir
implement
everyday
life
need
consid
treat
resist
bacteria
cf
difficulti
extub
newborn
neonat
intens
care
unit
petr
pulmonolog
pediatr
depart
perinatolog
center
depart
gynecolog
obstetr
faculti
medicin
univers
hospit
motol
pragu
czech
republ
email
petrpohunek
lfmotolcunicz
introduct
secur
airway
guarante
effect
ventil
cornerston
resuscit
manag
respiratori
failur
endotrach
intub
reliabl
method
provid
access
lung
deliveri
airoxygen
manag
airway
obstruct
direct
suction
indic
intub
manag
intub
child
special
challeng
intens
care
set
requir
care
judgment
respect
physiolog
need
children
differ
age
group
indic
intub
neonat
aspect
safe
manag
neonat
endotrach
intub
often
need
emerg
procedur
deliveri
room
case
perinat
complic
respiratori
failur
situat
endotrach
intub
may
chosen
elect
procedur
secur
airway
provid
posit
pressur
ventil
may
case
congenit
defect
sequenc
macroglossi
laryng
cyst
fetal
hydrop
diaphragmat
hernia
diaphragmat
paresi
short
endotrach
intub
use
surfact
administr
extrem
low
birth
weight
babi
insur
howev
recent
less
invas
surfact
administr
lisa
use
often
prevent
possibl
complic
even
short
intub
frequent
indic
endotrach
intub
respiratori
failur
requir
artifici
ventil
broad
spectrum
disord
may
lead
respiratori
compromis
newborn
prematur
babi
incid
respiratori
distress
rather
high
often
requir
posit
pressur
ventil
oxygen
supplement
depend
gestat
age
factor
ventil
regim
fraction
oxygen
bronchopulmonari
dysplasia
variou
sever
develop
determin
intens
durat
respiratori
support
need
reason
perinat
respiratori
failur
may
occur
either
directli
associ
respiratori
patholog
meconium
aspir
atelectasi
transient
tachypnea
newborn
complic
patholog
sepsi
metabol
disord
congenit
heart
defect
surgeri
congenit
defect
postnat
complic
current
techniqu
artifici
ventil
base
synchron
volum
guarante
regim
provid
effect
support
fulli
respect
physiolog
requir
newborn
assur
adequ
oxygen
reduc
risk
associ
posit
pressur
ventil
anoth
critic
issu
choic
endotrach
tube
appropri
size
larg
diamet
endotrach
tube
may
caus
trauma
ischem
injuri
airway
lead
immedi
complic
even
late
sequela
airway
stenosi
extub
newborn
nicu
durat
endotrach
intub
determin
underli
patholog
requir
ventil
support
desir
keep
intub
period
short
possibl
reduc
risk
possibl
complic
earli
extub
howev
inevit
carri
risk
cardiopulmonari
instabl
often
result
need
reintub
reinstitut
artifici
ventil
hand
prolong
intub
associ
increas
risk
airway
lung
injuri
increas
incid
infecti
complic
ventil
associ
pneumonia
neurodevelopment
impair
mainli
extrem
low
birth
weight
continu
monitor
evalu
respiratori
statu
child
therefor
mandatori
allow
appropri
time
extub
decis
extub
taken
care
evalu
cardiorespiratori
stabil
oxygen
requir
trend
overal
statu
babi
readi
switch
spontan
ventil
extub
alway
properli
plan
prepar
worst
scenario
unexpect
accident
extub
usual
lead
emerg
reintub
carri
signific
risk
hypoxemia
instabl
even
airway
injuri
rapid
emerg
reintub
variou
protocol
wean
mechan
ventil
extub
propos
unifi
concept
assur
effect
spontan
ventil
prevent
ventil
inhomogen
alveolar
collaps
first
step
reduct
sedat
guarante
unsuppress
central
respiratori
activ
child
maintain
adequ
spontan
trigger
breath
reduc
togeth
inspiratori
pressur
pin
recommend
tidal
volum
maintain
adequ
ventil
time
prevent
lung
injuri
level
mlkg
bw
complianc
resist
respiratori
tract
also
taken
consider
extub
tube
use
last
direct
suction
need
monitor
blood
gase
vital
sign
function
provid
stabl
result
child
extub
immedi
switch
nasal
cpap
especi
preterm
babi
residu
lung
patholog
ncpap
pressur
kept
higher
level
shown
effect
lower
pressur
especi
prematur
babi
pharmacolog
support
transit
caffein
methylxanthin
corticosteroid
may
consid
children
bpd
histori
difficult
intub
increas
risk
edema
airway
suspect
may
improv
rate
success
extub
possibl
risk
alway
weigh
nasal
intermitt
posit
pressur
ventil
nippv
shown
safe
effect
prevent
reintub
preterm
children
whose
respons
ncpap
extub
failur
properli
plan
prepar
extub
usual
success
nevertheless
even
proper
prepar
ventil
children
present
extub
failur
need
immedi
earli
need
reintub
usual
signal
anatom
problem
airway
obstruct
develop
remov
stent
tube
may
also
associ
switch
posit
pressur
ventil
spontan
breath
chang
pressur
gradient
airway
problem
mostli
observ
tracheobronchomalacia
extern
compress
airway
congenit
airway
defect
upper
airway
laryng
patholog
may
also
lead
quick
onset
respiratori
problem
may
help
evalu
airway
ultrathin
bronchoscop
stabil
reinstitut
adequ
ventil
care
extub
bronchoscop
may
help
reveal
locat
obstruct
mani
case
howev
reliabl
sever
rather
differ
time
interv
use
publish
studi
defin
reintub
extub
failur
therefor
comparison
publish
result
rather
difficult
mostli
use
interv
hour
practic
point
view
failur
extub
understand
need
reintub
child
new
patholog
could
explain
immin
respiratori
failur
indic
reintub
usual
frequent
major
apnea
inabl
maintain
hemoglobin
satur
kpa
rise
kpa
increas
work
breath
rise
respiratori
rate
retract
grunt
develop
combin
acidosi
intoler
ncpap
inappropri
respons
fail
extub
repres
high
risk
situat
especi
low
birth
weight
children
associ
high
morbid
even
increas
risk
therefor
variou
attempt
predict
success
extub
publish
base
score
physiolog
sign
character
respiratori
drive
respiratori
strength
simpl
ratio
dead
space
tidal
volum
vdvt
fail
predict
risk
extub
tidal
volum
moment
extub
ratio
spontan
breath
test
sbt
extub
score
start
hour
extub
show
signific
predict
valu
risk
sophist
studi
attempt
character
physiolog
ventil
predictor
extub
failur
electr
imped
tomographi
shown
help
assess
appropri
cpap
pressur
achiev
optim
ventil
homogen
thu
prevent
risk
measur
index
diaphragm
respiratori
muscl
ttdi
ttmu
abl
predict
extub
outcom
howev
sensit
specif
simpl
factor
mainli
gestat
age
birth
weight
perform
similarli
predict
extub
low
also
show
potenti
predict
extub
conclus
fail
extub
newborn
neonat
intens
care
set
alway
repres
high
risk
situat
may
associ
signific
deterior
child
even
lead
cardiopulmonari
instabl
death
right
time
extub
alway
well
judg
base
assess
respiratori
stabil
evalu
possibl
risk
failur
refer
walsh
mc
morri
bh
wrage
la
vohr
br
pool
wk
tyson
je
wright
ehrenkranz
ra
stoll
bj
fanaroff
aa
et
al
extrem
low
birthweight
neonat
protract
ventil
mortal
neurodevelopment
outcom
j
pediatr
buzzella
b
claur
n
dugard
c
bancalari
e
random
control
trial
two
nasal
continu
posit
airway
pressur
level
extub
preterm
infant
j
pediatr
ferguson
kn
robert
ct
manley
bj
davi
pg
intervent
improv
rate
success
extub
preterm
infant
jama
pediatr
lemyr
b
davi
pg
de
paoli
ag
kirpalani
h
nasal
intermitt
posit
pressur
ventil
nippv
versu
nasal
continu
posit
airway
pressur
ncpap
preterm
neonat
extub
lemyr
b
editor
cochran
databas
syst
rev
manley
bj
doyl
lw
owen
ls
davi
pg
extub
extrem
preterm
infant
predictor
success
outcom
follow
failur
j
pediatr
bousso
ejzenberg
b
ventura
amc
fernand
jc
fernand
ic
de
pf
vaz
fac
evalu
dead
space
tidal
volum
ratio
predictor
extub
failur
j
pediatr
rio
j
spasojev
doronjski
risk
factor
associ
failur
extub
newborn
j
matern
neonat
med
feb
rossi
f
de
yagui
acz
haddad
lb
deutsch
ad
rebello
cm
electr
imped
tomographi
evalu
air
distribut
prior
extub
infant
feasibl
studi
clinic
sao
paulo
bhat
p
peacock
jl
rafferti
gf
hannam
greenough
predict
infant
extub
outcom
use
index
arch
di
child
fetal
neonat
ed
neonat
pulmonolog
year
review
pediatr
pulmonologist
amir
kugelman
depart
neonatolog
rambam
medic
center
ruth
children
hospit
b
r
rappaport
faculti
medicin
technion
haifa
israel
email
amirkug
gmailcom
pediatr
pulmonologist
might
ask
consult
neonat
intens
care
unit
nicu
thu
awar
recent
trend
neonatolog
reflect
publish
literatur
field
neonat
pulmonolog
larg
trial
assess
influenc
prenat
steroid
rate
respiratori
morbid
associ
ttn
late
preterm
term
infant
recent
larg
multicent
random
trial
explor
prenat
betamethason
treatment
week
primari
outcom
studi
composit
treatment
first
hour
use
continu
posit
airway
pressur
nasal
cannula
least
hour
supplement
oxygen
fraction
inspir
oxygen
least
least
hour
extracorpor
membran
oxygen
mechan
ventil
stillbirth
neonat
death
within
hour
deliveri
rate
primari
outcom
lower
betamethason
group
compar
placebo
group
vs
p
rate
sever
respiratori
complic
also
lower
betamethason
group
vs
p
rate
rd
apnea
pneumonia
similar
two
group
rate
ttn
significantli
lower
studi
group
vs
p
also
reduct
bronchopulmonari
dysplasia
bpd
resuscit
birth
surfact
use
betamethason
group
contradictori
studi
trial
may
support
role
steroid
prevent
ttn
late
preterm
infant
current
clinic
trial
examin
effect
postnat
corticosteroid
ttn
late
preterm
term
infant
use
earli
system
steroid
extrem
preterm
infant
recommend
may
compromis
brain
develop
neurosi
infant
gestat
age
week
day
week
day
randomli
assign
earli
within
hour
birth
inhal
budesonid
placebo
longer
requir
oxygen
support
reach
postmenstru
age
week
day
primari
outcom
death
bpd
studi
conclud
among
extrem
preterm
infant
incid
bpd
lower
among
receiv
earli
inhal
budesonid
among
receiv
placebo
advantag
may
gain
expens
increas
mortal
recent
shinwel
et
assess
safeti
efficaci
inhal
corticosteroid
prevent
treatment
bpd
death
preterm
infant
inhal
corticosteroid
associ
signific
reduct
death
bpd
week
postmenstru
age
risk
ratio
rr
confid
interv
ci
p
trial
n
bpd
significantli
reduc
rr
ci
trial
n
use
system
steroid
significantli
reduc
treat
infant
conclud
preterm
infant
appear
benefit
inhal
corticosteroid
reduc
risk
bpd
effect
death
morbid
advers
event
data
respiratori
growth
development
outcom
eagerli
await
role
inhal
corticosteroid
establish
bpd
spontan
breath
infant
studi
kugelman
et
administ
inhal
steroid
dipropion
qvar
uniqu
small
particl
size
result
higher
lung
deposit
random
multicent
pilot
studi
studi
unabl
detect
signific
effect
inhal
qvar
respiratori
cours
establish
bpd
studi
underpow
possibl
benefit
qvar
could
mask
tendenc
toward
higher
use
addit
steroid
placebo
group
despit
near
univers
adapt
gentl
mechan
ventil
surfact
use
respiratori
support
bpd
remain
one
common
respiratori
morbid
low
birth
weight
vlbw
infant
recent
report
efficaci
administr
mixtur
prevent
bpd
infant
analysi
includ
studi
reveal
infant
receiv
instil
mixtur
demonstr
reduct
risk
bpd
rr
ci
nnt
although
mortal
differ
group
reduct
observ
composit
outcom
death
bpd
group
rr
ci
nnt
thu
review
conclud
administr
combin
associ
decreas
incid
bpd
alon
composit
outcom
death
bpd
vlbw
infant
howev
need
larger
trial
combin
therapi
recommend
standard
care
line
trend
minim
invas
therapi
kugelman
et
publish
studi
impact
continu
capnographi
ventil
neonat
random
studi
studi
aim
compar
time
spent
within
safe
rang
mmhg
convent
ventil
infant
monitor
distal
capnographi
infant
monitor
compar
mask
group
spent
significantli
p
less
time
unsaf
rang
level
high
vs
low
vs
respect
intraventricular
hemorrhag
ivh
periventricular
leukomalacia
pvl
rate
lower
monitor
group
p
found
significantli
p
associ
independ
factor
ga
rate
bpd
compar
group
studi
conclud
continu
found
improv
control
level
within
safe
rang
convent
ventil
nicu
bradley
et
report
nasal
therapi
nhft
commonli
use
respiratori
support
nicu
studi
object
determin
aspect
neonat
nhft
achiev
adequ
evid
base
support
consensu
among
experienc
clinic
investig
document
area
lack
consensu
promot
futur
investig
consensu
reach
mani
aspect
nhft
includ
need
adequ
heat
humidif
need
prevent
nare
occlus
maximum
flow
rate
lmin
assess
work
breath
either
flow
escal
wean
equival
nhft
nasal
continu
posit
airway
pressur
ncpap
support
infant
week
resolv
respiratori
distress
use
nhft
support
stabl
infant
ncpap
major
consensu
occur
initi
ga
flow
rate
rang
liter
per
minut
nhft
primari
therapi
mild
respiratori
distress
consensu
approach
discontinu
nhft
goal
gentl
support
minim
invas
respiratori
therapi
improv
long
term
respiratori
neurolog
outcom
prematur
infant
recent
incorpor
new
modal
respiratori
support
revisit
definit
bpd
object
studi
identifi
optim
definit
bpd
best
predict
respiratori
neurodevelopment
outcom
preterm
infant
conclud
defin
bpd
use
oxygen
alon
inadequ
oxygenrespiratori
support
better
indic
chronic
respiratori
insuffici
particular
oxygenrespiratori
support
week
post
menstrual
age
pma
identifi
best
predictor
seriou
respiratori
morbid
also
display
good
abil
predict
neurosensori
morbid
month
conclud
trend
modern
neonatolog
gentl
possibl
use
new
technolog
mode
therapi
achiev
goal
refer
c
thom
ea
blackwel
sc
tita
reddi
um
saad
gr
rous
dj
mckenna
ds
clark
ea
thorp
jm
jr
et
al
nichd
medicin
unit
network
nichd
medicin
unit
network
antenat
betamethason
women
risk
late
preterm
deliveri
n
engl
j
med
bassler
plavka
r
shinwel
es
hallman
jarreau
ph
carnielli
v
van
den
anker
jn
meisner
c
engel
c
schwab
et
al
neurosi
trial
group
earli
inhal
budesonid
prevent
bronchopulmonari
dysplasia
n
engl
j
med
shinwel
es
portnov
meerpohl
jj
karen
bassler
inhal
corticosteroid
bronchopulmonari
dysplasia
pediatr
kugelman
peniakov
zangen
shiff
riskin
iof
shori
bader
arnon
inhal
dipropion
bronchopulmonari
dysplasia
random
control
pilot
studi
j
perinatol
oct
doi
venkataraman
r
kamaluddeen
hasan
su
robertson
hl
lodha
intratrach
administr
prevent
bronchopulmonari
dysplasia
low
birth
weight
infant
systemat
review
pediatr
pulmonol
feb
doi
epub
ahead
print
kugelman
golan
shori
ronen
qumqam
n
riskin
bader
bromik
r
impact
continu
capnographi
ventil
infant
random
studi
j
pediatr
bradley
manley
b
collin
c
ive
k
kugelman
lavizzari
mcqueen
consensu
approach
nasal
therapi
neonat
j
perinatol
press
isayama
lee
sk
yang
j
lee
daspal
dunn
shah
ps
canadian
neonat
network
canadian
neonat
network
investig
revisit
definit
bronchopulmonari
dysplasia
effect
chang
panopli
respiratori
support
preterm
neonat
jama
pediatr
jan
doi
epub
ahead
print
bronchopulmonari
dysplasia
acut
long
term
manag
prevent
chronic
lung
diseas
judith
voynow
edwin
l
kendig
jr
professor
pediatr
pulmonari
medicin
children
hospit
richmond
vcu
richmond
va
usa
judithvoynow
vcuhealthorg
fifti
year
ago
northway
first
describ
bronchopulmonari
dysplasia
bpd
bpd
affect
approxim
preterm
infant
annual
us
major
caus
chronic
lung
diseas
morbid
preterm
infant
preterm
infant
diagnos
bpd
base
requir
supplement
oxygen
ventil
support
commonli
use
criteria
base
physiolog
challeng
test
week
age
assess
infant
requir
supplement
oxygen
epidemiolog
patholog
bpd
chang
dramat
past
year
old
bpd
occur
preterm
infant
surfact
defici
week
follow
respiratori
distress
syndrom
rd
introduct
two
therapi
antenat
steroid
intratrach
aerosol
surfact
markedli
improv
outcom
surviv
shift
demograph
bpd
earlier
preterm
infant
week
gestat
age
new
bpd
often
call
chronic
lung
diseas
newborn
cld
character
arrest
develop
larger
simplifi
alveoli
increas
interstiti
fibrosi
abnorm
pulmonari
vasculatur
decreas
branch
precapillari
arterioven
anastomos
comorbid
associ
bpd
includ
patent
ductu
arteriosu
increas
pulmonari
edema
abnorm
central
respiratori
drive
apnea
hypopnea
pulmonari
inflamm
injuri
pulmonari
hypertens
relat
hypoxemia
abnorm
pulmonari
vasculatur
preterm
birth
bpd
respiratori
infect
result
airflow
obstruct
persist
adulthood
predispos
chronic
obstruct
pulmonari
diseas
therefor
press
need
determin
intervent
prevent
bpd
chronic
lung
diseas
sever
larg
multicent
trial
test
therapeut
strategi
acut
postnat
period
reduc
incid
cld
sequela
two
major
intervent
safe
effect
caffein
intramuscular
vitamin
although
dexamethason
treatment
decreas
incid
bpd
earli
administr
high
dose
dexamethason
increas
risk
gastrointestin
perfor
poor
neurocognit
outcom
complic
limit
use
one
trial
dart
studi
low
dose
dexamethason
use
second
week
life
select
infant
fail
extub
treatment
result
success
extub
decreas
supplement
oxygen
requir
combin
intratrach
therapi
budesonid
surfact
superior
surfact
alon
reduc
risk
bpd
preterm
infant
mechan
ventil
contrast
trial
late
surfact
administ
intub
mechan
ventil
infant
age
day
tolsurf
decreas
risk
bpd
week
evid
postnat
drug
therapi
includ
inhal
nitric
oxid
ino
superoxid
dismutas
glutathion
precursor
cimetidin
prevent
bpd
postnat
strategi
prevent
reduc
sever
cld
includ
altern
mode
ventil
decreas
barotrauma
stretch
injuri
associ
mechan
ventil
determin
optim
rang
oxygen
administr
sever
larg
multicent
trial
compar
efficaci
altern
mode
ventil
support
one
therapi
synchron
nasal
intermitt
posit
pressur
ventil
snippv
compar
mechan
ventil
result
decreas
bpd
extrem
low
gestat
age
infant
mode
support
consid
equival
comparison
mode
therapi
exampl
nasal
continu
posit
airway
pressur
ncpap
equival
intub
administr
surfact
mechan
ventil
risk
subsequ
bpd
studi
compar
ncpap
nasal
intermitt
posit
pressur
ventil
reveal
differ
bpd
outcom
studi
australia
infant
week
gestat
demonstr
extub
nasal
cannula
flow
rate
lpm
noninferior
ncpap
cm
water
infant
maintain
ventil
avoid
reintub
altogeth
neonat
intens
care
extrem
low
gestat
age
infant
shift
noninvas
ventilatori
support
high
flow
nasal
cannula
ncpap
earli
possibl
infant
requir
intub
ventil
consensu
recommend
administr
surfact
three
larg
trial
surfact
posit
pressur
puls
oximetri
random
trial
support
benefit
oxygen
satur
target
boost
canadian
oxygen
trial
cot
evalu
impact
titrat
supplement
oxygen
achiev
lower
vs
higher
satur
rang
impact
level
support
death
bpd
comorbid
includ
neurocognit
outcom
support
boost
trial
combin
recruit
infant
reveal
infant
titrat
lower
satur
rang
greater
mortal
rate
infant
assign
rang
contrast
cot
studi
reveal
differ
mortal
low
high
satur
rang
arm
studi
given
concern
increas
mortal
rais
support
boost
trial
current
consensu
titrat
therapi
oxyhemoglobin
satur
low
rang
prevent
potenti
increas
risk
infant
death
sequela
bpd
first
year
life
variabl
infant
diagnos
bpd
long
term
respiratori
diseas
infant
diagnos
bpd
may
persist
respiratori
sign
symptom
review
pulmonari
function
studi
former
preterm
infant
perform
infant
children
adult
reveal
similar
trend
time
airflow
obstruct
common
find
across
age
small
airway
affect
evidenc
decreas
predict
increas
ratio
residu
volum
total
lung
capac
adult
decreas
airflow
spirometri
report
emphysema
ct
scan
exercis
intoler
know
new
alveolar
appear
continu
beyond
preschool
age
period
childhood
adolesc
rais
potenti
continu
lung
growth
potenti
overcom
neonat
injuri
one
studi
support
concept
intervent
may
improv
pulmonari
outcom
use
rais
volum
rapid
thoracoabdomin
infant
pulmonari
function
test
filbrun
et
al
report
airway
flow
significantli
increas
month
age
preterm
infant
optim
weight
gain
vs
less
robust
growth
recent
larg
multicent
observ
studi
prematur
respiratori
outcom
program
recruit
preterm
infant
week
gestat
hospit
unit
state
evalu
contribut
antenat
perinat
postnat
factor
respiratori
symptom
pulmonari
mechan
first
year
life
still
remain
mani
clinic
uncertainti
concern
diagnosi
bpd
risk
chronic
lung
diseas
first
diagnosi
bpd
base
level
supplement
oxygen
ventilatori
support
week
gestat
age
current
debat
concern
whether
diagnost
criteria
determin
optim
gestat
age
predict
futur
respiratori
diseas
second
although
much
stronger
data
concern
perinat
factor
increas
risk
bpd
still
uncertainti
concern
infant
develop
chronic
lung
diseas
mandat
continu
follow
infant
recruit
larg
cohort
studi
intern
insight
gain
discov
postnat
factor
either
confer
greater
risk
may
mitig
sever
futur
lung
diseas
third
bpd
rel
rare
diseas
variabl
phenotyp
therefor
larg
number
subject
multicent
clinic
trial
requir
definit
test
new
therapi
determin
whether
decreas
bpd
chronic
lung
diseas
rais
import
issu
need
establish
bpd
endotyp
better
inform
therapeut
trial
target
specif
pathway
investig
underway
identifi
host
factor
genet
epigenet
associ
transcriptom
metabolom
microbiom
profil
associ
risk
bpd
chronic
lung
diseas
refer
baraldi
e
filippon
chronic
lung
diseas
prematur
birth
n
engl
j
med
kugelman
durand
comprehens
approach
prevent
bronchopulmonari
dysplasia
pediatr
pulmonol
mcevoy
ct
jain
l
schmidt
b
abman
bancalari
e
aschner
jl
bronchopulmonari
dysplasia
nhlbi
workshop
primari
prevent
chronic
lung
diseas
ann
thorac
soc
suppl
islam
jy
keller
rl
aschner
jl
hartert
tv
moor
pe
understand
respiratori
outcom
prematur
bronchopulmonari
dysplasia
j
respir
crit
care
med
darlow
ba
morley
cj
oxygen
satur
target
bronchopulmonari
dysplasia
clin
perinatol
watterberg
kl
american
academi
pediatr
committe
fetu
newborn
polici
corticosteroid
prevent
treat
bronchopulmonari
dysplasia
pediatr
polin
ra
carlo
wa
committe
f
newborn
american
academi
pediatr
surfact
replac
therapi
preterm
term
neonat
respiratori
distress
pediatr
filbrun
ag
popova
ap
linn
mj
mcintosh
na
hershenson
mb
longitudin
measur
lung
function
infant
bronchopulmonari
dysplasia
pediatr
pulmonol
maitr
nl
ballard
ra
ellenberg
jh
davi
sd
greenberg
jm
hamva
pryhub
gs
prematur
respiratori
outcom
program
respiratori
consequ
prematur
evolut
diagnosi
develop
comprehens
approach
j
perinatol
manag
sever
pectu
excavatum
carinatum
children
adolesc
jorg
depart
pediatr
surgeri
hospit
de
braga
cuf
porto
portug
pt
govern
associ
laboratori
school
medicin
univers
minho
braga
portug
addresscontact
prof
jorg
school
medicin
univers
minho
campu
de
gualtar
braga
portug
telefon
jcp
meduminhopt
deform
anterior
chest
wall
dacw
distribut
spectrum
morpholog
sever
symmetri
associ
abnorm
thu
deform
may
occur
sternum
protrud
posteriorli
pectu
excavatum
forwardli
pectu
carinatum
find
like
pouter
pigeon
deform
poland
syndrom
sternal
cleft
associ
dacw
cover
present
quit
differ
pathophysiolog
treatment
pectu
excavatum
pectu
excavatum
may
present
birth
often
seen
childhood
even
adolesc
patient
evid
depress
rapid
growth
puberti
undergo
promin
deform
usual
aris
sporad
patient
direct
rel
histori
dacw
etiolog
yet
known
howev
data
suggest
involv
mechan
forc
sternum
convers
chang
sternal
morpholog
absenc
xiphoid
xiphoid
bifid
unlik
caus
higher
frequenc
normal
popul
believ
determin
posit
rotat
sternum
distribut
pattern
ossif
center
turn
depend
mechan
forc
exert
sternum
develop
andor
growth
accept
theori
explain
full
spectrum
morpholog
found
patient
pectu
excavatum
carinatum
cartilag
overgrowth
junction
exert
mechan
forc
sternum
bodi
caus
chang
posit
patient
pectu
excavatum
usual
healthi
case
may
find
deform
manifest
syndrom
seri
patient
connect
tissu
syndrom
eg
marfan
muscular
dystrophi
etc
neurofibromatosi
eg
von
recklinghausen
syndrom
describ
intern
literatur
patient
pectu
excavatum
refer
pediatr
surgeri
asymptomat
usual
motiv
lead
patient
famili
member
seek
help
impact
deform
impos
bodi
imag
although
mani
author
report
alter
cardiac
function
pulmonari
function
limit
physic
exercis
usual
scenario
howev
sever
depress
sternum
result
decreas
distanc
consequ
reduct
intern
thorac
volum
extrem
case
space
conflict
may
compromis
pulmonari
expans
caus
obstruct
flow
import
vessel
andor
trigger
arrhythmia
pressur
exert
heart
howev
predomin
patient
physiolog
impact
cardiorespiratori
system
make
routin
assess
pulmonari
cardiac
function
patient
pectu
excavatum
controversi
comprehens
studi
reserv
sever
case
present
symptom
children
adolesc
pectu
excavatum
awar
physic
deform
make
differ
psycholog
consequ
impact
obviou
especi
adolesc
imag
studi
document
dimens
chest
evalu
possibl
secondari
alter
spine
organ
plan
surgic
procedur
consid
essenti
comput
tomographi
ct
current
commonli
use
imag
test
sinc
allow
evalu
bone
cartilag
deform
character
sever
depress
evalu
sever
indic
haller
index
use
mani
clinician
therapeut
decis
cite
calcul
divid
distanc
posterior
surfac
sternum
anterior
surfac
spine
transvers
diamet
thorax
classic
haller
index
consid
object
criterion
surgic
correct
howev
experi
shown
criteria
taken
account
surgic
indic
consid
inher
radiosensit
popul
attempt
avoid
exposur
radiat
advers
effect
research
group
develop
imag
reconstruct
methodolog
similar
obtain
ct
use
magnet
reson
andor
laser
scanner
without
radiat
could
replac
ct
preoper
approach
patient
physic
exercis
may
play
role
correct
postur
attenu
deform
develop
certain
muscl
group
especi
case
slight
deform
seri
recommend
train
use
row
cano
shown
encourag
result
treatment
mild
pectu
excavatum
howev
highlight
physic
exercis
per
se
name
swim
treatment
pectu
excavatum
innov
approach
develop
evalu
includ
vacuum
bell
treatment
treatment
vacuum
bell
promis
altern
select
case
pectu
excavatum
provid
thorax
flexibl
particularli
younger
patient
mild
moder
deform
vacuum
bell
devic
center
deepest
depress
point
anterior
wall
chest
exert
neg
pressur
effect
elev
sternum
rib
immedi
applic
devic
durat
treatment
relat
age
patient
sever
deform
frequenc
use
devic
applic
vacuum
bell
may
lead
appear
petechia
subcutan
hematoma
indic
presenc
coagulopathi
vasculopathi
patient
sever
pectu
excavatum
surgic
treatment
consid
accord
patient
percept
psychosoci
impact
deform
patient
life
thu
surgic
correct
perform
obtain
inform
consent
parent
assent
adolesc
ideal
age
surgeri
adolesc
thorac
structur
still
elast
flexibl
hand
close
bone
matur
end
growth
minim
likelihood
recurr
two
wide
use
techniqu
modif
open
procedur
describ
primarili
mark
ravitch
minim
invas
procedur
describ
donald
nuss
ravitch
techniqu
good
result
neglig
oper
morbid
high
recurr
rate
although
vari
accord
experi
group
howev
techniqu
recommend
situat
complex
dpat
combin
excavatum
carinatum
case
pouter
pigeon
morpholog
signific
asymmetri
extens
defect
involv
upper
costal
cartilag
minim
invas
nuss
techniqu
procedur
done
two
transvers
incis
later
wall
thorax
continu
thoracoscop
visual
one
two
person
prosthesi
introduc
behind
sternum
rotat
convex
posit
elev
sternum
desir
posit
prosthes
rest
anterior
surfac
rib
stabil
current
possibl
perform
automat
custom
bend
prosthesi
surgeri
system
calcul
size
shape
prosthesi
base
reconstruct
costal
grid
patient
last
year
cumul
evid
implant
prosthes
advantag
case
sever
extens
depress
well
older
adolesc
less
elast
thorac
structur
prosthes
implant
year
remov
treatment
complet
esthet
result
case
regard
open
procedur
advantag
discreet
cutan
incis
rather
incis
anterior
chest
wall
oper
time
pectu
carinatum
classic
present
pectu
carinatum
protrus
lower
third
sternum
maxim
promin
junction
may
quit
evid
case
narrow
diamet
thorax
rib
protrud
anteriorli
less
curvatur
usual
sternum
may
rotat
due
differ
costal
growth
rate
two
hemithorax
less
frequent
pectu
carinatum
present
unilater
protrus
costal
cartilag
associ
rotat
sternum
opposit
side
like
pectu
excavatum
occur
sporad
mani
patient
rel
histori
dacw
type
may
also
part
connect
tissu
syndrom
diseas
classic
treatment
began
surgic
usual
modif
ravitch
procedur
still
use
case
mark
deform
current
first
line
conserv
treatment
describ
haje
bowen
consist
use
compress
brace
exert
select
pressur
sternum
advantag
invas
scar
requir
motiv
patient
compli
therapeut
scheme
daili
prolong
use
year
brace
use
throughout
day
except
period
physic
exercis
complic
local
pain
skin
abras
major
challeng
conserv
treatment
patient
complianc
complic
implic
use
brace
may
impact
patient
social
life
especi
adolesc
impli
frequent
patient
monitor
strict
provid
continu
posit
reinforc
although
patient
complet
recommend
protocol
achiev
degre
satisfact
quit
good
refer
nuss
kelli
dp
croitoru
et
al
review
minim
invas
techniqu
correct
pectu
excavatum
j
pediatr
surg
haje
sa
bowen
jr
preliminari
result
orthot
treatment
pectu
deform
children
adolesc
j
pediatr
orthop
lopez
patoir
cost
f
varlet
f
barthelemi
jc
tiffet
preliminari
studi
efficaci
cup
suction
correct
typic
pectu
excavatum
j
pediatr
surg
jl
rodrigu
pl
soar
tr
fonseca
jc
pinho
ac
j
automat
prebent
custom
prosthesi
pectu
excavatum
minim
invas
surgeri
correct
surg
innov
j
jl
b
pinho
ac
fonseca
jc
j
new
methodolog
assess
pectu
excavatum
correct
bar
remov
nuss
procedur
preliminari
studi
j
pediatr
surg
doi
epub
ahead
print
congenit
thorac
malform
resect
andrew
bush
imperi
colleg
royal
brompton
hospit
london
uk
email
abush
rbhtnhsuk
routin
perform
antenat
fetal
anomali
scan
pregnant
women
last
three
decad
thrown
mani
problem
larg
detect
abnorm
data
long
term
signific
find
particularli
case
congenit
thorac
malform
ctm
sometim
refer
congenit
pulmonari
airway
malform
cpam
imag
find
antenat
postnat
relat
close
patholog
doubt
symptomat
ctm
resect
whatev
age
patient
howev
agreement
center
approach
asymptomat
ctm
antenat
intervent
drainag
larg
cyst
fetal
surgeri
reserv
hydrop
babi
sinc
ctm
diminish
size
last
trimest
pregnanc
without
treatment
babi
antenat
ctm
undergo
chest
radiograph
soon
birth
low
sensit
high
resolut
comput
tomographi
hrct
contrast
delin
vasculatur
current
investig
surgeri
plan
optim
time
unclear
given
ctm
regress
first
one
two
year
life
uncertainti
best
must
share
honestli
famili
one
right
answer
asymptomat
child
need
acknowledg
follow
obtain
natur
histori
data
recommend
whatev
therapeut
decis
made
fact
publish
literatur
indisput
interpret
contenti
fact
infect
air
leak
bleed
complic
larg
report
seri
publish
describ
patient
nearli
antenat
diagnosi
ctm
reach
infanc
without
surgeri
becam
symptomat
complic
significantli
less
like
elect
surgeri
whether
mere
reflect
elect
surgeri
perform
older
bigger
children
unclear
recent
studi
compar
elect
resect
expect
manag
identifi
one
prospect
eight
retrospect
studi
seventi
patient
underw
elect
surgeri
asymptomat
surgic
complic
rate
patient
manag
conserv
develop
symptom
complic
rate
seem
high
suggest
select
bia
henc
overal
risk
complic
infect
bleed
air
leak
childhood
whether
risk
increas
age
known
certainli
lifetim
risk
complic
babi
asymptomat
ctm
current
computedrisk
malign
know
primari
intrathorac
malign
rare
childhood
occur
associ
ctm
risk
around
largest
seri
pleuropulmonari
blastoma
ppb
show
reliabl
radiolog
featur
predict
malign
period
popul
around
five
million
live
birth
studi
period
children
diagnos
ctm
cpam
incid
one
underw
resect
reason
resect
gener
poorli
document
total
five
ppb
diagnos
time
period
give
incid
one
live
birth
three
initi
diagnos
cpam
thu
incid
ppb
among
appar
benign
ctm
worryingli
clinic
radiolog
featur
distinguish
benign
malign
one
two
patient
ppb
without
lung
lesion
die
worri
recent
studi
resect
specimen
asymptomat
ctm
variou
sort
reveal
microscop
diseas
n
infect
microabscess
inflammatori
cell
infiltr
n
ppb
risk
malign
transform
reduc
elimin
surgeri
ppb
describ
complet
resect
ctm
tumor
marker
found
excis
ctm
may
associ
malign
includ
echinoderm
lymphoma
kinas
alk
oncoprotein
erythroblast
leukemia
viral
oncogen
homologu
rare
devast
complic
air
travel
small
unquantifi
risk
complic
air
travel
devast
fatal
cerebrovascular
accid
describ
patient
risk
treatment
although
resect
ctm
otherwis
well
child
safe
small
risk
surgic
complic
taken
togeth
view
risk
outweigh
elect
surgeri
skill
hand
answer
question
pose
titl
ye
howev
mani
would
disagre
better
mean
assess
risk
complic
present
unsatisfactori
state
affair
like
continu
place
ctm
patient
high
low
risk
categori
may
feasibl
algorithm
incorpor
radiolog
featur
mutat
analysi
radiolog
featur
suggest
uncompl
ctm
includ
antenat
detect
presenc
system
feed
vessel
hyperinfl
lung
featur
suggest
ppb
includ
bilater
multiseg
involv
although
larg
studi
patient
group
algorithm
use
caution
prospect
valid
anoth
cohort
ct
featur
overlap
ctmsequestr
ppb
although
presenc
feed
vessel
hyperinfl
lung
ctmsequestr
bilater
multiseg
involv
ppb
report
help
distinguish
featur
famili
histori
tumor
ppb
lung
cyst
renal
anomali
close
rel
childhood
malign
especi
wilm
tumor
medulloblastoma
suggest
enhanc
likelihood
mass
ppb
hope
futur
work
includ
molecular
test
tumor
marker
allow
risk
stratif
target
surgeri
children
refer
stanton
njere
n
patel
davenport
systemat
review
postnat
manag
congenit
cystic
lung
lesion
j
pediatr
surg
ng
c
stanwel
j
burg
dm
stanton
mp
conserv
manag
antenat
diagnos
cystic
lung
malform
arch
di
child
papagiannopoulo
ka
sheppard
bush
goldstraw
p
pleuropulmonari
blastoma
prophylact
resect
congenit
lung
cyst
effect
ann
thorac
surg
durel
j
thakkar
h
gould
fowler
lakhoo
k
patholog
asymptomat
prenat
diagnos
cystic
lung
malform
j
pediatr
surg
ng
c
stanwel
j
burg
dm
stanton
mp
conserv
manag
antenat
diagnos
cystic
lung
malform
arch
di
child
machicado
jd
davogustto
g
burgeoi
kaldi
p
jani
pp
gidwani
r
fatal
air
embol
rare
complic
bronchogen
cyst
airplan
passeng
j
respir
crit
care
med
feinberg
hall
nj
william
gm
et
al
congenit
pulmonari
airway
malform
distinguish
type
pleuropulmonari
blastoma
base
clinic
radiolog
featur
j
pediatr
surg
feinberg
hall
nj
william
gm
et
al
congenit
pulmonari
airway
malform
distinguish
type
pleuropulmonari
blastoma
base
clinic
radiolog
featur
j
pediatr
surg
hill
da
jarzembowski
ja
priest
jr
william
g
schoettler
p
dehner
lp
type
pleuropulmonari
blastoma
patholog
biolog
studi
case
intern
pleuropulmonari
blastoma
registri
j
surg
pathol
diagnosi
manag
plastic
bronchiti
bruce
k
rubin
virginia
commonwealth
univers
depart
pediatr
children
hospit
richmond
vcu
richmond
va
usa
email
brucerubin
vcuhealthorg
plastic
bronchiti
rare
disord
character
format
firm
branch
cast
fill
airway
firm
branch
cast
differ
sputum
plug
seen
patient
bronchiectasi
rare
form
branch
cast
usual
firm
white
grey
color
except
patient
sickl
cell
acut
chest
syndrom
often
stain
yellow
inflammatori
cell
associ
type
plastic
bronchiti
arbitrari
distinct
inflammatori
cast
relat
underli
etiolog
prognosi
better
classif
system
lymphat
plastic
bronchiti
children
congenit
heart
diseas
particularli
singl
ventricl
physiolog
alway
lymphat
form
plastic
bronchiti
howev
fewer
patient
singl
ventricl
physiolog
diagnos
pb
itkin
dori
univers
pennsylvania
demonstr
patient
characterist
abnorm
pulmonari
lymphat
drainag
thorac
duct
similar
abnorm
may
seen
patient
underli
lymphat
disord
sickl
cell
acut
chest
plastic
bronchiti
patient
develop
plastic
bronchiti
follow
viral
infect
unknown
extent
aberr
pulmonari
lymphat
gener
popul
without
plastic
bronchiti
second
form
eosinophil
plastic
bronchiti
cast
greenish
branch
stain
show
crystal
eosinophil
eosinophil
degrad
form
plastic
bronchiti
associ
asthma
appear
respond
high
dose
corticosteroid
inhal
heparin
presum
inhibit
tissu
factor
low
dose
macrolid
report
effect
patient
although
respons
inconsist
inhal
tissu
plasminogen
activ
tpa
breakdown
cast
format
also
caus
airway
inflamm
recommend
regular
therapi
proven
role
acetylcystein
dornas
alfa
hyperton
salin
bronchodil
asthma
medic
treat
plastic
bronchiti
definit
therapi
patient
lymphat
plastic
bronchiti
consist
pulmonari
lymphat
map
ablat
aberr
vessel
produc
signific
relief
often
appear
cure
plastic
bronchiti
center
lymphat
map
ablat
readili
avail
aggress
thorac
duct
ligat
also
proven
help
mani
case
refer
rubin
bk
plastic
bronchiti
clin
chest
med
madsen
p
shah
sa
rubin
bk
plastic
bronchiti
new
insight
classif
scheme
paediatr
resp
rev
dori
keller
ms
fogel
rome
jj
whitehead
kk
harri
itkin
mri
lymphat
abnorm
function
palliat
surgeri
ajr
j
roentgenol
dori
keller
ms
rychik
j
itkin
success
treatment
plastic
bronchiti
select
lymphat
embol
fontan
patient
pediatr
deng
j
zheng
li
c
z
wang
h
rubin
bk
plastic
bronchiti
three
children
associ
influenza
viru
infect
chest
impact
obes
infant
growth
pattern
childhood
wheez
john
henderson
school
social
commun
medicin
faculti
health
scienc
univers
bristol
uk
email
ajhenderson
bristolacuk
asthma
obes
increas
preval
compar
set
similar
period
time
tempt
specul
must
direct
link
two
howev
associ
two
phenomena
way
impli
way
relat
far
less
one
caus
howev
number
cross
section
longitudin
studi
establish
posit
associ
asthmawheez
high
bodi
mass
usual
express
bodi
mass
index
bmi
either
continuum
usual
use
accept
categor
threshold
overweight
obes
sever
possibl
explan
associ
includ
revers
causat
respiratori
symptom
overweight
confound
one
independ
variabl
includ
share
genet
factor
associ
high
bodi
mass
wheez
ill
mechan
effect
bodi
fat
distribut
respiratori
function
play
chanc
infant
growth
could
play
relationship
either
direct
link
earli
bodi
size
growth
later
mechan
associ
rapid
growth
earli
childhood
lung
function
develop
rais
question
signific
rapid
earli
growth
could
marker
intrauterin
advers
even
birth
weight
nomin
normal
rang
ie
growth
retard
infant
birth
weight
could
featur
variat
infant
nutrit
practic
obes
asthma
observ
evid
cross
section
studi
major
cross
section
studi
obes
asthma
report
posit
associ
overal
suggest
obes
girl
stronger
associ
asthma
male
counterpart
howev
consider
heterogen
risk
individu
studi
systemat
review
sex
modif
associ
obes
incid
asthma
children
report
stronger
effect
boy
girl
recent
cross
section
evid
suggest
fat
distribut
play
role
associ
central
obes
associ
asthma
also
report
associ
obes
stronger
nonallerg
compar
allerg
asthma
howev
also
suggest
link
high
bodi
mass
children
atop
sensit
therefor
although
cross
section
evid
support
associ
potenti
mechan
highli
uncertain
longitudin
studi
six
longitudin
studi
children
year
old
met
inclus
criteria
recent
systemat
prospect
associ
obes
asthma
diagnosi
least
year
measur
bmi
diagnosi
asthma
obesityoverweight
various
consid
bmi
centil
sex
age
bmi
major
describ
posit
associ
discord
risk
individu
studi
combin
effect
estim
show
posit
associ
overweight
centil
bmi
obes
centil
bmi
asthma
result
consist
earlier
find
adult
men
earli
childhood
growth
obes
asthma
analyz
detail
growth
data
children
birth
year
use
linear
spline
look
differ
part
growth
trajectori
found
rapid
weight
gain
birth
month
associ
later
asthma
diagnosi
bronchial
impact
earli
postnat
growth
asthma
could
mediat
causal
associ
obes
asthma
later
childhood
infant
size
rate
weight
gain
infanc
associ
obes
later
infant
obes
measur
varieti
differ
metric
includ
bmi
centil
cohort
studi
show
consist
associ
obes
outcom
rang
age
across
lifecours
preschool
late
adulthood
also
major
studi
rapid
weight
gain
infanc
measur
differ
period
show
posit
associ
later
childhood
adolesc
obes
anoth
possibl
explan
report
link
rapid
postnat
growth
lower
lung
function
infanc
beyond
small
airway
could
predispos
wheez
symptom
misclassifi
asthma
young
children
altern
rapid
weight
gain
feed
practic
infanc
may
direct
effect
immun
develop
causal
method
evalu
link
obes
asthma
children
one
major
problem
make
causal
infer
observ
associ
confound
measur
unmeasur
variabl
use
mendelian
random
approach
test
unconfound
associ
bodi
mass
asthma
birth
cohort
children
genet
risk
obes
gener
use
risk
score
base
risk
allel
includ
fto
assumpt
allel
randomli
assort
meiosi
use
instrument
variabl
high
bodi
mass
although
allel
explain
varianc
bmi
popul
found
evid
causal
link
high
bodi
mass
asthma
age
year
possibl
mechan
explain
link
obes
truli
causal
initi
asthma
children
number
mechan
advanc
explain
plausibl
explan
obes
associ
system
inflamm
may
give
rise
airway
inflamm
asthma
evid
adipocyt
sourc
cytokin
littl
evid
system
inflamm
obes
directli
associ
airway
inflamm
anoth
possibl
link
would
promot
allerg
inflamm
adipokin
effect
immun
system
like
us
other
report
stronger
associ
obes
asthma
found
evid
obes
associ
atopi
cohort
specif
phenotyp
suggest
adult
children
may
associ
increas
asthma
sever
evid
obes
establish
asthma
associ
poor
asthma
control
increas
exacerb
suboptim
respons
glucocorticoid
poor
respons
steroid
may
associ
airway
inflamm
consist
find
stronger
associ
asthma
possibl
receiv
recent
attent
share
genet
loci
underpin
asthma
obes
epigenet
effect
dietari
influenc
microbiom
promot
inflammatori
respons
refer
baird
j
fisher
luca
p
kleijnen
j
robert
h
law
c
big
grow
fast
systemat
review
size
growth
infanc
later
obes
bmj
egan
kb
etting
bracken
mb
childhood
bodi
mass
index
subsequ
asthma
systemat
review
prospect
cohort
studi
bmc
pediatr
beuther
da
sutherland
er
overweight
obes
incid
asthma
prospect
epidemiolog
studi
j
respir
crit
care
med
der
voort
howe
ld
granel
r
duijt
l
stern
ja
till
k
henderson
aj
influenc
childhood
growth
asthma
lung
function
adolesc
j
allergi
clin
immunol
granel
r
henderson
evan
dm
smith
gd
ness
ar
lewi
palmer
tm
stern
ja
effect
bmi
fat
mass
lean
mass
asthma
childhood
mendelian
random
studi
plo
med
obes
system
inflamm
respiratori
diseas
sejal
saglani
professor
paediatr
respiratori
medicin
nhli
imperi
colleg
london
royal
brompton
hospit
london
uk
email
ssaglani
imperialacuk
intrigu
aspect
relationship
obes
respiratori
health
although
obes
independ
risk
factor
condit
asthma
obes
patient
affect
respiratori
diseas
therefor
import
disentangl
true
causal
relationship
mere
associ
consid
triad
obes
system
inflamm
respiratori
diseas
major
research
date
investig
interact
obes
inflamm
respiratori
diseas
children
focus
asthma
updat
explor
relationship
context
asthma
one
biggest
conundrum
face
consid
obes
asthma
although
children
asthma
obes
known
whether
asthmat
children
increas
risk
weight
gain
due
modifi
lifestyl
factor
studi
aim
investig
impact
asthma
lifestyl
factor
also
associ
obes
shown
children
asthma
greater
sleep
latenc
plasma
triglycerid
compar
suggest
asthma
per
se
risk
factor
obes
although
specif
phenotyp
asthma
associ
obes
accept
describ
adult
patient
specif
sever
diseas
adult
onset
predominantli
femal
littl
evid
airway
inflamm
increas
evid
obes
asthma
phenotyp
children
obes
asthma
complex
influenc
numer
factor
includ
nutrit
impact
gut
lung
microbiom
metabol
airway
wall
mechan
genet
suscept
system
low
inflamm
system
level
obes
asthma
key
differ
adult
onset
pediatr
obes
asthma
phenotyp
role
matern
weight
pregnanc
rate
child
weight
gain
earli
postnat
life
matern
obes
associ
childhood
asthma
associ
alter
immun
profil
cord
blood
includ
switch
toward
cytokin
includ
interestingli
state
associ
increas
expect
allerg
inflammatori
mediat
inde
number
eosinophil
cell
lower
babi
born
obes
mother
underscor
like
fundament
differ
pathophysiolog
childhood
onset
obes
asthma
allerg
asthma
specif
system
inflammatori
profil
recent
describ
adult
obes
patient
high
phenotyp
system
inflamm
clinic
featur
metabol
dysfunct
occur
commonli
subset
obes
asthma
patient
associ
sever
data
togeth
cord
blood
data
matern
obes
suggest
mechan
underpin
obes
asthma
adult
children
may
similar
potenti
central
mediat
drive
diseas
furthermor
absenc
inflammatori
profil
may
explain
obes
asthma
rel
steroid
resist
phenotyp
experiment
studi
also
shown
although
steroid
may
help
reduc
compon
airway
inflamm
mice
fed
high
fat
diet
expos
hous
dust
mite
second
independ
inflammatori
compon
includ
macrophag
marker
type
inflamm
import
point
consid
assess
inflamm
associ
asthma
relev
tissu
specif
inflamm
versu
system
inflamm
airway
structur
cell
inflammatori
cell
key
determin
protect
patholog
may
relev
context
obes
asthma
sinc
evid
suggest
locat
eosinophil
differ
tissu
crucial
determin
effect
lung
specif
airway
wall
caus
inflamm
yet
locat
viscer
fat
improv
glucos
clinic
data
correl
lung
tissu
eosinophilia
obes
may
therefor
shed
light
role
eosinophil
obes
individu
asthma
improv
treatment
patient
nutrit
gut
airway
microbiom
downstream
immun
respons
critic
compon
grow
preval
obes
western
world
shift
toward
diet
high
fat
content
low
fiber
direct
impact
low
fiber
diet
specif
low
short
chain
fatti
acid
scfa
composit
gut
microbiom
metabolit
microbiota
shown
influenc
develop
allerg
airway
diseas
dietari
fiber
content
chang
composit
gut
lung
microbiota
gut
microbiota
metabol
fiber
increas
concentr
circul
scfa
therefor
mice
fed
diet
increas
circul
level
scfa
protect
allerg
inflamm
lung
wherea
diet
decreas
level
scfa
increas
allerg
airway
airway
mechan
dysanapsi
obes
asthma
addit
low
inflamm
addit
explan
rel
poor
respons
obes
asthma
steroid
may
presenc
alter
airway
mechan
obes
children
consist
shown
low
ratio
obstruct
pictur
may
explain
suscept
develop
sever
asthma
recent
find
report
relat
lung
structur
obes
children
presenc
airway
airway
dysanapsi
describ
physiolog
incongru
mismatch
develop
lung
parenchyma
size
specif
calib
length
airway
reflect
presenc
abnorm
ratio
despit
presenc
normal
valu
fvc
airway
dysanapsi
present
obes
children
without
asthma
consist
longitudin
measur
obes
present
howev
children
obes
asthma
presenc
dysnapsi
clinic
impact
manifest
sever
exacerb
increas
use
system
impact
weight
loss
respiratori
health
inflammatori
statu
sustain
weight
loss
use
dietari
lifestyl
modif
difficult
reveal
conclus
result
impact
asthma
control
inflammatori
statu
date
children
primarili
inabl
sustain
weight
loss
howev
impact
bariatr
surgeri
asthma
system
inflamm
investig
adult
obes
highlight
complex
relationship
obes
system
inflamm
asthma
adult
obes
asthma
low
ige
improv
airway
hyperrespons
ahr
weight
loss
chang
rest
airway
resist
contrast
obes
asthma
high
ige
improv
airway
mechan
resist
chang
ahr
weight
loss
data
suggest
least
phenotyp
obes
asthma
distinct
pathophysiolog
contribut
allergi
obes
exist
challeng
children
disentangl
phenotyp
target
treatment
accordingli
allerg
obes
asthma
phenotyp
perhap
acquir
phenotyp
relat
predominantli
diet
lifestyl
may
benefit
aggress
weight
loss
measur
may
becom
respons
steroid
impact
alter
airway
mechan
remov
second
group
predominantli
system
inflammatori
phenotyp
may
driven
like
predomin
genet
suscept
obes
asthma
may
benefit
aggress
weight
loss
measur
system
agent
antibodi
summari
mount
evid
associ
obes
asthma
children
increas
preval
howev
pathogenesi
link
two
condit
complex
obes
caus
varieti
mechan
metabol
immunolog
chang
airway
system
circul
significantli
impact
clinic
asthma
control
pathway
lead
reduc
sensit
steroid
molecular
mechan
drive
obes
asthma
uncov
suggest
presenc
two
pathophysiolog
phenotyp
within
obes
asthma
high
allerg
phenotyp
like
reflect
inher
suscept
ahr
ad
acquisit
obes
low
phenotyp
may
reflect
suscept
obes
associ
airway
dysnapsi
obstruct
airway
diseas
studi
confirm
phenotyp
children
investig
efficaci
phenotyp
specif
treatment
approach
need
help
tackl
challeng
obes
inflamm
asthma
refer
jensen
gibson
p
collin
c
hilton
j
wood
l
lifestyl
risk
factor
weight
gain
children
without
asthma
children
basel
forno
e
jc
effect
obes
weight
gain
weight
loss
asthma
incept
control
curr
opin
allergi
clin
immunol
wilson
rm
marshal
ne
jesk
dr
purnel
jq
thornburg
k
messaoudi
matern
obes
alter
immun
cell
frequenc
respons
umbil
cord
blood
sampl
pediatr
allergi
immunol
peter
mc
mcgrath
kw
hawkin
ga
hasti
levi
bd
israel
e
et
al
plasma
concentr
metabol
dysfunct
asthma
sever
analysi
two
cohort
lancet
respir
med
diaz
j
warren
l
helfner
l
xue
x
chatterje
pk
gupta
et
al
obes
shift
hous
dust
airway
cellular
infiltr
eosinophil
macrophag
effect
glucocorticoid
treatment
immunol
re
saglani
lloyd
cm
novel
concept
airway
inflamm
remodel
asthma
eur
respir
j
lloyd
cm
saglani
eosinophil
spotlight
find
link
obes
asthma
nat
med
trompett
gollwitz
es
yadava
k
sichelstiel
ak
sprenger
n
c
et
al
gut
microbiota
metabol
dietari
fiber
influenc
allerg
airway
diseas
hematopoiesi
nat
med
forno
e
weiner
dj
mullen
j
sawicki
g
kurland
g
han
yy
et
al
obes
airway
dysanapsi
children
without
asthma
j
respir
crit
care
med
chapman
dg
irvin
cg
kaminski
da
forgion
pm
bate
jht
dixon
ae
influenc
distinct
asthma
phenotyp
lung
function
follow
weight
loss
obes
respirolog
breath
obes
children
praud
pediatr
pulmonolog
divis
univers
sherbrook
qc
canada
email
jeanpaulpraud
usherbrookeca
worldwid
obes
epidem
respons
signific
respiratori
problem
children
adult
typic
observ
chronic
respiratori
problem
consequ
obes
respir
pronounc
sleep
present
short
updat
focus
respiratori
consequ
obes
sleep
children
adolesc
nevertheless
first
briefli
summar
overal
consequ
obes
lung
function
necessari
complet
understand
sleep
disord
breath
obes
children
overal
effect
obes
lung
function
consist
effect
obes
lung
function
decreas
function
residu
capac
morbid
obes
approach
residu
volum
decreas
function
residu
capac
due
mass
load
lung
adipos
tissu
abdomen
well
thorac
caviti
around
rib
cage
consequ
rest
ventil
take
place
lower
lung
volum
tether
action
elast
parenchyma
alveoli
intrapulmonari
bronchi
reduc
lead
turn
deleteri
consequ
follow
first
low
lung
volum
decreas
lung
complianc
increas
work
breath
secondli
decreas
function
residu
capac
decreas
pulmonari
oxygen
store
increas
risk
bronchial
closur
tidal
breath
especi
lower
pulmonari
region
consequ
mismatch
frequent
region
perfus
predomin
explain
frequent
mild
hypoxemia
observ
obes
summari
bronchopulmonari
consequ
obes
increas
work
breath
favor
mild
hypoxemia
even
rest
wake
breath
obes
children
even
absenc
signific
upper
airway
obstruct
deleteri
effect
obes
lung
function
tend
pronounc
night
inde
recumb
posit
hyperpress
diaphragm
lower
pulmonari
region
due
increas
abdomin
fat
mass
highest
addit
sleep
normal
associ
alter
breath
loss
wake
stimulu
breath
decreas
upper
airway
thorac
respiratori
muscl
activ
especi
rem
sleep
obes
import
risk
factor
breath
sdb
least
obes
children
potenti
sdb
addit
sever
sdb
proport
degre
obes
children
everi
bodi
mass
index
bmi
increment
one
lead
increas
risk
sdb
mechan
breath
obes
children
found
multipl
first
describ
mechan
effect
adipos
tissu
mass
lung
function
pronounc
supin
posit
secondli
number
mechan
tend
promot
upper
airway
obstruct
explain
high
frequenc
obstruct
breath
osdb
fatti
infiltr
upper
airway
especi
level
tongu
parapharyng
pad
often
consid
primari
causal
factor
upper
airway
obstruct
howev
magnet
reson
imag
studi
perform
obes
adolesc
found
even
age
adenotonsillar
hypertrophi
remain
main
factor
explain
upper
airway
obstruct
higher
frequenc
malocclus
recent
report
obes
vs
children
osdb
decreas
lung
volum
respons
reduc
tension
trachea
upper
airway
turn
consequ
increas
upper
airway
complianc
promot
upper
airway
collapseviscer
adipos
held
respons
upper
airway
obstruct
via
inflamm
high
metabol
activ
viscer
adipocyt
produc
mediat
would
lead
among
other
upper
airway
inflamm
vein
osdb
consid
one
manifest
metabol
syndrom
secondari
viscer
adipos
releas
growth
factor
secondari
obesityinsulin
resist
state
may
lead
soft
tissu
edema
upper
airwaysfin
blunt
respiratori
reflex
ventilatori
respons
reduc
ventilatori
drive
especi
upper
airway
dilat
muscl
observ
patient
reduct
ventilatori
drive
seemingli
relat
among
other
resist
leptin
cytokin
hormon
secret
larg
amount
adipocyt
diagnosi
obstruct
breath
must
made
high
index
suspicion
obes
children
snore
apnea
breath
difficulti
night
frequent
report
histori
take
well
nocturn
enuresi
excess
daytim
sleepi
hyperact
behavior
problem
andor
academ
difficulti
clinic
examin
addit
systemat
investig
system
arteri
hypertens
presenc
risk
factor
osdb
nasal
obstruct
orthodont
anomali
adenotonsillar
hypertrophi
note
ratio
independ
predict
obstruct
sleep
apnea
syndrom
osa
rr
per
unit
valu
propos
screen
test
help
priorit
overweight
obes
children
polysomnographi
usual
laboratori
test
investig
metabol
syndrom
especi
import
diagnost
workup
obes
children
usual
children
diagnos
sever
osdb
strongli
advis
overnight
attend
polysomnographi
prefer
test
establish
diagnosi
osa
howev
long
wait
list
rule
higher
sever
osdb
obes
children
requir
earli
diagnosi
treatment
although
home
sleep
apnea
test
report
viabl
altern
diagnos
pediatr
osa
frequenc
nocturn
hypoventil
obes
children
necessit
perform
monitor
addit
recent
result
suggest
overnight
puls
oximetri
clinic
examin
help
predict
osa
obes
children
suggest
clinic
context
beyond
test
seek
establish
diagnosi
osa
sleep
sedat
gain
popular
substanti
site
upper
airway
obstruct
guid
surgic
treatment
includ
presenc
obes
whether
test
indic
patient
osdb
persist
follow
adenotonsillectomi
remain
matter
debat
complic
osdb
overal
osdb
obes
potenti
yield
frequent
sever
complic
compar
osdb
children
cardiovascular
complic
childhood
obes
lead
caus
arteri
hypertens
osdb
accompani
higher
sympathet
activ
reactiv
well
increas
arteri
stiff
addit
childhood
obes
osdb
respons
endotheli
inflamm
dysfunct
consequ
obes
osdb
favor
cardiovascular
complic
especi
system
arteri
hypertens
metabol
syndrom
osdb
obes
interact
provok
metabol
dysfunct
especi
via
chronic
system
inflamm
one
current
hypothesi
state
gut
microbiom
inflammatori
connect
obes
osdb
disrupt
sleep
factor
facilit
obes
eg
diet
would
alter
gut
microbiom
increas
passag
lipopolysaccharid
system
circul
lead
turn
system
inflamm
neurobehavior
consequ
osdb
obes
lead
neurodevelopment
behavior
consequ
especi
hyperactivityattent
disord
lower
school
perform
henc
obes
sdb
addit
effect
neurobehavior
consequ
qualiti
life
depress
obes
associ
lower
anxieti
disord
depress
symptom
extrem
reduct
qualiti
life
similar
children
cancer
report
morbid
obes
decreas
qualiti
life
also
shown
osdb
osdb
obes
potenti
reduc
qualiti
life
affect
children
treatment
obstruct
breath
obes
children
adenotonsillectomi
must
remain
first
line
treatment
consid
howev
recent
shown
follow
adenotonsillectomi
osa
cure
obes
children
postop
thu
import
detect
residu
osa
ideal
overnight
polysomnographi
addit
obes
children
risk
factor
postop
cardiorespiratori
complic
vs
overnight
hospit
monitor
mandatori
follow
adenotonsillectomi
treatment
option
obes
children
osdb
includ
intens
weight
reduct
program
cpap
exercis
well
bariatr
surgeri
morbidli
obes
adolesc
syndrom
syndrom
pickwickian
syndrom
defin
associ
bodi
mass
index
arteri
hypercapnia
wake
sdb
absenc
caus
alveolar
hypoventil
children
syndrom
consid
extrem
osdb
spectrum
lung
physiolog
grossli
impair
due
sever
obes
mark
mechan
load
respiratori
system
respons
increas
work
breath
gross
ventilationperfus
anomali
lead
turn
chronic
hypoxemia
hypercapnia
consequ
increas
bicarbon
resist
leptin
would
respons
abnorm
ventilatori
drive
respons
hypoxia
hypercapnia
syndrom
bear
risk
polycythemia
pulmonari
hypertens
right
ventricular
failur
increas
morbid
mortal
regard
treatment
although
adenotonsillectomi
consid
howev
usual
insuffici
addit
postop
complic
frequent
sever
signific
mortal
risk
cpap
effici
bipap
often
necessari
weight
reduct
also
primari
import
bariatr
surgeri
often
consid
adolesc
refer
schwab
rj
kim
c
bagchi
keenan
bt
comyn
fl
wang
tapia
ie
huang
traylor
j
torigian
da
bradford
rm
marcu
cl
understand
anatom
basi
obstruct
sleep
apnea
syndrom
adolesc
j
respir
crit
care
med
evangelisti
shafiek
h
rabasco
j
forlani
montesano
barreto
verhulst
villa
mp
oximetri
obes
children
breath
sleep
med
gain
j
vgontza
j
calhoun
sl
f
liao
sawyer
md
bixler
eo
inflamm
mediat
associ
viscer
adipos
obstruct
sleep
apnea
adolesc
j
physiol
endocrinol
metab
katz
sl
vaccani
jp
barrowman
n
momoli
f
bradburi
cl
murto
k
ratio
predict
obstruct
sleep
apnea
children
j
clin
sleep
med
tan
hl
l
gozal
pediatr
home
sleep
apnea
test
slowli
get
chest
gazzaz
mj
isaac
anderson
alsufyani
n
alrajhi
h
sleep
endoscopi
chang
surgic
decis
surgic
children
snoringsleep
disord
breath
standard
adenotonsillectomi
retrospect
cohort
studi
j
otolaryngol
head
neck
surg
tagetti
bonafini
zaffanello
benetti
mv
vedov
fd
gasperi
e
cavarzer
p
gaudino
r
piacentini
g
minuz
p
maffei
c
antoniazzi
f
fava
c
breath
associ
blood
pressur
carotid
arteri
stiff
obes
children
j
hyperten
wentz
e
dahlgren
j
neurodevelopment
disord
highli
children
obes
studi
obes
rankin
j
matthew
l
cobley
han
sander
r
wiltshir
hd
baker
js
psycholog
consequ
childhood
obes
psychiatr
comorbid
prevent
adolesc
health
med
ther
lee
ch
hsu
wc
chang
wh
lin
mt
kang
kt
polysomnograph
find
adenotonsillectomi
obstruct
sleep
apnoea
obes
children
systemat
review
clin
otolaryngol
publish
research
bruce
k
rubin
virginia
commonwealth
univers
depart
pediatr
children
hospit
richmond
vcu
richmond
va
children
hospit
richmond
vcu
richmond
va
email
brucerubin
vcuhealthorg
children
hospit
richmond
vcu
richmond
vapublish
complet
research
project
manuscript
peer
review
journal
daunt
prospect
even
season
investig
mani
year
servic
editori
board
member
pulmonari
journal
publish
author
allow
dr
rubin
collect
number
tip
make
easier
manuscript
eventu
accept
publish
present
review
tip
manuscript
prepar
target
appropri
journal
prepar
effect
cover
letter
choos
review
deal
manuscript
reject
resubmiss
exampl
given
author
work
